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Abstract 
Dementia  is  a  clinical  syndrome  associated  with  progressive  deterioration  of  intellectual 
functions including loss of memory, difficulties with language, simple calculations, planning and 
judgment, and motor skills with eventually loss of autonomy. Currently there are an estimated 36 
million people worldwide with dementia and this  figure is  set  to increase to more than 115 
million  people  by  2050.  Given  the  prevalence  of  dementia  and  the  associated  significant 
financial  and human costs,  in  recent  years  there  has  been a  huge  burst  of  studies  aimed to 
identify the causes of this disorder and its underlain pathological mechanisms, in order to define 
therapeutic treatments to replace the nowadays available palliative cares. 
Among different subtypes of dementia, Alzheimer's Disease (AD) is the most frequent form, 
followed  by  Vascular  Dementia  and  Frontotemporal  Lobar  Degeneration  (FTLD)  which 
represents the second most common form in people younger than 65 years. All three of these 
diseases may have a genetic component and, despite considerable progress and efforts made in 
recent years to clarify their molecular basis, little is known about the pathological mechanisms 
determining these diseases. 
Three forms of dementia, which may have a genetic component, were included in this study: 
Alzheimer's  Disease,  Frontotemporal  Lobar  Degeneration  and Cerebral  Autosomal  Dominant 
Arteriopathy  with  Subcortical  Infarcts  and  Leuokoencephalopathy  (CADASIL)  which  is  a 
subtype of vascular dementia. The main objectives of this study included mutational analysis of 
the  genes  associated  with  these  diseases  with  the  dual  purpose  of  defining  their  mutational 
frequencies in an Italian series  and to evaluate the presence of possible  genotype-phenotype 
correlations.  The  secondary  purpose  is  to  be  able  to  draw  diagnostic  algorithms  useful  to 
clinicians in selecting which patients submit to genetic testing. 
8
Two clinical  cohorts were set  up; one consisting in patients with diagnosis of AD, FTLD or 
related disorders, and the other made up of patients with CADASIL. The mutational analysis was 
performed by two main techniques: Denaturing High Performance Liquid Chromatography and 
direct  sequencing.  The  analyzed  genes  encompassed:  Amyloid  Precursor  Protein  (APP), 
Presenilin1 (PSEN1)  and Presenilin2 (PSEN2) for Alzheimer's Disease;  Progranulin (PGRN),  
Microtubule  Associated  Protein  Tau  (MAPT), Valosin  Containing  Protein  (VCP), Charged 
Multivesicular  Body  Protein  2B  (CHMP2B), TAR  DNA  Binding  Protein  (TARDBP) for 
Frontotemporal Lobar Degeneration and NOTCH3 for CADASIL. 
The  mutational  analysis  of  AD-  and  FTLD-associated  genes  led  to  the  identification  of  8 
mutations:  three  novel  variations,  PSEN1 p.Ile437Asn,  PSEN2 p.Thr18Met  and  PGRN 
p.His400ThrfsX12  and  five  already  described  substitutions,  PSEN2 p.Arg71Trp  and 
p.Met174Val, PGRN p.Phe86SerfsX170 and p.Thr272SerfsX10 and MAPT c.IVS10+16C>T. 
The molecular data and in silico analyses performed in this study argue in favour of pathogenetic 
nature for  Presenilins variations even though the role of some of them is debated in literature. 
The substitution identified in PGRN and MAPT are mutations whose pathogenic mechanism has 
already been described. 
The  clinical  phenotype  associated  to  identified  mutations  was  not  unique  and,  especially 
mutations in the PGRN gene showed a marked variability in clinical presentations, even within 
the same family.  Furthermore,  the identification of a FTD-MND family linked to a locus on 
chromosome 9 further emphasizes the genetic heterogeneity of FTLD.
The mutational screening of  NOTCH3 gene led to the identification of 21 different mutations, 
including 7 novel variations, distributed unevenly along the gene. A geographical clustering was 
observed with mutations identified only in patients living in North-East Italy, a few in North-
West and other in Central Italy. Haplotype analysis was performed to assess a possible founder 
9
effected underlying this regionalization but,  although consistent,  it  was not confirmed as the 
majority of mutations was associated with the most common haplotype. 
The results of this study together were useful to define diagnostic algorithms that could help 
clinicians to identify patients suggestive of a molecular basis of disease to address to genetic 
testing.
Riassunto
La  demenza  è  una  sindrome  clinica  caratterizzata  da  declino  cognitivo  le  cui  principali 
manifestazioni comprendono la perdita di memoria, deficit del linguaggio, deterioramento delle 
capacità  di  pianificazione  e  di  giudizio,  cambiamenti  di  comportamento  e,  non  di  rado, 
compromissione delle funzioni motorie ed infine dell'autonomia. Oggigiorno, si stima che circa 
36 milioni di persone in tutto il mondo siano affette da demenza, stime che, secondo le ultime 
predizioni,  è  destinata  a  crescere  fino  a  115  milioni  nel  2050.  Considerando  non  solo  la 
prevalenza bensì anche l'impatto sociale ed economico che questa malattia comporta, negli ultimi 
anni la ricerca scientifica sta investendo molte risorse in studi finalizzati all'identificazione delle 
cause e dei meccanismi patologici che sottendono a questa malattia. Lo scopo ultimo è quello di 
riuscire  ad  identificare  dei  trattamenti  terapeutici  efficaci  che  vadano  a  sostituire  le  cure 
palliative, le uniche disponibili oggi per questa malattia. 
Esistono diverse forme di demenza e, tra esse, la Malattia di Alzheimer (MA) è la più frequente, 
seguita dalla Demenza Vascolare (DV) e dalla Degenerazione Frontotemporale Lobare (FTLD), 
la quale, rappresenta il sottotipo più comune dopo la MA negli individui al di sotto dei 65 anni. 
Tutti e tre questi disordini possono presentare una componente genetica e, malgrado i notevoli 
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investimenti  e progressi  degli  ultimi anni per chiarirne le basi  molecolari,  la conoscenza dei 
meccanismi patologici che li determinano è ancora limitata. 
Tre forme di demenza, che possono avere una componente genetica, sono state incluse in questo 
studio:  la  Malattia  di  Alzheimer,  la  Degenerazione  Frontotemporale  Lobare  e  l'Arteriopatia 
Cerebrale Autosomica Dominante con Infarti Sottocorticali e Leucoencefalopatia (CADASIL), 
quest'ultima  rappresentante  un  sottotipo  di  DV.  I  principali  obiettivi  di  questo  studio  hanno 
compreso l'analisi  mutazionale  dei  geni  associati  a  queste  malattie  con  il  duplice  intento  di 
definirne le frequenze mutazionali in una casistica italiana e di valutare l'esistenza di eventuali 
correlazioni genotipo-fenotipo. Lo scopo finale era quello di definire degli algoritmi diagnostici 
utili ai medici specialisti nella selezione dei pazienti da sottoporre ad indagine genetica. 
Sono state allestite due coorti: una comprendente pazienti con diagnosi di MA, FTLD o disordini 
correlati, e l'altra, pazienti con CADASIL. L'analisi mutazionale è stata eseguita mediante due 
principali  approcci:  la  Cromatografia  Liquida  Denaturante  (DHPLC)  ed  il  sequenziamento 
diretto.  Sono  stati  analizzati  i  seguenti  geni:  proteina  Precursore  dell'Amiloide  (APP), 
Presenilina1  (PSEN1) e  Presenilina2  (PSEN2) per  la  Malattia  di  Alzheimer;  Progranulina  
(PGRN),  Proteina Tau Associata ai Microtubuli (MAPT),  Proteina Contenente Valosina (VCP), 
Proteina  di  Modificazione  della  Cromatina  2B  (CHMP2B),  Proteina  Legante  TAR  DNA 
(TARDBP) per la Degenerazione Frontotemporale Lobare ed il gene NOTCH3 per il CADASIL. 
L'analisi  mutazionale  dei  geni  associati  a  MA e  FTLD  ha  portato  all'identificazione  di  8 
mutazioni:  3  nuove  variazioni,  PSEN1 p.Ile437Asn,  PSEN2 p.Thr18Met  e  PGRN 
p.His400ThrfsX12  e,  cinque  sostituzioni  già  descritte,  PSEN2 p.Arg71Trp  e  p.Met174Val, 
PGRN p.Phe86SerfsX170 e p.Thr272SerfsX10 e MAPT c.IVS10+16C>T. I risultati delle analisi 
molecolari e delle simulazioni al computer depongono a favore di una natura patogenetica per le 
variazioni dei geni Presenilina, malgrado il ruolo di alcune di esse sia dibattuto in letteratura. Le 
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sostituzioni identificate nei geni PGRN e MAPT sono mutazioni il cui meccanismo patologico è 
già stato descritto. 
Il  fenotipo  clinico  riscontrato  nei  pazienti  con  le  mutazioni  identificate  non  era  univoco  e, 
specialmente  le  mutazioni  nella  PGRN erano  associate  ad  una  notevole  variabilità  delle 
manifestazioni cliniche, anche all'interno di una stessa famiglia. Inoltre, l'identificazione di una 
famiglia  con  diagnosi  di  FTD-MND  in  linkage  al  cromosoma  9  sottolinea  ulteriormente 
l'eterogeneità genetica delle FTLD. 
L'analisi mutazionale del gene  NOTCH3 ha portato all'identificazione di 21 diverse mutazioni, 
incluse 7 nuove variazioni,  distribuite  non uniformemente  lungo il  gene.  Si  è  osservata  una 
clusterizzazione delle  mutazioni  in aree geografiche diverse:  la  maggior  parte  identificate  in 
pazienti  provenienti  dal  nord-est  Italia,  alcune  nel  nord-ovest  ed  altre  nell'Italia  centrale. 
Nell'ipotesi che questa regionalizzazione rispecchiasse un effetto fondatore, si sono studiati gli 
aplotipi  associati  a queste mutazioni:  i  risultati,  sebbene compatibili,  non hanno permesso di 
confermare  l'effetto  fondatore  in  quanto  la  maggior  parte  di  queste  variazioni  cadeva 
nell'aplotipo più frequente. 
I  risultati  di  questo  studio,  complessivamente  sono  stati  utili  per  definire  degli  algoritmi 
diagnostici  che  potrebbero  aiutare  i  clinici  ad  identificare  i  pazienti,  suggestivi  di  una  base 
molecolare, da sottoporre ad analisi genetica. 
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1. Introduction
1.1 Definition of dementia
Dementia - taken from Latin, originally meaning "madness", from de- "without" + ment, the root 
of mens "mind" - is a generic term that describes chronic or progressive dysfunction of cortical 
and subcortical function that results in complex cognitive decline with the substantial loss of 
intellectual  abilities,  severe  enough to  interfere  with social  or  occupational  functioning.  The 
word dementia has acquired different meanings in different contexts. Originally, the term was 
often  used synonymously with  “insanity”  and “madness”  in  general,  as  a  clinical  syndrome 
regardless of etiology but, in the late 19th century it was recognized that there is an organic brain 
defect  at  the bases of  this  disorder [1].  In the 1940s,  Mayer-Gross,  Guttman [2]  and others 
identified  the  fundamental  defects  that  constitute  the  syndrome  of  dementia.  Memory 
impairment that  is  evident  in learning,  retention and recall  of  both new information and the 
distant  past  was  considered essential  to  the  diagnosis.  However,  dementia  is  more  than  just 
forgetfulness [3]. At least one of the following symptoms is usually required as well: impairment 
of  thinking,  reasoning,  communication,  orientation,  practical  abilities  (i.e.,  greater  difficulty 
maintaining learned skills or managing everyday activities) and personality changes resulting in 
lack of insight and judgement,  disinhibition,  aggressiveness, emotional bluntness and lack of 
empathy.  Other  psychiatric  features,  such  as  anxiety,  depression,  suspiciousness,  delusions, 
obstinacy and anancastic-like behaviour, seem to be more related to the patient’s awareness of, 
and reactions and responses to, cerebral dysfunction and its consequences. These secondary or 
accessory symptoms are also influenced by the patient’s  premorbid personality and previous 
experience, as well as related to better preserved brain functions [4]. However, dementia may 
evolve  according  to  extraordinary,  miscellaneous  and variable  scenarios,  so  that  a  symptom 
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should be interpreted cautiously. What is regarded as a primary symptom in one type or stage of 
dementia may be a secondary symptom in another [5, 6].
1.2 Epidemiology of dementia
Epidemiological studies define the occurrence of dementia as either prevalence - the proportion 
of people with dementia in a defined population at a given point in time - or incidence - the rate 
of new dementia cases that develop in a defined population during a specified time interval. 
Whereas prevalence indicates the probability that a person will have dementia at a certain point 
in time, incidence indicates the probability of developing the disease. Meta-analysis of several 
studies have led to the establishment of dementia occurrence not as a separate entity but, in 
relation to and influenced by other factors such as age, type of dementia, gender, geographic or 
ethnic factors. Considering these elements, dementia prevalence is closely related to age and, it is 
approximately 1% at ages 60–64, 1.5% at 65–69, 3% at 70–74, 6% at 75–79, 13% at 80–84, 24% 
at 85–89, 34% at 90–94 and 45% at 95 and up [7]. Alzheimer's Disease (AD) and Vascular 
Dementia (VaD) represent the most frequent type of dementia accounting for 60-70% and 10-
20% of the total prevalence respectively. Dementia is not gender specific, but results of several 
epidemiological  studies  found a  higher  prevalence  in  women  while  it  does  not  seem to  be 
influenced by the geographic origin of  patients. The incidence of dementia is also age-related, 
showing a rapid rate increase proportional to aging. The incidence rates of dementia per 1000 
person-years is approximately 1 at ages 60–64, 3–5 at 65–69, 8–10 at 70–74, 11–18 at 75–79, 
20–40  at  80–84,  30–60  at  85–89  and  50–120  at  90  and  up  [8,  9].  Incidence  rate  is  even 
influenced by the type of dementia and, for example, it decreases in VaD dementia after age 80 
while in Frontotemporal Dementia (FTD) it settles at very low levels (below 1) at any age. 
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1.3 Mortality and management of dementia
Due to increasing life expectancy the number of people suffering from dementia will increase 
rapidly in both developed and developing countries. More than 25 million people suffered from 
dementia  in  2000.  By  2030,  that  is  expected  to  rise  to  63  million,  65% of  whom in  less 
developed countries [10]. The increasing prevalence of dementia in the population make it one of 
the disease with the greatest social impact in the world (as well as for each affected individual). 
In fact, dementia represents a major cause of death in the elderly with an approximately double 
risk of dying than those without dementia and the estimated average survival time is 4.5 years 
from the onset of the disease [11, 12]. Given the progressive and disabling nature of dementia, 
patients frequently require institutional care with a consequent high demand and consumption of 
resources (emotional,  organizational and economic).  The rate of institutionalization is indeed 
relevant: roughly half of people with dementia move to institutions after 3 years from symptoms 
onset [13]. 
1.4 Risk factors for dementia
There are currently no drug treatments effective in fighting this disorder and this is mainly due to 
the  fact  that  the  underlying  etiological  and pathological  processes  are  not  well  defined.  So, 
considering the constant increase in the prevalence of dementia in the elderly population, the 
severity of this disease, its social impact, the best approach right now is to prevent or delay its 
onset. For this reason, many studies have focused their research on the identification of possible 
risk factors for the development of dementia.
The  most  significant  risk  factor  for  dementia  is  age:  both  the  incidence  and  prevalence  of 
disorders leading to dementia increase, almost exponentially, with age. Familial aggregation is a 
modest risk factor, valid only for Alzheimer's disease (this means that first-degree relatives of 
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patients with dementia have a higher risk of developing the disorder), while there are insufficient 
data to confirm its relevance in other forms of dementia. Moderately strong evidence argue in 
favour of an ApoE ε4 role as risk factor for dementia while it is a strong risk factor for AD after 
age-onset of 65 years [14, 15]. Smoking and moderate drinking are not risk factor for dementia 
while elevated blood pressure in midlife represents a moderate to strong risk factor for dementia 
in general and in particular for VaD and AD [16-19]. There is a positive correlation between 
diabetes and dementia while no significant association was identified for specific form like AD 
[20-23].  Also cholesterol,  obesity and homocysteine  are  not  associated  with  risk of  develop 
dementia with the exception of VaD [24-29]. Association studies between antihypertensive drugs 
and  dementia  demonstrated  that  these  treatments  have  protective  effects  in  elderly  people 
preventing the development of dementia (in particular VaD type); by contrast,  an association 
with statin treatment or non-steroidal anti-inflammatory drugs (NSAIDs) was not supported by 
significant evidences [30-36]. Several findings suggest that depression may be a risk factor for 
dementia, but the current scientific evidence is insufficient while there are moderately strong 
evidence of association with low education [37-40]. 
1.5 Classification of dementia
Dementia is not a single nosological entity but a collection of several different syndromes that 
differ in clinical presentation, neuroradiological features, etiology, neuropathology and molecular 
genetics.  The classification  of  dementia's  subtypes  has  been  controversial  since  the  late  19th 
century  and  the  major  obstacle  is  represented  by  the  different  approaches  of  specialists 
(neurologists, psychiatrists, geriatricians, internists)  in conceptualize the dementia syndromes 
without  integration  of  various  aspects  of  the  same  disorders.  Current  most  widely  used 
classifications are based primarily on clinical presentations or neuropathological findings and 
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presumed  etiological  factors.  Clinical  criteria  for  dementia  diagnosis  and  classification  are 
included in Diagnostic and Statistical Manual of Mental Disorders (DSM) 5th edition, and in the 
International Classification of Disease (ICD) 10th edition guidelines. ICD-10 defines four main 
categories of dementia: dementia of Alzheimer type (DAT), Vascular dementia (VaD), dementia 
in  disease  specified  elsewhere  (such  as  Pick's  disease  and  Creutzfeldt-Jacob's  disease),  and 
dementia “not otherwise specified”. A Swedish consensus report from dementia research centers 
in Lund, Gȍteborg, Stockholm and Umeå offered a clinical classification based on predominant 
clinical features, as well as type and location of the brain disease [41]. Three main etiology-
based categories were primary degenerative dementia, VaD and other secondary dementias.
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2. Alzheimer Disease
This disorder takes its name from the German psychiatrist and neuropathologist Alois Alzheimer 
who described in 1906 for the first time the histopathological brain changes in a patient who was 
followed up and treated  for  five years  until  her  death because of  the  onset  and progressive 
worsening  of  behavioural  and  psychiatric  symptoms,  including  paranoia,  delusions, 
hallucinations  and  impaired  memory  [42].  Alzheimer  identified  two  main  brain  changes, 
subsequently referred to as amyloid plaques and neurofibrillary tangles, that now are recognized 
as neuropathological hallmarks of this disorder [43].
2.1 Epidemiology
Alzheimer's Disease (AD) represents the most common form of dementia in elderly people as 
confirmed  by  data  from neuropathological  studies  where,  50-70% of  patients  with  an  ante 
mortem clinical diagnosis of dementia, presented brain histopathological changes consistent with 
a  diagnosis  of  AD.  Estimate  the  occurrence  of  this  disease  is  difficult  because  of  different 
inclusion  criteria used to define the epidemiological series. Nevertheless, the prevalence of AD 
is nearly 3% at age 65, with a rapid increase to around 50% of the population over 85 years [44, 
45]. Incidence rate also increases with age, from approximately 0.5% per year among individuals 
aged 65-70 to approximately 6-8% for individuals over age 85 [46,47].
2.2 Risk factors
2.2.1 Genetic risk factor 
The  epsilon  4  (ε4)  variant  allele  of  apolipoprotein-E (APOE)  is  the  only  one  worldwide 
recognized genetic risk factor for both sporadic and familial form of AD after 65 years. In a 
18
cross-sectional study of over 65, the  ε3/ε4 genotype (where  ε3 is the most frequent allele in 
control population – normal allele) had a 3-fold increased risk to develop AD, while the ε4/ε4 
genotype had a 14-fold increased risk compared with the  ε3/ε3 genotype (supporting a dose-
dependent effect) [48]. Indeed,  longitudinal studies have shown that  ε4 regulates the age of 
onset rather than susceptibility to the disease (the average age of onset is moved from 84 years in 
non-carriers of the  ε4, to 68 years in  ε4 homozygous) [49]. However, while  APOE is a well-
defined susceptibility factor, APOE ε4 is neither necessary nor sufficient for developing AD: half 
of individuals with apoE4 never develop AD regardless of how they live, while many patients 
with AD do not have ApoE4 [50]. Beyond any moral evaluation, considering the low sensitivity 
and specificity of the APOE genotyping for Alzheimer's, it can not be used as a routinary test, nor 
to confirm the clinical diagnosis of AD nor as a predictive test in healthy individuals.
2.2.2 Medical illness and behavioural risk factors
A family history of Down syndrome is associated with a 2-3-fold increase of Alzheimer's risk 
[51], also a history of depression may be associated to AD although is not clear whether it can 
actually represent an early stage of dementia rather than being a causal factor [52]. There is a 
positive association between AD and traumatic head injury even though it remains inconsistent 
[53].  Cardiovascular disease seems to act as a comorbidity [54, 55] and prospective studies have 
shown a 2-4-fold increase in AD risk, probably through with a complex interaction with cerebral 
vessels [56].
2.2.3 Behavioural protective factors
Mental and leisure activity (in particular frequent intellectual, passive and physical activities) as 
well as high education level have been associated with a lower risk to develop AD [57, 58]. Also 
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medications with anti-inflammatory drugs may be associated with a lower risk to develop AD, 
probably reducing local inflammatory response to amyloid deposition in the brain [59]. 
2.3 Clinical diagnosis of Alzheimer's disease
The National  Institute  of  Neurological  Disorders  and Stroke-Alzheimer  Disease and Related 
Disorders (NINCDS-ADRDA) are the most frequently used criteria for AD [60]. These criteria 
classify AD based on the degree of certainty of the diagnosis, and whether AD is associated with 
other disease processes (i.e., Probable vs. Possible  AD). The criteria for probable AD include 
dementia  established  by  clinical  examination  and  documented  by  the  mini-mental  state 
examination (MMSE) [61], dementia test score [62] or a similar examination, and confirmed by 
neuropsychological tests, deficits in two additional areas of cognition, progressive deterioration 
of memory and other cognitive functions, no disturbance of consciousness, onset between the 
ages of 40 and 90, most often after 65, and absence of systemic disorders or other brain disease 
that could account for the progressive deficits. The diagnosis of probable AD is supported by 
progressive deterioration of specific cognitive functions, such as aphasia, apraxia and agnosia, 
impaired  daily  life  activities  and  altered  patterns  of  behaviour,  family  history  of  similar 
disorders,  laboratory  results  showing  normal  lumbar  puncture,  normal  or  non-specific  EEG 
changes, evidence of cerebral atrophy on CT with progression documented by serial observation. 
By  contrast,  the  diagnosis  of  Possible  AD  requires  a  history  and  progression  of  dementia 
consistent with AD, but in which clinical  evidence of some other disease process is  present 
(including cerebrovascular disease or stroke, head injury, depression,..). 
2.4 Clinical presentation of Alzheimer's disease
The clinical hallmark symptom of AD is impaired memory and, in particular, auditory verbal and 
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visual  delayed  recall,  confrontation  naming  and  cognitive  flexibility/divided  attention  tests 
represented the best predictors of AD [63]. Actually,  AD is not a unique entity starting with 
memory deficit and evolving with subsequent impairments in other cognitive functions, indeed, 
it  may have different clinical  presentation.  Language deficits  are the second most prominent 
cognitive manifestation of AD and in some cases they can be the initial clinical symptom. Also 
fluency and, to a lesser degree, auditory comprehension are usually impaired in AD [64]. In the 
early phases of the disease visuoconstructional and visuospatial drawing abilities are impaired, as 
well as problem-solving, concept formation, cognitive flexibility accompanied by ideational or 
ideomotor  apraxia  [63,  64].  Importantly,  most  AD  patients  are  unaware  of  their  cognitive 
deficits, or are unable to recognize the magnitude of these deficits [65].
The most common neurological, non-cognitive, signs in AD patients are myoclonic movements, 
and extrapyramidal signs (EPS) which manifest only with disease progresses. The characteristic 
EPS in AD are  bradykinesia  and rigidity which  are  often  associated  to  a  severer  and faster 
evolution of the disease [66]. Psychotic symptoms (e.g., delusions, hallucinations) and disruptive 
behaviours (e.g., aggressive behaviour, psychomotor agitation, wandering) are common in AD 
patients while depressive symptoms can occur in up to 86% of the cases [64, 65, 67].  
AD  may  also  manifest  with  atypical  clinical  presentation,  overlapping  with  other 
neurodegenerative disorders: as frontal lobe syndrome with significant behavioural or executive 
dysfunctions (resembling  Frontotemporal Dementia); with prominent language impairment as 
primary symptom (resembling Primary Progressive Aphasia) or with a corticobasal syndrome 
(resembling Corticobasal Degeneration).   
2.5 Age at onset of Alzheimer's disease and illness duration
Both age at onset and disease duration vary considerably from study to study, based on autopsy 
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proven cases and in families with identified AD-associated genes mutations. Nevertheless, two 
groups were arbitrary defined based on age of onset: Early-Onset AD (EOAD) with onset usually 
in the 40s or early 50s (range: 30-60 years) with a rapid progression of the symptoms lasting for 
nearly 5-6 years before death; and Late-Onset AD (LOAD) with onset age after 60-65 years and 
a 8-10 years typical disease duration. 
2.6 Structural and functional neuroimaging findings in Alzheimer's disease
The first degenerative changes in the disease occur in the medial temporal lobe (MTL), including 
the  hippocampus  and entorhinal  cortex  (Appendix  1).  A substantial  number  of  studies  have 
shown that  Magnetic  Resonance  Imaging (MRI)  measurements  of  hippocampal  atrophy can 
distinguish Alzheimer's disease from cognitively normal elderly people with 80-90% accuracy 
[68]. Moreover, considering that entorhinal cortex volume might precede hippocampal atrophy, 
MRI  measurements  of  its  volume  have  a  high  predictive  value  for  incipient  disease  in  its 
prodromal phase [69, 70].       
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Fig. 1. MRI and FG-PET in Alzheimer's 
Disease 
A: coronal MR images of a norm al older 
subject (left) and a patient with Alzheim er’s 
disease (right). Hippocam pus (H) and 
entorhinal cortex (EC) are labeled on the 
normal subject and show severe atrophy in the 
AD patient. B: FDG-PET im ages of a patient 
with clinically diagnosed frontotemporal lobar 
dem entia (upper row) and a patient with 
clinically diagnosed Alzheim er’s disease (lower 
row). The FTLD patient shows reduced glucose 
metabolism  in frontal cortex (F), whereas the 
AD patient shows reduced m etabolism in 
temporoparietal (TP) and posterior cingulate 
cortex and precuneus (PC).
[Jagust W, et al. Positron em ission tomography 
and m agnetic resonance imaging in the 
diagnosis and prediction of dem entia. 
Alzheimer’s & Dem entia. 2006;2:36–42]
A
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Functional imaging by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) are 
useful  to  differentiate  AD  patients  from normal  elderly  people  with  a  93% sensitivity  and 
specificity [71]. FDG-PET in AD patients discloses a characteristic pattern of hypometabolism in 
the temporal, parietal and posterior cingulate cortex [68].    
2.7 Cerebrospinal fluid (CSF) markers of Alzheimer's disease
Biological markers represent useful tools as indirect measure of disease severity and progression. 
In the case of AD, cerebrospinal fluid (CSF) may be considered the better source of diagnostic 
biomarkers given is direct contact with the extracellular space of the brain where AD pathology 
is  restricted  and  biochemical  changes  are  likely  to  be  reflected.  AD-specific  biomarkers, 
reflecting the central pathogenic processes of amyloid β aggregation and hyperphosphorylation 
of tau protein, are represented by amyloid β1-42 (Aβ42), total tau (t-tau) and phospho-tau (p-tau) 
[72-74]. In AD the concentration of Aβ42 in cerebrospinal fluid is low and that of t-tau is high 
compared with those in healthy controls [72, 73]. Concentrations of different phosphorylated tau 
epitopes may also be high [75, 76]. Noteworthy, the sensitivity and specificity of these markers 
are higher, reaching a elevated diagnostic value, if are combined [77, 78]. 
2.8 Treatments
The nowadays recognized effects of AD neuropathogenesis process are deficiencies of the brain 
cholinergic system and other neurotransmitters. 
Drugs with symptomatic  effects  on behaviour  and cognition have been developed,  including 
acetylcholinesterase  inhibitors  such  as  donepezil,  rivastigmine  and  galantamine  [79]. 
Memantine, an NMDA receptor antagonist, has shown some effectiveness in the treatment of 
moderate to severe AD, leading to improvement in learning and memory processes controlled by 
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NMDA receptor [80]. Risperidone and olanzapine have shown efficacy in reducing the rate of 
common  behavioural  signs  in  AD  patients,  such  as  aggression,  psychomotor  agitation  and 
psychosis  [81,  82].  Other  drugs  treatments  under  investigation  include  the  use  of  anti-
inflammatory agents (NSAIDs), estrogens, nerve growth factors, statins, BACE inhibitors and 
antioxidants [83]. 
Disease-modifying therapy by Aβ immunisation obtained good results in AD transgenic mice 
models with fibrillar Aβ [84], where Aβ deposition were attenuated but, on the contrary, human 
trials of this approach was halted because of encephalitis in a few subjects [85].  
2.9 The genetics of Alzheimer's disease
Alzheimer's disease is a classic example of a genetically complex disorder that may present in 
two different  forms:  familial  (rare)  versus  seemingly non-familial  (common)  cases.  Familial 
forms  account  for  nearly  25% of  all  AD cases  and,  only 1% are  Early-Onset  Familial  AD 
(EOFAD) with an autosomal dominant pattern of inheritance of the disease while many of the 
remaining familial cases have a Late-Onset (LOAD) most often not showing any overt pattern of 
familial segregation. 
2.9.1 Early-Onset Familial Alzheimer's Disease (EOFAD)
Early-Onset  Familial  Alzheimer's  Disease  (EOFAD)  is  a  single-gene  disorder,  mendenianly-
inherited disorder, associated with mutations in three genes:  Amyloid Precursor Protein (APP), 
Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) [86-88]. These three loci, account for different 
proportion of EOFAD with PSEN1 being the most frequent mutated gene (20-70% of EOFAD) 
followed by APP (10-15%) and PSEN2 that is the rarest cause of EOFAD. Clinical presentation 
of EOFAD patients do not differ from non-familial AD cases nor from LOAD.
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2.9.1.1 Amyloid Precursor Protein (APP)
Amyloid  Precursor  Protein (APP)  gene,  located  on  chromosome  21q21,  encodes  a  type-I 
integral-membrane  protein  expressed  in  many  tissues  and  concentrated  in  the  synapses  of 
neurons.  Experimental  evidences  implicate  this  protein in  neural  plasticity and regulation of 
synaptogenesis  [89,  90].  The  precursor  protein  may  undergo  a  proteolytic  cleavage  by 
alternatively an α- or β-secretase leading to the formation of the soluble fragment amyloid-α 
peptide  (sAPPα)  and C-terminal  transmembrane  10  kDa fragment  in  the  first  case,  and  the 
soluble  amyloid-β peptide (sAPPβ) and  C-terminal  transmembrane 12 kDa fragment  in  the 
second.  The  10 and 12 kDa fragments  are  subjected to  a  further  proteolytic  cleavage by γ-
secretase,  producing  two  different  extracellular  peptides:  p3  and  Aβ  respectively,  and  a 
cytoplasmic fragment (AICD). In reality, there are two γ-secretase cleavage sites so there may be 
the  formation of  two different  Aβ peptide,  40 (Aβ40) or  42 (Aβ42) aminoacids  long.  Aβ42 
peptide represents the main component of neuritic plaques, the neuropathological hallmark of 
AD, and it is encoded only by exon 16 and 17 of the gene. 
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Fig. 2. The metabolism of the largest isoform of amyloid precursor protein (APP770) with amyloid-β and p3 
generation.
The first 28 residues of the Aβ domain are located outside the membrane whereas the remaining 12–14 residues are in 
the transm em brane dom ain of APP. APP can be processed along two m ain pathways: (A)  the nonam yloidogenic 
pathway and (B) the amyloidogenic pathway.
Aβ: Amyloid-β; AICD: APP intracellular dom ain; APP: Am yloid precursor protein; CTF: C-term inal fragm ent; KPI: 
Kunitz protease inhibitor dom ain; sAPP: Soluble APP; SP: Signal peptide.
[Portelius E, et al. Targeted Proteom ics in Alzheim er's Disease: Focus on Am yloid-Beta. Expert Rev 
Proteom ics. 2008;5(2):225-237]  
Mutations in APP lead to an unbalance in the formation of Aβ peptides with an increase of Aβ42 
isoform. There are two types of APP mutations:
• missense mutations, in exon 16 and 17, mostly localize near secretases cleavage sites 
forming  mutational  clusters  such  as  Swedish,  Flemish,  Dutch,  Florida  and  London 
mutations [91-95];
• entire gene duplication [96].
Clinical presentation associated to APP mutations is typical of AD, with an age at onset between 
40-60 years.
2.9.1.2 Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2)
Presenilin 1 and its high homologous Presenilin 2 genes, located on chromosome 14q24.2 and 
1q42.13 respectively, codify for two polytopic membrane proteins forming the catalytic subunit 
of γ-secretase complex involved in APP cleavage [97]. 
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Fig. 3. PSENs and g-secretase complex in amyloid b-peptide production and neurodegeneration.
The g-secretase com plex cleaves Notch (left) to generate a fragm ent (NICD) that m oves to the nucleus and regulates the 
expression of genes involved in brain development and adult neuronal plasticity. The complex also helps in generating the 
amyloid b-peptide (Ab; centre). Mutations in presenilin-1 that cause early-onset Alzheimer's disease enhance g-secretase activity 
and Ab production, and also perturb the ER calcium  balance. Consequent neuronal degeneration m ay result from  membrane-
associated oxidative stress, induced by aggregating form s of Ab (which create Ab plaques), and by the perturbed calcium  
balance.
[Mattson M, et al. Neurobiology: Ballads of a protein quartet. Nature. 2003;422:385-387]  
Both proteins are expressed ubiquitously, in peripheral tissues and in the brain where they mainly 
localized in synaptic vesicles, synaptic adhesion site and growth cones of neurites [98]. When 
secreted, PSEN1 and PSEN2 undergo a proteolytic cleavage (probably by caspase3) leading to 
the formation of a N-terminus (NTF) and a C-terminus fragments (CTF). Released fragments 
interact  with  nicastrin  (Nct),  anterior  pharynx defective  1  (Aph-1)  and presenilin  enhancer2 
(PSENEN) proteins to form the γ-secretase complex [99]. 
Presenilins identified mutations lead to an increase in the ratio of Aβ42 to Aβ40 peptides; this 
change in isoforms balance seems to occur through increased Aβ42 production, decreased Aβ40 
production or a combination of both changes [100]. The majority of  Presenilins  mutations are 
missense substitutions mostly localized in transmembrane domains. 
Presenilins mutations are associated to different clinical presentation: age at onset is earlier in 
PSEN1 usually in  the 40s  and 50s,  while  in  PSEN2 it  ranges  from 40 to  75 years;  disease 
duration is  shorten in  PSEN1 mutation carriers  with a  complete  disease penetrance (95% in 
PSEN2). 
2.9.2 Late-Onset Alzheimer's disease (LOAD)
Late-Onset  Alzheimer's  Disease  (LOAD)  is  characterized  by  a  considerable  more  complex 
pattern of genetic and non-genetic factors that remains only poorly understood. Apolipoprotein E 
(APOE) is the only genetic risk factor that has been demonstrated to be associated with both 
familial and sporadic late-onset AD [101, 102]. Since the discovery of this association, no other 
genetic risk factors has been found to consistently confer susceptibility to disease risk, despite 
intensive efforts in many laboratories worldwide [103]. 
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2.9.2.1 Apolipoprotein E (APOE)
Apolipoprotein  E (APOE),  located  on  chromosome 19q13.32,  codifies  for  an  apolipoprotein 
playing an important role in the regulation of plasma lipid and cholesterol metabolism within 
many organs and cell types in human body [104]. 
Three major alleles occur at the APOE locus - ε2, ε3 and ε4 – which translate into combination 
of two aminoacid changes at residue 112 and 158 of the apoE protein (ε2: Cys/Cys; ε3: Cys/Arg; 
ε4: Arg/Arg, respectively). While the ε4 allele has been demonstrated to significantly increase 
the risk for AD, its minor allele - ε2 – has been associated with a decreased risk [105]. The 
potential pathophysiological effects of  APOE assume that the different variant alleles directly 
influence Aβ-accumulation by affecting Aβ aggregation or clearance [106-108].
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Fig. 4. Roles of apoE in lipid redistribution among cells in the CNS and apoE isoform-specific 
differences in neuropathology. 
ApoE is synthesized by astrocytes, activated m icroglia, and neurons. Three potential detrimental roles 
for apoE4: (1) enhanced Aβ production, (2) potentiation of Aβ1–42-induced lysosom al leakage and 
apoptosis, and (3) enhanced neuron-specific proteolysis resulting in translocation of neurotoxic apoE4 
fragm ents in the cytosol, where they are associated with cytoskeletal disruption and mitochondrial 
dysfunction. 
[Mahley R, et al. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, 
including Alzheim er’s disease. PNAS. 2006;103(15):5644-5651]
2.9.3 Other putative Alzheimer's disease loci
The association between APP, PSEN1, PSEN2, APOE and Alzheimer's disease was defined with 
the widely used candidate gene approach but was not successful in identifying other loci  of 
potential  relevance,  probably  because  this  method  is  focused  on  a  preconceived  functional 
hypothesis. To overcome this limitation recent studies have used a different approach based on 
large-scale genotyping technologies that enable to perform comprehensive, unbiased genome-
wide association (GWA) analyses. At least fifteen Alzheimer's disease genome-wide association 
studies  (GWAS) have been  published in  the last  three years  [109],  and the most  significant 
findings of all associative studies (study design, sample size, results, and polymorphism details, 
including genotype and allele frequencies) are collected and reported in AlzGen internet database 
(http://www.alzgene.org)  maintained by Bertram  et al. [103], where results of meta-analyses 
studies are also available. Nearly forty genes have shown a statistically significant association 
with AD in different GWAS but, none of these obtained consistent replication in the follow-up 
data  sets  except  for  clusterin (CLU),  complement  component  3b/4b  receptor  1 (CR1), 
phosphatidylinositol  binding  clathrin  assembly  protein (PICALM)  [110,  111]  and  bridging 
integrator 1 (BIN1) [112]. Interestingly, all four of these genes codify for proteins involved in Aβ 
metabolism,  in  particular:  CLU  seems  involved  in  Aβ  fibrillization[113],  CR1  in  amyloid 
clearance [114], PICALM and BIN1 in Aβ transport and clearance [115, 116].     
2.10 The neuropathology of Alzheimer's disease
2.10.1 Macroscopic findings
The external appearance of the brain in AD is not a useful diagnostic tool, usually presenting 
mild generalized frontotemporal  atrophy not greater  than that  observed in  a  number of age-
matched control brains [117]. There are no pathognomonic changes on brain slices but, usually 
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are observed atrophy of hippocampal formation, some expansion of the third ventricle whereas 
the aqueduct and fourth ventricle have normal size. The white matter  do not usually present 
visible abnormalities but, some reduction in overall volume (between 3 and 19%) [118]. In the 
deep grey nuclei atrophy is restricted to the caudate and putamen while globus pallidus, thalamus 
and substantia innominata are spared. The other consistent finding in AD is loss of pigmentation 
in the locus ceruleus.   
2.10.2 Microscopic findings
A definite and unbiased diagnosis of AD (as well as that of other dementias) may derived only 
from immunohistochemical analyses of brain specimens. The major microscopic findings in AD 
are  extracellular  senile  and  neuritic  plaques,  intracellular  neurofibrillary  tangles,  dystrophic 
neurites and neuropil threads. 
Senile or  diffuse  plaques consistent  of  Aβ peptides,  not  in  the  β-pleated sheet  conformation 
typical  of  amyloid,  not  associated  to  astrocytic  and  microglial  cells  activation  and  without 
involvement of neuropils. 
Neuritic plaques are composed of a  central  amyloid core,  constituted by β-pleated sheet  Aβ 
peptides,  with  finger  of  fibrillary  amyloid  extending  into  the  surrounding  neuropil  and 
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Fig. 5. Neuropathological hallmarks of Alzheimer's Disease.
A: Typical diffuse plaque with irregular outline and neuritic plaques showing the characteristic central core of amyloid 
surrounded by a neuritic reaction. B: neurofibrillary tangle. C: amyloid angiopathy with am yloid deposition in 
cerebral arteries. 
association with activated glial cells. Both senile and neuritic plaques are made up of 39 to 43 
aminocid  long  Aβ  peptides  even  though  the  most  frequent  species  are  Aβ1-40  and  Aβ1-42 
peptides.  While the presence of senile plaques is  visualized by Bielschowsky and MS silver 
stains, Congo red stain is specific for neuritic plaques.    
Neurofibrillary  tangles,  dystrophic  neurites  and  neuropil  threads consist  in  accumulation  of 
hyperphosphorilated tau protein in the form of paired helical filaments (PHF). The visualisation 
of all these changes requires the use of several specific stains, different from the more routine 
histological stains like haematoxylin and eosin, not useful to define the degree of neurofibrillary 
pathology. 
All  these  microscopic  findings  are  widespread  not  only  in  cortical  regions  but  also  and 
conspicuously in subcortical structures that are responsible for the clinical symptoms resulting 
from the loss of cholinergic, serotoninergic and noradrenergic supply.
Not  infrequently,  amyloid  deposition  in  AD  brains  may  occur  in  the  cerebral  arteries 
(congophilic angiopathy) as occurs in other disorders (i.e., Icelandic form of hereditary cerebral 
haemorrhage with amyloidosis – HCHWA). 
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3. Frontotemporal Lobar Degeneration
Frontotemporal  Lobar  Degeneration  (FTLD)  represents  the  second  most  common  form  of 
presenile primary cortical dementia after Alzheimer's disease. FTLD is a pathological term used 
to  define   three  clinical  and  neuropathologically  heterogeneous  syndromes  characterized  by 
personality  and/or  behavioural  changes  or  language  dysfunctions:  frontotemporal  dementia 
(FTD), progressive nonfluent aphasia (PNFA) and semantic dementia (SD).   
3.1 Epidemiology
The prevalence of FTLD is not well defined as several population-based studies have reported 
different estimates. Two UK and one Italian studies reported the highest prevalence of 15-22 per 
100,000 inhabitants in the age group 45-64 years [119-121] while in a Dutch series the estimate 
was 4 per 100,000 in the same age range [122]. Two studies investigated the incidence of FTLD 
obtaining consistent results with incidence rate of nearly 4 per 100,000 person-years in the age-
group of 45-64 years [123, 124]. 
3.2 Risk factors
Unlike Alzheimer's disease, only few studies have investigated risk factors of FTLD and those 
already reported mainly regard candidate genetic risk factors. The main difficulties in assessing 
this topic derived from the wide heterogeneity in clinical and neuropathological presentation of 
these syndromes, affecting the accuracy in patients enrollment. Some of the candidate genetic 
risk factors of FTLD include: 4 SNPs of Progranulin gene [125-127], haplotype B of Cystatin C 
[128], the allele ε4 of apolipoprotein E [129], heterozygosity of the codon 129 polymorphism of 
Prion Protein [130] and haplotype H1 of  Microtubule-associated Protein Tau [131]. All these 
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association findings did not obtained consistent replication in the following studies. Two recently 
association studies have indicated ubiquitin associated protein 1 [132] and three SNPs within the 
TMEM106B gene [133] as possible candidate risk factors, even though these results have not yet 
been tested in other replication analyses.  
3.3 Clinical diagnosis of Frontotemporal Lobar Degeneration
Clinical diagnosis of FTLD is made according to international guidelines reported in Consensus 
clinical diagnostic criteria of The Lund and Manchester Groups [134] and their implementation 
by Nearly et al.  [135]. These criteria encompass core and supportive diagnostic features that 
differ from one to another clinical syndrome (FTD vs PNFA vs SD) but have in common an 
insidious onset and gradual progression, and several supportive (onset before 65 years, positive 
family history of similar disorder in first-degree relative, bulbar palsy, muscular weakness and 
wasting) or diagnostic exclusion (clinical, biochemical, neuroimaging) features.  
3.4 Clinical presentation of Frontotemporal Lobar Degeneration
Frontotemporal  Lobar  Degeneration  encompasses  three  distinct  clinical  syndromes: 
Frontotemporal  Dementia  (FTD),  Progressive  Nonfluent  Aphasia  (PNFA)  and  Semantic 
Dementia (SD). Even though they are distinguished on the bases of predominant onset symptoms 
- behavioural changes in FTD and language impairment in PNFA and SD – which are associated 
to  distinct  regional  pattern  of  brain  atrophy,  these  clinical  entities  tend  to  overlap  with  the 
progression of the disease, as a result of atrophy spread in several brain regions. 
3.4.1 Frontotemporal dementia 
Frontotemporal dementia (FTD) is characterized by personality and behavioural changes which 
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may be revealed in an apathetic and passive state or as a disinhibited and childlike variant [136, 
137].  Not  uncommonly,  these changes  are  so dramatic  to  be misdiagnosed as  depression or 
mania respectively. Patients frequently show emotional shallowness, with loss of warmth and 
empathy towards others, appearing self-centered. There is a dramatic loss of insight, with frank 
denial or a very shallow recognition of the illness. Stereotyped behaviours are very common, 
ranging from aberrant motor behaviours (i.e., rubbing, picking, clapping, rocking) to complex 
compulsions (repetitive checking of clock, hygiene rituals, counting) [138]. Changes in eating 
behaviour  (overeating,  weight  gait)  and hyperorality (excessive drinking,  alcohol  intake)  are 
highly characteristic. Patients are often perseverative, discussions focus on recurrent themes and, 
in later  disease stages, they manifest  echolalia and mutism. Behavioural  changes are usually 
accompanied  by  less  severe  cognitive  impairment  mainly  characterized  by  disorganization, 
difficulties  in  planning,  problem-solving,  affected  executive  functions,  working  memory, 
attention, abstract reasoning [139]. Unlike Alzheimer's disease, verbal and visual memory as well 
as temporal and spatial orientation and praxis are usually preserved in FTD.
3.4.2 Progressive Nonfluent Aphasia
The main clinical findings in Progressive Nonfluent Aphasia (PNFA) is represented by impaired 
speech production [140]. Patients disclose difficulties in appropriate words finding, a slow rate 
of speech, with agrammatisms, phonemic paraphasis errors. Repetition is impaired, reading is 
non-fluent and effortful while language comprehension is preserved. In contrast to FTD, PNFA is 
not  characterized by personality or behavioural  changes in the first  stages,  spatial  skills  and 
short-term memory are spared until late in the course. These prominent difficulties in language 
production make cognitive functions seem more affected than they really are,  in fact,  PNFA 
patients lead an almost normal life [141].  
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3.4.3 Semantic Dementia
While PNFA is a disorder of word production, Semantic Dementia (SD) is characterized by a 
progressive loss of knowledge about words and concepts [142]. As in the case of FTD, also SD 
may manifest in two different variants (depending of regional localization of brain atrophy). One 
variant  is  characterized by fluent,  anomic aphasia  with word-finding difficulties  and naming 
(semantic memory), loss of words meaning even though reading and writing are preserved. SD 
patients often disclose inability to recognize and put objects in their correct context. Depression 
is another prominent finding while behavioural disturbances are uncommon in the first stages of 
the disease [143]. The other SD presentation is characterized by behavioural changes with flat 
affect, emotional blunting and alteration in social conduct [144]. Patients may exhibit excessive 
verbal  output,  hyperphagia  and loss  of  fear.  In  the late  stages  of  the disease,  these patients 
disclosed other behavioural symptoms recalling those of FTD.      
3.4.4 Frontotemporal lobar degeneration with motor neuron disease
A small  number  of patients  with a  clinical  syndrome of FTLD (the most  common is  FTD), 
variable from 4 to 15%, may develop signs of motor neuron disease (MND) during the course of 
the illness and its presence worsens and speeds up the progression of the disease. MND is a 
neurodegenerative disorder characterized by degeneration of upper and lower motor neurons, 
leading  to  progressive  muscle  wasting,  weakness  and  spasticity  which  ultimately  results  in 
profound global paralysis and death, usually due to respiratory failure. Roughly 50% of MND 
patients develop behavioural changes fulfilling criteria for FTLD syndrome [145]. The clinical 
overlapping between these two entities is also associated to a co-occurrence of neuropathologic 
findings  of  the  single  disorder,  adding  further  evidences  arguing  in  favour  of  a 
clinicopathological continuum.   
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3.5 Age at onset of Frontotemporal Lobar Degeneration syndromes and illness duration
Onset is most commonly in middle age between 45 and 65 years although there is a broad range 
in the age at onset (21-85 years) with about 20% of patients older than 65 years. Also illness 
duration is variable ranging from 2 to 20 years, with an average of 8 years, reduced to nearly 3 
years in FTLD-MND cases.
3.6  Structural  and  functional  neuroimaging  findings  in  Frontotemporal  Lobar 
Degeneration
During the first stages of the disease, there are no prominent structural brain changes detectable 
by MRI but, as the disease progresses, focal atrophy of frontal and anterior temporal structures is 
visible on T2 and T1 images (the latter are useful to detect atrophy asymmetry, very common in 
FTLD  subjects).  Distribution  of  atrophy  among  different  brain  regions  varies  according  to 
associated FTLD clinical syndrome. 
In FTD atrophy mainly affects frontal and paralibic regions (anterior cingulate cortex and frontal 
insula) as well  as hippocampus,  striatum and thalamus,  usually with a right-hemisphere bias 
[146]. Asymmetrical atrophy in the left hemisphere mostly localized in the inferior frontal lobe 
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Fig. 6. Brain MRI of FTLD syndromes. 
(A) Frontal atrophy on axial fluid attenuated inversion recovery MRI of a patient with behavioural variant 
of FTD (bvFTD). (B) Axial T1-weighted image with left tem poral lobe atrophy in a patient with semantic 
dem entia (SD). (C) Coronal T1-weighted MR im age of a patient with progressive non-fluent aphasia 
(PNFA) and left inferior frontal and superior tem poral atrophy. 
[Seelar H, et al. Clinical, genetic and pathological heterogeneity of frontotem poral dem entia: a review. J 
Neurol Neurosurg Psychiatry. 2010; Oct 22. Epub ahead of print]
and anterior insula is a common finding in PNFA patients [147]. Left hemisphere, anterior and 
inferior temporal lobes are usually affected by atrophy in patients with SD [148]. MRI in patients 
with FTLD-MND usually discloses atrophy in motor and premotor cortex,  anterior temporal 
lobes, and middle and inferior frontal gyri [149].
Functional imaging results essentially mirror the structural imaging findings for each clinical 
subtypes and these techniques are useful tools to differentiate FTLD from other dementias, in 
particular from AD. The more widely used functional imaging assays in FTLD diagnosis are 
18FDG-PET and 99mTC-HMPAO SPECT which reveal frontal and anterior temporal lobes glucose 
hypometabolism or hypoperfusion [150-152]. 
3.7 Cerebrospinal fluid (CSF) and plasma markers of Frontotemporal dementia
Unlike Alzheimer's disease, CSF profile is not useful in making a diagnosis of FTLD in fact, 
several studies reported conflicting results. CSF t-tau in FTLD may settle down to normal values 
or it may vary widely (either increase or decrease), phosphorylated tau is normal compare to AD 
and also Aβ1-42 levels are often unchanged [153]. 
ELISA quantification of plasma, serum and CSF levels of progranulin protein are a useful tool to 
identify  and  discriminate  FTLD patients  harbouring  a  PGRN mutation  [154],  while  several 
studies are investigating the possible diagnostic relevance of plasma or CSF TDP-43 levels for 
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A B
Fig. 7. 18F-FDG brain images in FTLD.
Differential glucose m etabolism pattern in healthy controls (A) and FTLD patients (B).
[Koeppe RA, et al. 11C-DTBZ and 18F-FDG PET Measures in Differentiating Dem entias. Journal of 
Nuclear Medicine. 2005;46(6):936-944.] 
which  early  results  indicated  an  association  with  neuropathologically  confirmed  FTLD-TDP 
[155].  
3.8 Treatments
There are currently no standard pharmacological treatments for FTLD but only symptomatic 
drugs  therapies,  focused  on  treating  behavioural  symptoms  (disinhibiton,  impulsiveness, 
depression) and compulsive and stereotypical behaviours. Moreover, most drugs are designed to 
settle again the balance in the neurotransmitters systems that, like AD, are highly affected in this 
disorder (serotonergic, glutamatergic systems) [156]. Despite these therapeutic approaches, none 
of these treatments delay the progression of the disease.    
3.9 The genetics of Frontotemporal Lobar Degeneration
A positive family history occur in up to 40% of patients with FTLD, with an autosomal dominant 
pattern of inheritance in roughly 10% of cases consistent with a strong genetic component of the 
disease [157-159]. Actually, several studies, carried out over the past fifteen years, allowed to 
identify  some  of  the  molecular  bases  of  this  disorder,  strongly  emphasizing  the  genetic 
heterogeneity  of  this  disorder.  Mutations  in  two  genes,  Microtubule-Associated  Protein  Tau 
(MAPT) and Progranulin (PGRN) explain nearly 40% of familial cases, representing the major 
causes of FTLD unlike the genes Valosin Containing Protein (VCP) and Charged Multivesicular  
Body Protein 2B (CHMP2B) that have a low mutational frequency accounting for less than 4%. 
TAR-DNA Binding Protein (TARDP) and  Fused in Sarcoma (FUS) genes mutations have been 
identified in 5% of Amyotrophic Lateral Sclerosis (ALS) subgroup of MND but occasionally 
also in familial cases of FTLD-MND. A locus on chromosome 9p13.2-21.3 have been associated 
to several families with FTLD-MND even though the causative gene has not yet been identified. 
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3.9.1 Microtubule-Associated Protein Tau
Microtubule-Associated Protein Tau (MAPT) gene, located on chromosome 17q21, codifies for a 
low molecular weight protein,  tau, belonging to MAP family of proteins plenty expressed in 
central nervous system where their main function is binding and stabilization of microtubules, 
mantaining neuronal integrity and axoplasmic transport [160]. In adult brain, MAPT is expressed 
in six isoforms that differ in two regions: N-terminus domain for alternative splicing of exon 2 
and 3, and C-terminus domain for the presence of three or four tandem repeats sequences (3R-
tau or 4R-tau), codified by exon 9 to 12, involved in microtubules binding [161]. The interaction 
between tau and microtubules is  tightly regulated by phosphorylation state of tau: nearly 80 
phosphorylation sites clustered around the repeats and, hyperphosphorylation of these sites has a 
negative effect on proteins interaction.   
MAPT mutations,  first  associated  to  frontotemporal  dementia  with  parkinsonism  linked  to 
chromosome 17 (FTDP-17) in 1998, affect exon 1 and 9 to 13 codifying for the C-terminus 
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Fig. 8. Tau Structure and 
Function.
Four repeat sequences (R1-R4) 
make up the m icrotubule-binding 
domain (MBD) of tau. Norm al 
phosphorylation of tau occurs on 
serine (S; inset, above horizontal 
bar) and threonine (T; inset, below 
horizontal bar) residues, numbered 
according to their position in the 
full tau sequence. 
Hyperphosphorylated sites specific 
to paired helical filament tau in 
Alzheimer’s disease tend to flank 
the MBD. Tau binding promotes 
microtubule assembly and stability. 
Excessive kinase, reduced 
phosphatase activities, or both 
cause hyperphosphorylated tau to 
detach and self-aggregate and 
microtubules to destabilize.
[Querfurth HW, et al. Mechanisms 
of disease. Alzheimer's Disease. N 
Engl J Med. 2010;362:329-344.]
domain of tau, including the microtubules binding repeats. Different mutations mechanism have 
been identified:
• splice-site intron 10 and few exon 10 mutations affect alternative splicing of exon 10 
leading to imbalance of 3R- and 4R-tau isoforms (while in normal condition they are 
produced in equimolar amount) [162];
• mutations  affecting  the  structure  of  protein,  its  ability  to  bind  microtubules  and  its 
phosphorylation [163];
• mutations causing a direct  increase of tau tendency to form aggregates into filaments 
[164].
FTDP-17 associated  to  MAPT mutations  is  inherited  as  autosomal  dominant  trait  with  high 
penetrance  and  variable  clinical  presentations,  including  behavioural  and  language  FTLD 
subtypes  but  also  other  neurodegenerative  disorders  like  Corticobasal  Dementia  (CBD), 
Progressive Supranuclear Pulsy (PSP) and Amyotrophic Lateral Sclerosis (ALS). The average 
age at onset is 55 years (range 45-65) and a disease duration ranging from 8 to 10 years. 
3.9.2 Progranulin
Progranulin gene, located on chromosome 17q21, encodes for progranulin which is a secreted 
growth factor involved in inflammatory processes, wound healing and tumour progression [165, 
166]. Progranulin is a precursor protein which, after protease cleavage, gives rise to 7 granulin 
peptides those, together with full-length protein are expressed in central nervous system and in 
several peripheral tissues. In the brain,  PGRN mRNA is highly expressed in cortex pyramidal 
neurons, in Purkinje cells and hippocampal pyramidal cells, where it exerts its putative roles as 
neurotrophic factor and stimulator of neuritic outgrowth [167, 168].  
PGRN mutations are mostly frameshift mutations predicted to introduce a premature stop codon 
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in mRNA and subsequent degradation of the messenger by a mechanism of Non-sense Mediated 
Decay  (NMD)  [169-171].  The  results  of  degradation  is  the  establishment  of  a  state  of 
haploinsufficiency  that  seems  sufficient  to  trigger  off  a  process  of  neurodegeneration, 
strengthening the role of normal progranulin in neuronal survival. In contrast to MAPT, PGRN 
mutations  have  incomplete  penetrance  (50%  by  age  60  years  but  90%  by  age  70  years) 
Mutations in this gene are associated with variable clinical presentations, also within the same 
family, including the most common behavioural variant of FTD, PNFA (account for up to 25% of 
all  cases) and 10-30% of patients disclose an AD-like amnestic presentation.  Extrapyramidal 
features are frequent and include CBD and parkinsonism, while MND is very rare [172-174]. 
Also age at onset of the syndrome is variable, with an average of 60 years (range 35-89 years) 
and a mean illness duration of 8 years (range 3-22).    
3.9.3 Valosin Containing Protein
Valosin Containing Protein (VCP) gene, located on chromosome 9p13, codifies for an adenosine 
triphosphatase  functioning  as  molecular  chaperone  and  involved  in  protein  degradation  in 
endoplasmic reticulum. 
Mutations in this gene are associated to Inclusion Body Myopathy, Paget's disease of bone and 
Frontotemporal Dementia (IBMPFD), characterized by variable clinical presentations (inclusion 
body myopathy in 90% of cases; Paget's disease of bone in 45% and FTD in 38%), age at onset 
(range 40 to 60 years) and penetrance degree [175]. 
3.9.4 Charged Multivesicular Body Protein 2B
The  gene  product  of  Charged  Multivesicular  Body  Protein  2B (CHMP2B),  located  on 
chromosome 3p11, is a component of Endosomal Sorting Complex Required for Transport III 
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(ESCRT-III) complex involved in the degradation of surface receptor proteins and the formation 
of endocytotic multivesicular bodies. Mutations in this gene have been identified only in a few 
FTLD cases and in only one patient with MND [176, 177].
3.9.5 Chrmosome-9p-linked FTD-MND
Several families with frontotemporal dementia associated to motor neuron disease (FTD-MND), 
have been associated to a locus on chromosome 9 (9p21.3-13.3) but, all attempts to identified the 
disease genes have not yet been successful [178]. 
3.9.6 TAR-DNA Binding Protein and Fused in Sarcoma
Mutations in TAR-DNA Binding Protein (TARDBP) and Fused in Sarcoma (FUS) genes, located 
on  chromosomes  1p36.22  and  16p11.2  respectively  and  both  codifying  for  DNA/RNA 
processing proteins  implicated in  transcription and splice-site  regulation,  are  associated  with 
MND or ALS (accounting together for nearly 10% of familial cases). 
Missense variations in these genes were rarely identified in FTLD patients with or without MND 
but, whether these variations may represent a rare cause of FTLD is still debated, since, for some 
of them there is no conclusive evidence about their possible pathogenic nature [179-181].
3.10 The neuropathology of Frontotemporal Lobar Degeneration
3.10.1 Macroscopic findings
During the early phase of the FTLD clinical syndromes, there are no remarkable brain changes 
while with the illness progression several regions are affected by different pattern of atrophy 
which correlate with disease severity [182]. Gross findings in FTLD patients are represented by 
usually but not always symmetrical atrophy of frontal and/or temporal lobes. Depigmentation of 
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substantia nigra, atrophy of basal ganglia and white matter changes (axonal and myelin loss, and 
gliosis) are frequent. 
3.10.2 Microscopic findings
The clinical and genetic heterogeneity of FTLD is also reflected at neuropathological level where 
the  identification  of  distinct  histological  profiles  led  to  the  definition  of  four  major 
neuropathological subgroups: FTLD-tau, FTLD-TDP, FTLD-FUS and FTLD-UPS [183, 184]. 
This classification is based on the distinct types of protein aggregates or inclusions that occur in 
the different categories but, this does not imply a chief role for these proteins in the pathogenesis 
of the disease (although this seems to be the case for some of them). 
3.10.2.1 FTLD-TDP neuropathology
FTLD-TDP is  considered  the  most  common  histological  profile  observed  in  FTLD,  where 
abnormal  hyperphosphorylated,  ubiquitinated  and  N-terminal  truncated  TDP-43  protein 
(encoded  by  TARDBP)  accumulates  to  form  cytoplasmic  inclusions  [185].  Depending  on 
quantity,  shape  and  distribution  of  the  inclusions,  four  distinct  FTLD-TDP  pathological 
subgroups are recognized (named FTLD-TDP Type 1 to 4) [186]. FTLD patients with mutations 
in  PGRN,  VCP or associated to 9p21.3-13.3 locus, have displayed neuropathological findings 
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Fig. 9. FTLD neuropathological subgroups.
A: FTLD-tau with hyperphosphorylated tau deposition in neurons and glial cells;  B: FTLD-TDP with cytoplasm ic 
hyperphosphorylated, ubiquitinated and truncated TDP-43 inclusions; C: FTLD-FUS with  sm all, round, com pact 
neuronal cytoplasm ic FUS inclusions; D: FTLD-USP with ubiquitin-positive intraneuronal inclusions.
A B C D
typical  of  these categories  (FTLD-TDP Type 3 for  PGRN,  Type  4 for  VCP and  Type 2 for 
9p21.3-13.3 locus).   
3.10.2.2 FTLD-tau neuropathology
FTLD-tau  represents  the  second  most  common  histopathological  subgroup  of  FTLD, 
characterized by aggregation and deposition of hyperphosphorylated tau protein in neurons and 
glial cells [187]. Actually, deposits of abnormal hyperphosphorylated tau are an hallmark not 
only of Alzheimer's disease (neurofibrillary tangles, neuropil threads and dystrophic neurites) but 
also  of  several  other  disorders  named  “tauopathies”.  The  main  differences  between  these 
pathological entities are the isoforms and hyperphisphorylation degree of tau in inclusion bodies 
and their brain regional distribution. Several of these pathology are associated with clinical FTD 
(FTLD-tau),  including Pick disease (PiD), progressive supranuclear pulsy (PSP), corticobasal 
degeneration  (CBD),  argyrophilic  grain  disease  (AGS)  and  multiple  system  tauopathy  with 
dementia (MSTD) [188-192]. FTLD-tau includes patients harbouring a MAPT mutation that may 
display a neuropathological profile typical of PiD, CBD or PSP.  
3.10.2.3 FTLD-FUS neuropathology
A variable proportion of FTLD post mortem confirmed cases (5-20%) does not have deposition 
of abnormal protein tau,  nor TDP-43 but, inclusions of ubiquitinated protein FUS similar in 
morphology and distribution to that observed for TDP-43 [193]. FUS aggregates have also been 
identified in other two rare pathologic variants of FTLD, including Basophilic Inclusion Body 
Disease (BIBD) and Neuronal Intermediate Filament Inclusion Disease (NIFID) [194, 195]. 
3.10.2.4 FTLD-UPS neuropathology
There is a fourth rare FTLD neuropathological subtype,  characterized by the absence of tau, 
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TDP-43  and  FUS  deposition  but,  by  inclusions  enriched  in  not  yet  identified  ubiquitinated 
proteins detectable only using antibody against the ubiquitin proteasome system (UPS) [196]. 
Mutations in  CHMP2B gene are associated to this histopathologic profile [197], even though 
they do not explain all FTLD-UPS identified cases.   
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4. Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy 
(CADASIL) is a high penetrance hereditary form of vascular dementia in which occlusion of 
small  arteries  in  the  brain  of  adults  results  in  small  deep  brain  infarcts.  The  heterogeneous 
clinical presentation includes recurrent migraine (usually with aura), focal deficit secondary to 
brain infarcts and, as the disease progresses, cognitive decline and eventually dementia. 
4.1 Epidemiology
Nearly 500 CADASIL families have already been reported worldwide but, the exact prevalence 
of this disorder is still unknown. The better estimate is 4.14 cases per 100.000 habitants, reported 
in an epidemiological study from Scotland, UK [198], even though this value is considered an 
underestimation of the real prevalence due to the occurrence of sporadic cases and difficulties in 
recognized family history [199].
4.2 Risk factors
Being a vascular type dementia, CADASIL is associated to the risk factors involved in vascular 
dementia  in  general.  This  form  of  dementia  occurs  predominantly  in  patients  affected  by 
cerebrovascular  disease,  coronary  artery  disease,  and  peripheral  vascular  disease,  including 
patients with myocardial infarction, stroke, transient ischemic attacks (TIAs), cigarette smoking, 
diabetes  mellitus,  increased  serum  homocysteine,  hyperlipidemia,  hyperfibrinogenemia  and 
hypertension (which triple the risk for vascular dementia) [200-202]. 
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4.2.1 CADASIL molecular basis
Mutations in  Notch3 gene are the only well recognized genetic cause of autosomal dominant 
familial forms of CADASIL. Notch3 genetic locus, mapping on chromosome 19, was associated 
with CADASIL in 1993 [203] and three years later linkage studies led to the identification of 
disease causing gene [204]. Since its discovery, more than 150 mutations have been identified. 
4.3 Clinical diagnosis of CADASIL
The  diagnosis  of  CADASIL should  be  considered  in  middle-aged  patients  showing  typical 
clinical and neuroradiological features [205] including: 
• clinically: onset in the second-third-fourth decade (but earlier or later presentations are 
encountered)  with  migraine  (usually  with  aura),  isolated  or,  more  often,  recurrent 
subcortical  infarcts  (lacunar  strokes),  mood changes,  progressive cognitive decline or 
subcortical-type dementia (pseudo-bulbar palsy); 
• neuroradiologically:  symmetrical  and  periventricular  white  matter  lesions  on  T2-
weighted MRIs;
• positive family history for abovementioned disorders (but family history is not essential 
because de novo mutations are possible [199].
A definite diagnosis of CADASIL can derived by the finding of mutations in Notch3. Evaluation 
of Granular Osmiophilic Material (GOM) presence (pathological hallmark of CADASIL) in skin 
biopsy may be a supplementary diagnostic tool giving its high specificity (nearly 100%) but, not 
sufficient to exclude the clinical diagnosis due to its low sensitivity (less than 50%) [206].  
As other form of dementia, clinical and neuroradiological findings in CADASIL patients may 
overlap with features peculiar to other diseases, in particular, those with signal abnormalities in 
white  matter.  This  group  includes  Binswanger's  disease   (white  matter  infarcts),  amyloid 
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angiopathy (recurrent lobar hemorrhages), multiple sclerosis (a great mimic of the disease in the 
first stages), familial hemiplegic migraine (migraine associated to stroke-like symptoms). 
4.4 Clinical presentation of CADASIL
Clinical presentation and disease severity vary also within the same family but the main clinical 
symptoms include: migraine with aura, transient ischemic attack (TIAs), fixed focal neurologic 
deficits caused by lacunar infarcts, cognitive decline and dementia.
The most characteristic initial symptom is migraine usually with aura, reported in 20-40% of 
CADASIL patients with a variable mean age at onset frequently in the 20s years, associated to 
the appearance of punctate hyperintensities in deep hemisphere or periventricular white matter 
[207]. The most frequent clinical events in CADASIL are transient or fixed ischemic insults, 
recurrent in about two thirds of patients with first symptoms onset between 45-50 years. Lacunar 
associated symptoms include pure motor stroke, ataxic hemiparesis, pure sensory stroke, sensory 
motor stroke while, focal neurologic deficits encompass dysarthria, monoparesis, paresthesia of 
one  limb,  isolated  ataxia,  non-fluent  aphasia  [208].  Epilepsy  is  another  common  symptom, 
occurring in 5-10% of patients, starting usually after the onset of ischemic strokes (mean age of 
onset,  50  years).  A variable  proportion  of  CADASIL subjects,  at  least  20  to  40%,  develop 
psychiatric disorders (usually after age 40 years in patients with previously ischemic episodes) 
including depression (the most common manifestation), mood disturbances, anxiety, psychotic 
events and rarely schizophrenia [209]. Cognitive impairment and dementia represent the second 
most common clinical features in CADASIL patients with onset symptom usually characterized 
by deficits of executive functions often associated to attention and memory disturbances. With 
the  progression  of  the  disease,  other  cognitive  domains  are  involved,  arising  language 
dysfunctions,  alterations of visuospatial  abilities  and loss of autonomy in daily life activities 
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[210].  Dementia  develops  in  at  least  one  third  of  patients,  presented  in  about  60%  of 
symptomatic subjects aged 60 years and reaching nearly 80% at the time of death [208, 211]. 
Dementia is always associated to pyramidal signs with gait problems, urinary incontinence and 
pseudobulbar  symptoms  as  most  frequent  presentations.  In  advance  stages  of  the  disease, 
patients become bedridden and aphatetic and, they usually decease after inhalation pneumonia. 
Unusual  clinical  presentations  in  CADASIL may  involve  parkinsonism  and  extrapyramidal 
signs,  deafness,  visual  impairment  (with  possible  involvement  of  optic  nerve  and  retina), 
polyneuropathy or myopathy and myocardial infarction. 
4.5 Age at onset and illness duration
The heterogeneity in clinical manifestations affects the age at onset of the disease, strictly related 
to the type of first symptom. Nevertheless, the age of onset is usually given on the basis of the 
first ever stroke (not migraine that usually appears earlier) therefore, the average age at onset is 
45 years and the illness duration varies between 10 and 30 years.
4.6 Structural neuroimaging in CADASIL
Magnetic  Resonance  Imaging (MRI)  is  crucial  for  CADASIL diagnosis.  It  always  discloses 
signals  abnormalities  in  Notch3 mutation  carriers  over  age  35 years  and may identify brain 
lesions also in presymptomatic patients [212]. 
MRI images routinely used to confirm a clinical diagnosis of CADASIL include T2-weighted or 
FLAIR sequence,  T1-weighted images,  diffusion weighted images and SWI or gradient-echo 
T2* images (Fig.  10). The former show variable widespread areas of increased signal in the 
white matter  associated with focal hyperintensities in basal ganglia,  thalamus and brainstem. 
Detection of signal abnormalities in the external capsule and the anterior part of the temporal 
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lobes are useful in differentiate CADASIL from other small-vessels diseases [213]. MRI T1-
weighted images disclose punctiform or larger focal hypointensities in both white matter and 
basal  ganglia,  complementary to  identified  T2 hyperintensities  and  corresponding to  lacunar 
infarctions [212]. MRI signal abnormalities within the temporal white matter and particularly 
within the subcortical white matter are considered a characteristic feature of CADASIL. Silent 
and recent ischemic lesions are occasionally detected in CADASIL on diffusion weighted images 
[214] while microbleeds suggestive of microhemorrhages are detected on gradient-echo or T2*-
weighted images [215]. 
4.7 Cerebralspinal fluid (CSF) markers of CADASIL
Few studies aimed to detect  biomarkers of prediction or evolution of the disease have been 
carried  out  on  blood  and  cerebrospinal  fluid  but  none  of  these  succeeded  in  identifying 
significant consistent and reproducible variations correlating with the disease status [216-218]. 
Nevertheless, CSF levels of β-amyloid 1-42 (Aβ42), total tau protein (t-tau) and phosphorylated 
tau-protein (p-tau)  are  useful  in  differentiate  CADASIL  from  other  form  of  dementia.  In 
particular, low CSF Aβ42 levels allow the discrimination between CADASIL and Alzheimer's 
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Fig. 10. Typical brain MRI findings in CADASIL.
FLAIR im ages dem onstrate HSI lesions in the anterior temporal lobe (A) and bilateral external 
capsules (B). Multiple lacunar infarctions (C) are noted in bilateral periventricular and deep white 
matter with punctate HSI lesions. CADASIL: cerebral autosomal dom inant arteriopathy with 
subcortical infarcts and leukoencephalopathy, FLAIR: fluid attenuated inversion recovery, HSI: high-
signal-intensity.
[Choi JC, et al. Cerebral autosomal dom inant arteriopathy with subcortical infarcts and 
leukoencephalopathy: a genetic cause of cerebral sm all vessel disease. J Clin Neurol. 2010;6:1-9.] 
disease patients from normal values identified in healthy controls or FTD subjects moreover, 
unchanged CSF t-tau and p-tau are useful to differentiate CADASIL from AD where they vary 
significantly [219-221].   
4.8 Treatments
No  disease-modifying  treatments  are  nowadays  available  but  only  symptomatic  therapies. 
Effective treatments of migraine with aura are based on acetazolamide [222] while for acute 
attacks  conventional  analgesics  and  non-steroidal  anti-inflammatory  drugs  are  preferred. 
Administration  of  anticoagulants,  like  aspirin,  in  secondary  prevention  of  cerebral  ischemic 
events  should  be  avoided  because  they  may  promote  intracerebral  hemorrhages  [223]. 
Antihypertensive  drugs  could  worsen  hypoperfusion,  the  presumed  mechanism  of  cerebral 
lesions in CADASIL. The only randomized controlled trial to be done in CADASIL tested the 
efficacy of donepezil (an acetylcholinesterase inhibitor used in Alzheimer's disease) in patients 
with cognitive impairment. This study did not show positive results in improving cognitive but 
executive functions [224]. Two other important aspects of CADASIL treatment are rehabilitation 
procedures following an ischemic event and, psychological support for patients and families. 
4.9 The genetics of CADASIL
CADASIL is caused by mutations of  NOTCH3 gene, located on chromosome 19p13.1, which 
encodes a single-pass transmembrane receptor, whose expression is restricted solely to vascular 
smooth muscle cells (VSMC) of arterial walls [225], involved in differentiation and maturation 
of VSMC and probably in regulation of cerebral blood flow and vascular miogenic tone [226, 
227]. The N-terminal extracellular domain of the protein consists of 34 epidermal growth factor 
(EGF)-like repeats,  each containing six cysteine residues (Fig.  11).  All  CADASIL mutations 
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occur in exons 2-23 encoding for the EGF-like repeats. They are mainly missense mutations, 
although in-frame deletions or insertions may occur [228], that lead to the gain or loss of one 
cysteine.  Whether the mutations cause a loss or a gain of the NOTCH3 signaling function [229, 
230], or abnormal misfolding [231] remains unclear.
4.10 The pathology of CADASIL
4.10.1 Neuropathological macroscopic findings
Macroscopic  examination  of  the  brain  shows a  diffuse  myelin  pallor  and  rarefaction  of  the 
hemispheric white matter predominating in periventricular areas and centrum semiovale. These 
lesions are associated with lacunar infarcts located in the white matter and basal ganglia. In the 
cortex there is the widespread of neuronal apoptosis [232, 233]. 
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Fig. 11. The classic NOTCH signaling pathway.
The Notch receptor locates at cell surface as a 
heterodimer following protease cleavage (S1) during 
protein m aturation. The extracellular domain 
(NECD) – containing up to 36 EGF-repeats and 
three cysteine-rich Notch/LIN-12 repeats (LNG 
domain) – associates non-covalently with a 
membrane-tethered intracellular domain (NICD) – 
with a RAM dom ain, six tandem  ankyrin repeats and 
a praline-, glutamate-, serine, threonine-rich 
sequence (PEST domain). The interaction between 
the DLS-ligand and the Notch receptor leads to two 
additional proteolytic cleavages – S2 (mediated by a 
metalloproteinase family protein TNFa-converting 
enzyme, TACE) and S3 (within the transmembrane 
domain, by a g-secretase) – resulting in the release 
of the NICD, which then translocates to the nucleus, 
where it interacts with CBF1/RBP-Jk to activate 
transcription of target genes HES and HESR (or 
HRT).
[Andrè C, et al. CADASIL Pathogenesis, clinical and 
4.10.2 Neuropathological microscopic findings
Microscopic investigations show a thickening of cerebral  and leptomeningeal arterioles wall, 
with a reduction of the lumen and, a stenosis of penetrating arteries in the cortex and white 
matter [234]. A distinctive feature is the presence of a PAS-positive granular material within the 
media extending into the adventitia. On electron microscopy, the smooth muscle cells appear 
swollen and often degenerated. There is a granular, electron-dense, osmiophilic material (GOM) 
within the media, located close to the cell surface of smooth muscle cells [235]. 
4.10.3 Skin biopsy
The granular, electron-dense, osmiophilic material is present not only in the brain but also in the 
media of arteries located in the spleen, liver, kidneys, muscle and skin. The presence of GOM in 
the skin vessels now allows confirmation, in the living patient, of the diagnosis of CADASIL 
using skin-punch biopsies (Fig. 12) [236]. 
This  diagnostic  method is  useful  in  predicting and confirming  Notch3 mutation carriers  but, 
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Fig. 12. Osmiophilic granules seen on electron microscopy.
Electron m icroscopy (EM) of NOTCH3 m utation carrier skin biopsy 
revealing granules osm iophilic m aterial (GOM) embedded within the 
basem ent membrane of several arterioles indenting the cell m em brane of 
considering that skin biopsies are still an invasive approach and that the absence of GOM does 
not exclude the disease (in same cases the vessel changes may be focal, requiring a thorough 
evaluation of the biopsy specimen),  this  technique can not be considered a  gold standard in 
CADASIL diagnosis. A promising alternative to electron microscopy GOM identification, may 
be  represented  by  an  immunohistochemistry  by  anti-NOTCH3 antibody  to  identify  the 
accumulation of the small aggregates that NOTCH3 ectodomain forms around the degenerating 
vascular smooth muscle cells in proximity to GOM deposits. This method seems to have not only 
high specificity (100%) but also high sensitivity (96%) [237]. 
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5. Aims of the study
Whereas  Alzheimer's  Disease  and  Frontotemporal  LobarDegeneration  are  both 
neurodegenerative disorders while CADASIL is a form of vascular dementia, the latter will be 
dealt separately from other. 
In  the  mutational  analysis  of  Alzheimer's  Disease  and  Frontotemporal  Lobar  Degeneration 
associated genes, four main aims have been pursued:
• development  of  optimal  experimental  conditions  (primer  design,  PCR  amplification 
profiles, DHPLC analysis conditions and MLPA);
• evaluation of mutational frequency of AD and FTLD associated genes in an Italian series;
• identification  and  definition  of  possible  correlations  between  genotype  and 
clinical/pathological presentations of these disorders;
• definition of possible diagnostic algorithm for genetic testing.   
In the mutational analysis of NOTCH3, three main aims have been pursued:
1) evaluation  of  mutational  frequency  of  NOTCH3 in  an  Italian  series  of  CADASIL 
patients;
2) definition  of  distribution  of  NOTCH3 mutations  along the  gene  in  order  to  define  a 
possible useful diagnostic approach;
3) adding  more  data  to  reinforce  the  correlation  between  the  presence  of  a  NOTCH3 
mutation and the typical CADASIL pathological findings (deposition of GOM). 
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6. Patients and Methods 
Mutational, microsatellites and haplotype analyses were performed on DNA samples extracted 
from peripheral blood samples or from frozen brain tissues, and stored at -20°C for subsequent 
uses.
 
6.1 Patients
Enrolled patients were visited by neurologists and neuropsychiatrists in dementia medical clinic 
at  G.B. Rossi  Hospital  in Verona or referred from centers in North- and Central-Italy.  After 
obtaining informed consent for genetic analysis, patients underwent venous blood sampling for 
DNA extraction. 
6.1.1 Patients with AD or FTLD
AD-  and  FTLD-associated  genes  were  analyzed  in  210  patients  and  the  whole  series  is 
summerized in two tables which distinguish cases whose DNA was extracted from peripheral 
blood (Table 1) and those with DNA extracted from frozen brain tissue (Table 2). The series was 
subdivided according to clinical diagnosis and, for each subtypes are given, the number of index 
cases, age of onset of the disease and data about family history. The neuropathological diagnosis 
has been reported for autopsy cases. Noteworthy, these informations were not available for all 
patients,  especially those  enrolled  in  hospitals  or  care  facilities  outside  G.B.  Rossi  Hospital 
where this  study was performed.  In addition,  this  study included even patients  with clinical 
diagnosis  suggestive  of  possible  atypical  presentations  of  AD  and  FTLD  (as  stated  in  the 
introduction);  among  this  group  there  were  also  Mild  Cognitive  Impairment  (MCI)  that  is 
considered to represent the prodromal phase of AD and the Creutzfeldt-Jacob Disease (CJD) 
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which is a form of rapidly progressive subacute dementia that can sometimes be misdiagnosed 
instead of an Alzheimer's with rapid clinical evolution. 
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Table 1. Clinical series with DNA samples extracted from peripheral blood.
Abbreviations: MCI, Mild Cognitive Impairment; EPS, Extrapyram idal Signs; AD, Alzheim er's Disease; FTD, Frontotemporal 
Dem entia; PNFA, Prim ary Non-fluent Aphasia; MND, Motor Neuron Disease; LBD, Lewy Body Dementia; CBD, Corticobasal 
Dem entia; PSP, Progressive Supranuclear Pulsy; CAA, Cerebral Am yloid Angiopathy; Unknown, data not available; (n), 
number of index cases whose age of onset was available.
Diagnosis N. of index cases Mean age at onset (n) Inheritance
Familial Sporadic Unk nown
MCI 13 66,5 ± 9,49 (8) 5 1 7
DEMENTIA 48 65,5 ± 8,04 (8) 11 37
DEMENTIA + EPS 5 47,5 ± 3,54 (2) 1 4
AD 41 63,96 ± 9,81 (24) 17 1 23
FTD 59 59,65 ± 7,6 (23) 12 6 41
PNFA 7 53,83 ± 4,4 (6) 2 5
FTD + MND 5 55 ± 7,55 (3) 1 1 3
LBD 2 72,5 ± 10,61 (2) 2
CBD 4 56 (1) 4
PSP 7 69 (1) 1 6
PSP/CBD 2 2
CAA 2 54 (1) 1 1
The choice of samples extracted from postmortem brain tissue was driven by the pathological 
diagnosis  (performed  by  histological  and  immunohistochemical  studies)  of  AD  or  FTLD. 
Otherwise, samples extracted from peripheral blood were mainly selected by the outcome of 
clinical  and  neuropsychological  tests  according  to  diagnostic  criteria  for  either  dementia 
subtypes. Nevertheless, the clinical picture is not always plain or well defined to drawing up with 
certainty the clinical diagnosis of a particular form of dementia. In these cases, informations 
about familial aggregation of the disorder plays an important role. In this study 50 out of 210 
were familial cases of dementia, 16 were apparently sporadic while for remaining informations 
were not enough to rule out or support a positive family history. The terminology “familial case” 
means that in a patient family one or more cases of dementia or related illnesses occur but this 
not  necessary imply a  genetic  cause  which  actually  is  the  basis  for  defining  a  character  as 
inheritance. The terminology “apparently sporadic” means that family history informations seem 
to  exclude  a  disease  familiarity  but,  this  is  not  always  true  considering  the  difficulties  in 
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Table 2. Clinical series with DNA samples extracted from frozen tissue.
Abbreviations: AD, Alzheimer's Disease; FTD, Frontotem poral Dem entia; PSP, Progressive Supranuclear Pulsy; CBD, 
Corticobasal Dem entia; CJD, Creutzfeldt-Jacob Disease; UPS, Ubiquitin Proteosom e System .; Unknown, data not 
available; (n), number of index cases whose age of onset was available.
Clinical Diagnosis Case index Inheritance Pathological diagnosis (n)
Familial Sporadic Unknown
AD 3 72,33 ± 2,52 (3) 2 1
DEMENTIA 3 1 2 AD (3)
FTD 2 80 (1) 1 1
PSP 1 65 (1) 1
CBD 1 73 (1) 1 FTLD-UPS (1)
CJD 5 5 AD (3); LBD + AD (2)
Mean age at onset 
(n)
Tauopathy (1); AD (2)
Tauopathies (2)
Tauopathy (1)
collecting this type of data from patients and their relatives and possibility of de novo mutations. 
“Unknown inheritance” is often regarding outpatients examined in other hospitals, for whom a 
detailed history is not available.   
6.1.2 Patients with CADASIL
Six  hundreds  twenty-eight  patients  overlapping  clinical  and/or  radiological  criteria  for 
CADASIL were referred to Neuropathology laboratory at  G.B. Rossi  Hospital  for molecular 
screening of NOTCH3. Five hundreds seventy-seven were unrelated index cases while fifty-one 
were family members belonging to twenty-two families. 
6.1.3 Controls series
For mutational analysis (of either AD and FTLD associated genes or NOTCH3) and the study of 
NOTCH3 haplotypes,  it  was  necessary to  establish two series  of  cognitively normal  control 
subjects. Patients referred to Neuropathology laboratory at G.B. Rossi Hospital with clinical and/
or molecularly confirmed diagnosis for other disorders of central or peripheral nervous system, 
with a normal cognitive profile and without positive family history for dementia, were included 
in this group of controls after obtain informed consent.
In particular,  492 unrelated subjects were selected to define the frequency of identified non-
synounimous nucleotide variations, to confirm or rule out their possible pathogenetic role while, 
for NOTCH3 haplotypes analysis a cohort of other 50 cognitive normal subjects was enrolled in 
order to define the frequency of different haplotypes in our population.
6.2 DNA extraction from peripheral blood leukocytes
DNA extraction from peripheral blood leukocytes was performed starting from a 5 to 10 ml of 
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whole blood collected in a anticoagulant Ethylenediaminetetraacetic Acid (EDTA) tube by Salt-
in-out protocol, as following:
• all blood volume was transferred in 50 ml sterile falcon;
• 3 volumes of  1X cold hemolysis  solution (155 mM NH4Cl,  10 mM KHCO3,  1  mM 
EDTA, pH 7.4) were added and, after vigorous inversions, the tube was placed on ice for 
20 min;
• the tube was spinned at 2000 rpm for 10 min at 4°C in a Beckman GS-6R refrigerated 
centrifuge;
• the supernatant was aspirate with vacuum and the pellet washed with 15 ml of 1X cold 
hemolysis solution and incubated on ice for 20 min;
• the tube was spinned at 2000 rpm for 10 min at 4°C, the supernatant was aspirate with 
vacuum and the pellet resuspended in 3 ml of 1X lysis solution (10 mM TriHCl, 75 mM 
NaCl, 24 mM EDTA, pH 8);
• entire volume was transferred in a 15 ml sterile falcon and 450 μl of 10% SDS and 300 μl 
of Pronase (1g/50ml) were added. The tube was placed in water bath at 37°C for 1-2 
days;
• after digestion, 1.5 ml of saturated NaCl solution (35g/100ml) was added and tube shaked 
vigorously for a few sec and then spinned at 2500 rpm for 15 min at room temperature;
• the supernatant was transferred to a new tube and DNA was precipitated with 2 volumes 
of 100% ethanol;
• two 70% ethanol were carried out and then, DNA precipitate was transferred to a 1.5 ml 
eppendorf tube letting to dry ethanol excess;
• 1 ml of 1X TE (100 mM Tris, 0.1 mM EDTA, pH 7.5) was added to dry DNA left to 
completely dissolve at 4°C for a few days and then stored at 20°C.
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6.3 DNA extraction from frozen brain tissue
DNA extraction from frozen brain tissue was performed with DNA Isolation Kit for Cells and 
Tissue (Roche Applied Science), starting from 400 mg frozen tissue, according to manufacturer's 
instructions. DNA yields were determined via spectrophotometry. 
6.4 DNA amplification 
For each gene included in the study, a genomic clone was selected from the GenBank database:
4) Progranulin (PGRN): NM_002087.2;
5) Microtubule-Associated Protein Tau (MAPT): NM_001123066.3;
6) Valosin Containing Protein (VCP): NM_007126.3;
7) Charged Multivesicular Body Protein 2B (CHMP2B): NM_014043.3;
8) TAR DNA Binding Protein (TARDBP): NM_007375.3;
9) Amyloid Precursor Protein (APP): NM_000484.3;
10) Presenilin1 (PSEN1): NM_000021.3;
11) Presenilin2 (PSEN2): NM_000447.2;
12) Apolipoprotein E (APOE): NM_ 000041.2;
13) NOTCH3: NM_000435.2
Pairs  of  oligonucleotides  were  designed  for  each  coding  exon  using  Primer3  software 
(http://frodo.wi.mit.edu/primer3/) following a few criteria: amplicons maximum of 400-600 bp 
in  length,  intron-exon boundaries included in the amplicon,  similar  melting temperatures for 
primer pair, avoiding primer sequences prone to form secondary structures or dimers (Table 2-
12). For each exon, the best amplification conditions were tested in order to obtain specific PCR 
products,  including the choice  of  DNA polymerase,  the right  concentration  of  salts,  organic 
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compounds  like  DMSO  (to  facilitate  double  strand  separation),  primers  and  the  optimal 
amplification cycle. 
PCR reactions were run on GeneAmp 9700 thermocycler (Applied Biosystems) or Mastercycler 
ep gradient S (Eppendorf) and, after amplification, analysis of PCR products was performed by 
agarose gel electrophoresis (1% agarose). 
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PCR standard mix reactions (per sample):
5X Colorless GoTaq Reaction Buffer (Promega) 1X
2 mM mix dNTPs 40 μM
primer forward 0.2 μM
primer reverse 0.2 μM
GoTaq DNA Polymerase (Promega) 1 unit
DNA sample 200 ng
H2OmQ (to adjust total volume to 10 μl)
TOTAL 30 μl
10X PCR Gold Buffer (Applied Biosystems) 1X
25 mM MgCl2 Solution 2.5 mM
2 mM mix dNTPs 40 μM
primer forward 0.2 μM
primer reverse 0.2 μM
AmpliTaq Gold (Applied Biosystems) 2 units
DNA sample 200 ng
H2OmQ (to adjust total volume to 10 μl)
TOTAL 30 μl
10X Reaction Buffer (Transgenomic) 1X
25 mM MgSO4 Solution 2.5 mM
2 mM mix dNTPs 40 μM
primer forward 0.2 μM
primer reverse 0.2 μM
Optimase Polymerase (Transgenomic) 0.75 unit
DNA sample 200 ng
H2OmQ (to adjust total volume to 10 μl)
TOTAL 30 μl
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PCR amplification profiles:
APP, PSEN1, PSEN2, PGRN
94°C 5 min
94°C 30 sec
T annealing 30 sec 40 cycles
72°C 30 sec
72°C 2 min
16°C ∞
MAPT
94°C 5 min
94°C 30 sec
T annealing 35 sec 40 cycles
72°C 40 sec
72°C 2 min
16°C ∞
VCP, CHMP2B 
94°C 5 min
94°C 30 sec
T annealing 30 sec 40 cycles
72°C 30 sec
72°C 2 min
16°C ∞
TARDBP
94°C 5 min
94°C 30 sec
T annealing 30 sec 35 cycles
72°C 30 sec
72°C 2 min
16°C ∞
APOE
94°C 7 min
94°C 30 sec
T annealing 30 sec 38 cycles
72°C 30 sec
72°C 2 min
16°C ∞
NOTCH3
94°C 7 min
94°C 30 sec
T annealing 30 sec 38 cycles
72°C 30 sec
72°C 2 min
16°C ∞
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DNA polymerasePrimer sequence (5' → 3')
Forward Reverse
1 CCCACCTCTATATTGATAAGTAGCC TTCTTCTGTTGTCTCCGGCT 256 62* Gold 62 / 63 / 64
2 TGGCGTGGGCTTAAGCAGTT TCTGGCCAATCCAAGATGAC 263 60 62.7 / 63.7
3 ATCTTGGATTGGCCAGAGGA AGGTGGTAGAGTGCAGGAAA 263 60 60.7 / 61.7
4 GCTTTTCCTGCACTCTACCA GTTCCAGACTCCACATGCTG 211 60 63.2 / 64.2
5 CCACCAGCTCCTTGTGTGAT TGGTCCTGACTCCGTCTTCA 279 64 61.1 / 62.1
6 GTATGTGGAGGGAAGTGGGG AACTTTTTCCTACACTTGGAGTC 286 60 63.3 / 64.3
7 CCTCATTGACTCCAAGTGTAGG CCCCTGTAAGGTGCGTGTCA 253 62* 63.7 / 64.7
8 GAGCCTGGAAGTGACAAAGA ACCTTGCAGTGATCCTAAGG 248 60 63.1
9 CAAAGGGTTGATACCCCTGA TGTGGTCCTCACAGCACACA 276 62* 62.4 / 63.4
10 TGAGCACAGTGTGGCAGGCA GCAGAAAGCAATAGGAGCTTGG 373 64 62.3 / 62.7
11 CACATAGTGGCTACCTACAACG TGGCATTATGTTCCTGTCCC 347 60 64.3 / 64.9
Table 3: PGRN  primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Table 3: PGRN primers
DNA polymerasePrimer sequence (5' → 3')
Forward Reverse
12 AGCTAAGCCCAGTGAGGGGA TTGGACGAGGTGGGACCTGG 352 64 63.9 / 64.3
13 ATCCTGGGGCTGGGTATGGC AGGTGCTAGGGAGGCCTGAG 273 64 64.6 / 65.6
DNA polymerase
Forward Reverse
1 CAACACTCCTCAGAACTTATC CAGTGATCTGGGCCTGCTGTG 229 53.5 Gold 59.5 / 61.5 / 62.5
9 CGAGTCCTGGCTTCACTCC CTTCCAGGCACAGCCCTACC 370 65.5 64.3 / 65.3
10 GGTGGCGTGTCACTCATCC CGCACTCACACCACTTCC 198 60 Gold 59.1 / 60.1 / 61.1
11 CTTCTCATTGAGTTACACCC CTCACCAGGACTCCTCCAC 256 57 Gold 59.4 / 60.4
12 AGATGCTCTTGTGTGTGTTGTG CAGCATCCAACCCACCCTAC 170 62* Gold 58.4 / 59.4
13 CTTTCTCTGGCACTTCATCTC CCTCTCCACAATTATTGACCG 299 60 Gold 62 / 63 / 64
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon
Go Taq
Go Taq
Table 4: MAPT primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
DNA polymerase
Forward Reverse
1 AAGCCGCTTGCGGGTTTGTC GGTCTCCACCTCTCTGACGC 261 64* 67.6/68.6
2 GGGACAGCTTCATCTATTCA CCCACTCTATCTGCAGTCAC 319 58 57.9/58.9
3 TGACTGCAGATAGAGTGGGG GACAGGTGCCAAGAACTTGG 381 62* Gold 57.7/58.7
4 TATCAGCTATCTGTGCCAGG AATAAATAAATACAGGGGAAAAGC 359 54* Gold 55.6/59.6
5 GGGCACTATCTAATGAGCTTGG CTCCCAAAGTACTGGGATTACAG 365 61* Gold 59.7/60.2
6 GCACACTAGGTAGTGGAATGAT CAATAATGAAAGCCATGCAT 327 58 Gold 56.8/58.8
7 TTGAAGCCTGATTCTCACCC CATGGGTGCAAAAAGGATGT 296 58 58.1/59.1
8 CCTGTCTCTGGGCCAAACAA TGAGTCTGCCAGAACAGGATG 312 58 57.6/58.6
9 ATGCCATCGCTCCCAAAAGA CCAATCACTGTGAAGGGCTTC 340 58 59.5/61.5
10 GGACAATCCTGTGCTGGCTG CAAAACCCATCTCCTCACATC 314 58 58.8/59.8
11 GGACCCAGGGATAGCAGTCA TCTGGCTCAAGGCCCACTAG 373 58 60.1/61.1
Table 5: VCP primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
DNA polymerase
Forward Reverse
12 ACTTCCGGGTAAGGACCACA GCTCTCACAACTCTTGCAGC 323 58 60.4/61.4
13 CCATTGGGTACACCATGAAA TGAGCAGCCAGCACTAAGAA 418 58 57.4/59.4
14 TGAGCCACCACGTTTGCCTA AAGAGCACTCCGTACCAGCC 442 58 61/63
15 AAAGAAGGGGCAAACTGTAG CTTTCCAACAGCTTCTACTCTC 355 62* Gold 60.4/61.4
16 ATTGGAAGGGCAAGGAGACC CACAACTACCCCTCTAGCTTCC 355 62* Gold 59.1/60.1
17 CAAAAGGGATGGGAGTCCTA TGTTCAGACTGGAGAATGGAG 329 62* Gold 61.9/92.9
Table 5: VCP primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Go Taq
DNA polymerasePrimer sequence (5' → 3')
Forward Reverse
16 TGGGTAGGCTTTGTCTTACAG TAGCACAGGATGAACCAGAG 218 65 Gold 67.4/68.4
Table 6: APOE primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon
DNA polymerase
Forward Reverse
1 CCTGTCCTTTGCCAGCGTT TGTGGGACCACTTGATCCAG 219 62* 64.4/65.1
2 CGCCCAGCCAATATAAGATTT CCATGTGCCTTCTTCCTAGTTAG 294 62* 53.8/55.8
3 GGACAAAGGGTCTGTTATGT GGAGGTGCTTTTAAATCTGCT 386 62* 53.3/54.3
4 CGGCAGGATGGATATCTTTT CTTCGTGAATGAGAATATGAGAC 312 62* 52.9/54.9
5 TTCACTGAGTTTGCCTTCTG CCATGCACCTCCTAGTAAAAA 313 62* 54.8/55.8
6 CAGACCTCTTTACAGCACATC TAGCCATGGGTTAGGAAACA 340 62* 55.2/57.2
Table 7: CHMP2B primers
amplicon length 
(bp)
Annealing Tm   
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
DNA polymerase
Forward Reverse
2 TTCTGACATGAATGTTGTTCAT GACACACACCTGAACACACTT 347 57.5 56.8/57.8
3 TGCTTCTCATTTCTAGATGTAGG TGCTAGATACTCATTCACATGGTA 306 57.5 55.6/56.6
4 GGAACTATGATTTGGGAATGG CCTGCCGCTATCTTTTCTAAG 308 57.5 56.6/57.6
5 CTATCCAAGGCGAATGATTT TCCAAAGTGCTGGGATTGTA 341 57.5 55/60
6A GCTTGTAATCTAAGTTTTGTTGCT CATCATGGCTGGATTAATGC 339 57.5 55.4/58.4
6B TCAAGGTAGTAATATGGGTGGTG TGAATTCCCACCATTCTATACC 383 57.5 59.6/60.6
Table 8: TARDBP primers
amplicon length 
(bp)
Annealing Tm   
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Optimase
Optimase
Optimase
Optimase
DNA polymerasePrimer sequence (5' → 3')
Forward Reverse
16 TGGGTAGGCTTTGTCTTACAG TAGCACAGGATGAACCAGAG 263 55 54.5 / 55.5
17 TCCCCTGCATTTAAGAAATG CTAAGCCTAATTCTCTCATAGTCT 310 53 56.6 / 58.6
Table 9: APP primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon
Go Taq
Go Taq
DNA polymerase
Forward Reverse
3 ATTGTAGTGCACAAAGTTCTGT AGGTGAGGGGAGATGATAAG 244 55 57.9 / 58.9
4 CTGCTGAGAATCTGATTTACTG TGTAAAGAAAAGCCACACTG 351 56.6 Gold 56.9 / 60.5
5 GGTGATCTCCATTAACACTG CAACCATAAGAAGAACAGGG 244 55 57.9 / 58.9
6 GTACTTTTTAAGGGTTGTGGG TCATCAACAAAGTACATGGC 213 55 54.1 / 55.1
7 TGGTGAAAATTATTGTACATCT AAAGAAAACACTCCAGTGGG 330 53 57 / 58
8 CCATTTACAAGTTTAGCCCA GTTACATGTGCTTCAGTTCC 228 56.6 Gold 52.7 / 53.7
9 ATGGCTTGTTGTTGTCTATG GACCAAAGAAAGACGATAAAAAC 248 53 54.1 / 55.1 / 56.1
10 CAGCTAGTTACTGTTTCCATGTA AAAAGGTTGATAATGTAGCTACC 325 53 55.9 / 58.9 / 60.9
11 GTGAAATCATAGCAAAGAGTGAC ACAGAACTGCCTTAAAGGGA 256 55 55.7 / 56.7
12 GAGTTTTGCCTGAAAATGCT CAGGAAAATCACCTTTGTCC 300 55 56.1
Table 10: PSEN1 primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
DNA polymerase
Forward Reverse
4 CACAGGAAAGTGGAACAAGG TAAGGTACAGTAGCCGCAGG 260 58 62.2 / 63.2
5 TTACATGGATAGGCTGCCGT AGTGACCAACACAGGCTGCT 360 58 61.2 / 62.2
6 GGTCCAGAATCACTCAAGGTG CTAAAGGCGGCTGTTTCACG 307 58 63.2 / 63.4
7 CCTAATGAAGAGCATTCAGGC CTCATGCCCATGTCCACTTGT 245 58 58.4 / 59.4
8 GCTGTAATGCCTCCACTGAG TGCAGCACTGGGGACGATTT 343 62 61.5 / 62.5
9 CAGGGCAGGCTCTTCTTCAG AAAGCCACGGCCAGGAAGCA 252 62 59.7
10 CTTTCTGGGACGCAGACTGG TCCTGAACTCATGCCTCTCAG 280 58 62.9
11 GTAACACTCTGACCAGCTGTTG GAGCCTCCACCCTCTGTCTC 256 58 61.3
12 TTCTGGGCCAGAGTTTCTCT ATCCCTAGGGATCCTGAGAC 287 58 61.5 / 62.5
13 ACCATGACTCACAGCTCCTG AACTATACAACTGCATCCAATG 286 58 61.8 7 62.8
Table 11: PSEN2 primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
DNA polymerase
Forward Reverse
1 GGAAGGAGGGAGGAGGGGAGG CACTCCCCCTCTGCCGCCCT 205 65.5 Gold 67.5/68.5
2 GGGCACCTGGCTGATCCTCCA CACACACAGGGCCCACTGGTG 162 65.5 Gold 65.2/66.2
3 TGTGCTGCCCAACCAAGCCATC TGTGCTGCCCAACCAAGCCAT 252 66* Gold 65
4 TAGTCGGGGGTGTGGTCAGT GGAAGGGGGCAAGGATGG 474 66* Gold 65.1/66.1
5 CCCTACTCAGGAGAGTCAGAG GTCCAAGCCACCTGGCGCATG 272 64* Gold 62.8/63.8
6 CCAGGTGGCTGGACTGCTGC CAAGTCAGACTTCTTATTTGCC 308 62.5* Gold 63.6/64.6
7 ATGGAGTGCGATCGGTGTGG CTTTCCCAGCCCATTCACAG 283 62.5* Gold 62/63
8 TGTGAATGGGCTGGGAAAGA CCCACTTACACCCCATTCTG 359 61 Gold 65/66
9 CCATAGGGTAGCCCCCG TGCCCCTTCCCAGACATG 209 58 Gold 62.7/63.7
10 GTGTACTGCTCTCACCCTTTC CAAGTCTGTTATTGGCCCTG 181 58* Gold 64.5/65.5
11 TGGGCAGGCCCCTGGCAAGT CCCAAACCCTCTGTGCCCCT 341 66* Gold 63.6/64.6
Table 12: NOTCH3 primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
DNA polymerase
Forward Reverse
12 GAATGGTGCATCTAGTGGG GACTTCACCCTCGATCTAGG 221 62 60.4/61.4
13 TTGTCCCTGCTGACTTTGTTC GTCAGGCCAGGGAGGTG 305 62 Gold 62.2/64.2
14 CTTCTCAGCCTCAGACACTG GGGAGGAGAGAGTAGAGGAG 301 62 63.6/64.6
15 TCAATCATTTCCCTCCAGGA CCCAGCATCATCCCTGATAG 320 58 62.3/63.3
16 CCCTGCTCTGTACCCTGTAA AGGCACACAGTTCAAGCTTAT 276 62 Gold 62.4/63.4
17 CCAAGGCATATCCCAGTCAG CGTTGCTGTCCCCACTTCGT 382 58 64.2/65.2
18 ACTCAGGAAGGAGGGCAGGG AGAAACTGTGCCCCGACTTG 302 62 64.4/65.4
19 CAAGTCGGGGCACAGTTTCT AGCAGGAGGTACGTGCATGA 285 58 63.7/64.7
20 TGAATGATCTGTGTGATGGA GCCCAGACGCACCCAAGCAT 322 58 63.1/64.1
21 GTATGTCCAGGTGGGTCTGT GGTCAAGAGGGAATGAAGAC 255 55 61.6/62.6
22 GATGAGAGGCTGTCTTCATT GCATGTAGATCAGCCACAAT 379 55 62.6/64.6
Table 12: NOTCH3 primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
DNA polymerase
Forward Reverse
23 AGGTAAGCGTTGGCGAAGGG CACGCCCCTACTACTCCAGA 269 58 63.4/64.4
24 A CTCCCCACCCTCATTTTTAT TGTTGCACTCGCGGTCGCAG 429 58 68.7/69.7
24 B CCTTCTTCCGCTGCGCTTGC CTGGGATGGATGCATAGACA 382 58 67.1/68.1
25 TTGTCTCCTCTGACCCCTGA TGAAACACACAAGACCTGGA 464 58 64.3/65.3
26 CTTGGTACCAGGGGGTGCAT TTTGGCCTCAGGCGGGGCTT 292 65.5 63.3/64.3
27 AAGCCCCGCCTGAGGCCAAA TCAAGGCGGGGTCCAGGGTT 354 65.5 65.2/65.7
Table 12: NOTCH3 primers
amplicon length 
(bp)
Annealing Tm 
(°C)
Oven Temperature 
(°C)Exon Primer sequence (5' → 3')
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Go Taq
Table 13: Real-Time PCR primers
Gene
Forward Reverse
B2M 2 TTACTGAAGAATGGAGAGAGAATTGAAA GACCAGTCCTTGCTGAAAGACA
UBC 1 GGGTCAATATGTAATTTTCAGTGTTAG TTGTCTAACAAAAAAGCCAAAAACG
PGRN 3 ATGCAGGTTTCTCTGTGTTCCA CCCAGCTGCACCTGATCTTT
8 TCCTCTCTGCTTCCCTCACAGT TGTAGACGGCAGCAGGTATAGC
11 GCTGGCTACACCTGCAACGT GGGCAGAGACCACTTCCTTCT
APP 5 ATGACTACGGCATGTTGCTG CACATTGTCACTTTCTTCAGC
11 CCCCATGGACATATGTGTTT TTCCACTCTGGCCATGTGTG
18 GCTCTCCTCTTGTTTTTCAGG ATCTGCTCAAAGAACTTGTAG
Exon Primer sequence (5' → 3')
6.5 PCR products purification by ethanol precipitation
If used in direct sequencing, PCR products were purified from primers and salts excesses which 
can interfere with the reaction. Ethanol precipitation was carried out as following:
 entire PCR volume was transferred to a 1.5 ml eppendorf tube and 2 volumes of 100% 
cold ethanol and 1/10 of final volume of 3M Sodium Acetate (pH 5.2) were added and 
mixed throughly;
 the tube was spinned at 14000 rpm for 16 min at 4°C in a Eppendorf  5417R refrigerated 
centrifuge;
 the supernatant was discarded and 200 μl of 75% cold ethanol were added to the pellet 
and mixed throughly;
 the tube was spinned at 14000 rpm for 11 min at 4°C;
 the supernatant was discarded and 200 μl of 75% cold ethanol were added to the pellet 
and mixed throughly;
 the tube was spinned at 14000 rpm for 6 min at 4°C;
 the supernatant was discarded and the pellet was air- or vacuum-dried and then, dissolved 
in 10-20 μl of H2OmQ and stored at -20°C until usage.
6.6 Mutational analysis
Mutational screening of AD, FTLD and CADASIL associated genes was performed by two main 
techniques:  the  Denaturing  High  Performance  Liquid  Chromatography  (DHPLC)  and  direct 
sequencing. 
6.6.1 Denaturing High Performance Liquid Chromatography
The DHPLC technology allows the identification of sequence variations in DNA fragment or 
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PCR  products.  It  is  mostly  used  for  the  identification  of  single  nucleotide  polymorphisms 
(SNPs),  point  mutations,  small  deletions  and  insertions.  This  technology  is  based  on 
heteroduplex  detection  whose  chromatographic  profile  is  easily  distinguishable  from 
homoduplex  peaks  and,  therefore,  provides  a  good  method  for  the  identification  of  new 
mutations. The choice to use DHPLC for mutation screening in this study arises from its high 
degree of sensitivity. In this study Transgenomic WAVE ® 3500 HT System was used and its 
basic principle is as follows. Wildtype and tested allele are amplified separately, mixed, heated 
at  94°C  for  5  min  and  then  cooled  at  room  temperature  promoting  the  formation  of 
homoduplexes  and heteroduplexes (if  a  nucleotide variation is  present).  When a  mutation is 
present, there are four possible configurations: wildtype homoduplex, mutant homoduplex and 
two heteroduplexes.  The samples are placed on a 96-well  plate and injected into a DNASep 
separation cartridge containing hydrophobic beads. The cartridge is located inside an oven which 
controls  and  maintains  a  constant  temperature  fixed  by  the  operator.  Negatively  charged 
phosphate backbone of DNA fragments interact with the positively charged ammonium group of 
triethyammonium acetate (TEAA) present in the buffer flow path injected in the cartridge with 
the  samples.  As  a  result  of  these  interactions,  the  DNA will  be  indirectly  bound  to  the 
hydrophobic beads of the cartridge from which it will be subsequently removed by increasing 
concentration  of  an  organic  solvent,  acetonitrile  (ACN),  which  competes  with  TEAA:  the 
outcome  is  the  release  of  the  DNA  fragments  from  the  cartridge.  Heteroduplexes,  with 
mismatched  base  pairs,  elute  off  of  the  cartridge  first  followed  by  the  homoduplexes.  The 
fragments  pass  through  the  UV  detector  which  detects  the  absorbance  over  time.  This 
information  is  sent  to  Navigator  Software  on  PC  and  translated  into  a  chromatogram 
characterized  by a  variable  number  of  peaks,  depending on the  genotype  of  analyzed  DNA 
fragments. If no nucleotide variation is present, homoduplexes DNA fragments elute off of the 
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cartridge at the same time producing a single peak on the chromatogram on the contrary, if there 
is a nucleotide variation two or more peaks will be visible. The ideal analysis conditions (melting 
profiles,  analysis  temperatures  and  TEAA and  ACN  concentrations)  closely  depend  on  the 
nucleotide sequence. For this reason, fragment specific methods are created by WAVE Navigator 
software (Transgenomic) which predicts (and controls) both the oven temperature and the ACN 
gradient analyzes through algorithms generated on the basis of the studied nucleotide sequence. 
Oven temperatures used to perform mutational analysis of each exons are reported in Tables 2-
12.
 
6.6.2 Direct sequencing
Direct sequencing is a variant of “di-deoxynucleotide sequencing method” developed in 1977 by 
Frederick Sanger. This technique consists in the elongation of a template DNA starting from a 
short  oligonucleotide  primer  complementary  to  a  specific  region.  In  this  reaction  a  DNA 
polymerase incorporates deoxynucleotide bases present in solution in high concentration, and 
chain  terminating  nucleotides  (di-deoxynucleotides)  present  in  low  concentration.  Limited 
random incorporation of di-deoxynucleotides results in a series of related DNA fragments that 
differ in length (the ending point is strictly related to the di-deoxynucleotide insertion site). In 
Sanger  method  radioisotopes  were  used  to  label  the  primer  and  four  separate  incorporation 
reactions,  one for each di-deoxynucleotide,  were performed.  Once elongation reactions were 
finished, the fragments were size-separated by polyacrylamide gel electrophoresis and individual 
bands  were  detected  by  autoradiography.  The  template  complementary  sequence  was 
reconstructed by reading the gel bands  from the bottom up (in order of increasing molecular 
weight). 
The automated direct sequencing follows the same basic principle of the Sanger method, but no 
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longer  includes the use of radioisotopes  labelled primers but  di-deoxynucleotides conjugated 
with a separate fluorescent dyes (which fluoresce at different wavelength). The variant allows to 
perform a single amplification reaction. The different fluorophores are excited with a laser beam 
and,  each  fluorescent  signal  (corresponding  to  different  conjugated  di-deoxynucleotides)  is 
translated  by  a  software  in  chromatographic  peaks  of  a  particular  colour,  occurring  in  the 
reconstructed  sequence  in  positions  corresponding  to  the  associated  di-deoxynucleotides. 
According to the peaks order cthe software reconstructs the nucleotide sequence. If the software 
is  unable  to  discriminate,  for  the  same  nucleotide  position,  between  two peaks  of  different 
colours, none of the four DNA bases (A, G, C, T) are attributed. 
In this work automated direct sequencing was carried out using Capillary Array Electrophoresis 
Sequencer  CEQTM 8800  (Beckman  Coulter)  and  the  GenomeLab  Dye  Terminator  Cycle 
Sequencing (DTCS) with the Quick Start Kit  (Beckman Coulter). Each sequence reaction were 
performed in duplicate (once with the forward primer and one with the reverse), shrewdness 
useful in confirming possible ambiguities in the sequence or identify mutations. 
DNA sequencing reaction per sample was prepared as follows:
DTCS 2 μl 
primer Forward (or Reverse) 10 pmol 
purified PCR 30-50 ng 
H2OmQ (to adjust total volume to 10 μl)
TOTAL 10 μl
and  the  sequencing  reaction  program  is  run  on  GeneAmp  9700  thermocycler  (Applied 
Biosystems) or Mastercycler ep gradient S (Eppendorf) with the following conditions:
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96°C 20 sec
50°C 20 sec 30 cycles
60°C 4 min
4°C ∞
After thermal cycling program, the sample was purified by ethanol precipitation as follows:
 a fresh Stop Solution/Glycogen was prepared for each sample and transferred in a 1.5 ml 
labeled eppendorf tube: 2 μl of 3M Sodium Acetate (pH 5.2), 2 μl of 100 mM Na2-EDTA 
(pH 8.0) and 1 μl of 20 mg/ml of glycogen;
 the 10 μl of sequencing reaction and 60 μl of 100% cold ethanol were added to the Stop 
Solution and mixed throughly;
 the tube was spinned at 14000 rpm for 16 min at 4°C in a Eppendorf  5417R refrigerated 
centrifuge;
 the supernatant was discarded and 200 μl of 75% cold ethanol were added to the pellet 
and mixed throughly;
 the tube was spinned at 14000 rpm for 11 min at 4°C;
 the supernatant was discarded and 200 μl of 75% cold ethanol were added to the pellet 
and mixed throughly;
 the tube was spinned at 14000 rpm for 6 min at 4°C;
 the supernatant was discarded and the pellet was air- or vacuum-dried and then, dissolved 
in 35 μl of Sample Loading Solution (Beckman Coulter) and stored at 4°C until usage.
Nucleotide  changes  were  numbered  starting  from the  A of  the  ATG initiation  codon of  the 
GenBank cDNA clones.
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6.7 Phylogenetic conservation and in silico analysis
Presenilins phylogenetic study was performed by Blastp program (http://expasy.org/tools/blast/) 
which inputs protein sequences to sequence databases and returns an output file containing a list 
of potentially matching sequences (chosen on the bases of calculated statistical significance). 
In silico analysis  was  carried  out  by  SIFT  (http://sift.jcvi.org/)  and  PolyPhen2 
(http://genetics.bwh.harvard.edu/pph/) amino-acid-substitution (AAS) prediction methods, which 
predict  the  possible  impact  of  a  particular  aminoacid  substitutions  on  protein  structure  and 
function.  SIFT  uses  an  analysis  algorithm  based  only  on  sequence  homology  (scores  are 
calculated using position-specific scoring matrices with Dirichlet priors); PolyPhen2 refers to 
sequence conservation as well as it considers SWISS-PROT annotations (such as transmembrane 
domains and secondary structures) and informations from protein-structure database in order to 
model the position of amino acid substitution.
6.8 PCR products cloning
Frameshift  nucleotide  deletions  or  insertions  are  difficult  to  be directly interpreted on PCR-
sequence. In these cases one of the strategies that will overcome this difficulty, is the cloning of 
affected gene portion into a vector. Nucleotide sequencing of separate alleles enables to identify 
the type and the position at which this change is occurred. 
In this study cloning reactions were carried out using the commercial kit pSTBlue-1 AccepTor 
Vector Kit (Novagen) following manufacture's protocol.
Briefly, the procedure requires:
− preparation of the insert by PCR amplification with a non-proofreading DNA polymerase 
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[the GoTaq polymerase (Promega)] ;
− purification of insert (chloroform: isoamyl alcohol treatment);
− ligation reaction at 16°C for 2 hours;
− transformation of NovaBlue SinglesTM Competent Cells, followed by an outgrowth step at 
37°C for 45 min, shaked at 200-250 rpm;
− plating of transformed cells on LB agar medium containing ampicillin (or kanamycin), 
X-gal and IPTG;
− incubation overnight at 37°C;
− transformants  and  recombinants  selection:  pSTBlue-1  vector  containing  a  dual 
kanamycin/ampicillin  resistance  and  the  open  reading  frame  (ORF)  codifing  for  a 
functional lacZ α-peptide located in the polylinker. The antibiotic resistance is necessary 
for  the  transformed  cells  to  survive  when  plated  on  agar  containing  the  appropriate 
antibiotic.  The  lacZ α-peptide  complements  the  lacZ ω-fragment  expressed  by  the 
competent  cells  forming an active  β-galactosidase which can cleave the chromogenic 
substrate X-gal to yield a blue colony phenotype. Inserts are cloned within lacZ α-peptide 
ORF preventing the production of functional  α-peptide, which results in white colony 
phenotype  when  plated  on  X-gal/IPTG  indicator  plates.  Whereby,  pSTBlue-1  vector 
provides for blue/white screening of recombinants.  
− Insert  checking:  a  variable  number  of  transformed  colonies  (white  phenotype)  were 
dissolved in 30 μl of H2OmQ and used as template 
PCR mix for colonies DNA amplification (per sample):
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5X Colorless GoTaq Reaction Buffer (Promega) 1X
2 mM mix dNTPs 40 μM
primer forward 0.2 μM
primer reverse 0.2 μM
GoTaq DNA Polymerase (Promega) 0.75 units
dissolved colony 10 μl
H2OmQ (to adjust total volume to 10 μl)
TOTAL 30 μl
The appropriate PCR cycle was run on GeneAmp 9700 thermocycler (Applied Biosystems) or 
Mastercycler  ep  gradient  S  (Eppendorf)  and  PCR  products  were  separated  by  agarose  gel 
electrophoresis (1% agarose). The dissolved colonies actually containing the insert were used for 
subsequent direct sequencing reactions (according to 5.6.2 procedures). 
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Fig. 13. pSTBlue-1 Vector. 
The pSTBlue Vector is a general purpose vector with dual opposed prom oters, 
both ampicillin (Ap) and kanamycin (Kan) resistance, and a wide array of 
flanking restriction sites. 
6.9 Gene copy number variations analysis
Complete APP duplication and PGRN deletion have been reported in literature [238-240] to be 
associated with Alzheimer's disease and Frontotemporal Lobar Degeneration respectively. In this 
study, gene copy number variations (CNV) of APP and PGRN were investigated by Real-Time 
PCR and/or Multiplex Ligation-dependent Probe Amplification (MLPA) assay of MRC Holland. 
6.9.1 Real-Time PCR
Real-Time PCR is an assay in which the progression of PCR reaction is monitored as it occurs, 
not at the end of the process; this allows to detected the PCR product as it accumulates each 
cycle and not the final amount at the end-point step. In this study Real-Time PCR was carried out 
on a  7300 Real-Time PCR System (Applied Biosystem) by SYBR Green I  chemistry,  using 
iTaqTM SYBR® Green  Supermix  With  ROX  2X  (BIO-RAD),  and  performing  a  relative 
quantitation. A relative quantitation (RQ) determinates the change in expression of a target DNA 
(RNA) sequence in a test sample relative to the same sequence in a calibrator sample. Relative 
quantitation  is  commonly  used  to  compare  expression  levels  of  wild-type  (calibrator)  with 
mutated (test sample) alleles or the expression levels of a gene in different tissues. Besides target 
sequence, in a RQ assay an endogenous control is also essential because it is used as an active 
reference (usually a gene present at a consistent expression level in all experimental samples, 
both test and calibrator) to normalize quantitation of a target DNA for differences in the amount 
of DNA added to each reaction. Indeed, SYBR Green I is a double-stranded DNA Binding dye 
which binds nonspecifically to all double-stranded DNA sequences. For this reason, in this study, 
a singleplex PCR method was used where target sequence and endogenous control are amplified 
separately. A pair of primers for three exons of target  PGRN and  APP genes  and one exon of 
endogenous  Beta-2-microglobulin (B2M)  and  Ubiquitin C (UBC)  genes  were designed using 
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Primer3 software (http://frodo.wi.mit.edu/primer3/) [Table 13] in order to define amplicon 80-
120 bp long. A DNA sample of a patients with trisomy 21 (APP maps on chromosome 21) was 
available as positive control for APP duplication.
PCR reaction mix (per sample):
2X iTaqTM SYBR® Green Supermix With ROX 1X
primer forward 450-600 nM
primer reverse 450-600 nM
DNA template 100 ng
H2OmQ (to adjust total volume to 25 μl)
TOTAL 25 μl
Real-Time PCR cycle:
95°C 10 min
95°C 15 sec
60°C 1 min
At the end of PCR reaction, contamination of DNA samples was excluded by a dissociation stage 
consistent in a gradually slow temperature elevation over several minutes in order to determine 
the melting temperature of the target DNA sequence and rule out the presence of nonspecific 
PCR products. 
6.9.2 Multiplex Ligation-dependent Probe Amplification (MLPA) 
MLPA consists of a multiplex PCR method detecting abnormal copy numbers of genomic DNA 
and it is able to distinguish sequences differing in only one nucleotide. In contrast to a standard 
multiplex PCR, a single pair PCR primers is used for amplification, with a mixture of MLPA 
probes  that  hybridise  to  the  target  sequence.  The  resulting  amplification  products  (usually 
86
40 cycles
ranging  between  130  and  480  nt  in  length)  can  be  analysed  by  capillary  electrophoresis. 
Comparing the peak pattern obtained to that  of reference samples indicates which sequences 
show aberrant copy numbers. 
The MLPA reaction can be divided in five major steps: 
1) DNA denaturation  and  hybridisation  of  MLPA probes:  the  DNA is  denatured  and 
incubated  overnight  with  a  mixture  of  MLPA probes,  which  consist  of  two separate 
oligonucleotides,  each  containing  one  of  the  PCR primer  sequences.  The  two  probe 
oligonucleotides hybridise to immediately adjacent target sequences.
2) ligation reaction: only when the two probe oligonucleotides are both hybridised to their 
adjacent targets can they be ligated during the ligation reaction.
3) PCR  reaction:  only  ligated  probes  will  be  exponentially  amplified  during  the  PCR 
reaction thus the number of probe ligation products is a measure for the number of target 
sequences in the sample.
4) separation of amplification products by capillary electrophoresis.
5) data  analysis.  Probe  oligonucleotides  that  are  not  ligated  only  contain  one  primer 
sequence.  As  a  consequence,  they  cannot  be  amplified  exponentially  and  will  not 
generate a signal. 
In this study, the SALSA P275-B1 MAPT-PGRN and SALSA P170-B2 APP kits (MRC Holland) 
were used according to the manufacturer's protocol. Two hundreds ng of genomic DNA for each 
patients  were  used.  MLPA amplification  products  were  analyzed  using  a  Capillary  Array 
Electrophoresis Sequencer  CEQTM 8800 (Beckman Coulter). Raw data analysis was performed 
by Fragment Analysis software (Beckman Coulter) while normalisation of the electrophoresis 
results  and  interpretation  of  data  were  carried  out  using  MRC  Coffalyser  software 
(http://old.mlpa.com/coffalyser/download.html). 
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6.10 Microsatellites Analysis
Microsatellites  DNA (also  called  Simple  Sequence  Repeats  –  SSR)  are  1-4  nucleotide-long 
tandem repeat sequences. The number of repeats in a given microsatellite can be highly variable, 
a characteristic that makes them genetic useful markers, used for mapping, linkage analysis and 
to  trace  inheritance  patterns.  When  used  to  identify   a  specific  chromosome  or  locus  (i.e. 
associated to a definite disorder), the difference in the number of repeats between alleles are 
evaluated.  A disease  inheritance  pattern  within  a  family  may  be  traced   by  microsatellites 
analysis which allows the identification of mutant allele by comparing the alleles of affected and 
unaffected individuals. 
In this study, the association to the 9p21.3-13.3 chr9 locus was evaluated for a family with FTD-
MND  and  a  neuropathological  patter  compatible  with  the  FTLD-TDP subtype.  The  SSRs 
analysis (performed genomic DNA samples of 2 affected and 1 unaffected family members) was 
done  in  collaboration  with  the  Neurodegenerative  Brain  Disease  Group,  VIB-Department  of 
Molecular Genetics, University of Antwerp, Belgium where the assay was carried out by the 
group  of  Christine  Van  Broeckhoven  and  Marc  Cruts.  The  analysis  involved  the  following 
markers:  D9S285,  D9S157,  D9S1684,  D9S1846,  D9S1870,  D9S171,  D9S1679,  D9S1833, 
D9S1121, D9S259, chr9_7, D9S319, D9S1853, D9S43, D9S304, W1226, D9S1845, D9S165, 
D9S1804,  D9S1859,  D9S772,  ATA124G,  D9S273,  D9S1799,  D9S1837,  D9S175,  D9S1780. 
Polymerase chain amplification reactions and analysis was performed as described [241, 242].
6.11 Protein serum quantification by ELISA assay
Progranulin levels in serum or plasma were demonstrated to be a predictor of  PGRN mutation 
carriers, both in symptomatic patients and asymptomatic family member, vice versa, the analysis 
may  be  useful  to  interpret  the  pathological  meaning  of  unclear  variations  (not  frameshift 
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mutations). 
In this study, progranulin serum levels were quantified both in patients affected by FTLD and in 
control subjects using Progranulin (human) ELISA Kit (AdipoGen). Serum protein assay was 
performed according  to  the  manufacturer's  protocol.  Duplicate  serum PGRN levels  for  each 
sample were averaged.
6.12 Haplotype analysis
6.12.1 NOTCH3 mutation carriers
Genotyping  was  performed on  134 individuals  including  103,  affected  (64)  or  healthy (39), 
individuals  from 22  available  families,  and  31  unrelated  probands  for  whom no  additional 
pedigree members were available (Table 14). 
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Mutation 
Families  
N. Unrelated 
N.  Affected  Unaffected 
R90C      3 
C108S      1 
R133C 1  2   1 
R141C 2  3  2 1 
C146R 3  12  6 1 
R169C      1 
C174Y 1  5    
C201R 1  2  1  
R207C      3 
C251R      1 
C271F 1  2    
C366W      1 
S396C 5  11  4 5 
G528C 1  3  1 1 
R592C 1  2  1  
C606R      1 
R607C 1  5  1  
C939R      1 
R1006C 5  17  23 7 
G1013C      1 
R1231C      2 
 
Table 14. Pedigree and unrelated index cases included in genotype and haplotype analyses.
For each m utation the num ber of available families and unrelated index cases is reported. 
The total number of analyzed affected and unaffected fam ily members is also reported.
6.12.2 Tagging SNPs of NOTCH3 gene
A set  of  single  nucleotide  polymorphism  (SNP)  was  selected  from  the  HapMap  database 
(caucasoid population, http://www.hapmap.org, rel#24) by a tag selection algorithm that searches 
for  the  marker  subset  presenting  maximum  entropy 
(http://www.well.ox.ac.uk/rmott/SNPS/running.shtml). The following 5 SNPs were selected to 
tag  the  most  common  NOTCH3 haplotypes  in  the  Caucasian  population:   rs3815188, 
rs10423702,  rs10426042,  rs4809030  and  rs1044009  (Fig.  14).  Each  SNP was  analysed  by 
DHPLC, nucleotide sequencing and Illumina ASPE Assay.
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Fig. 14. Block structure for NOTCH3 from HapMap Genome Build 36. 
The linkage disequilibrium  (LD) plot was obtained using Haploview and HapMap Build 36. The scale at the top of the 
figure depicts the HapMap region for NOTCH3 (Chrom osome 19: 15,131,445 to 15,172,792), and roughly 7 kb 
upstream and downstream of this region. Single nucleotide polymorphisms (SNPs) genotyped by HapMap are identified 
in blue (m inor alleles) and red (m ajor alleles). Gene regions with the direction of their respective reading frame, exons, 
and introns, are also given. 5 SNPs in boxes are the tagSNPs selected in this gene region. The r2 LD color scheme is 
depicted. Two blocks are delineated using the default block definitions from Haploview [Gabriel SB, et al.  The structure 
6.12.3 SNPs Genotyping by Illumina ASPE Assay
The set of five selected SNPs was analyzed using Illumina VeraCode Universal Capture Beads 
technology  by  ASPE  (Allele-Specific  Primer  Extension)  chemistry  combined  with  Illumina 
BeadXpress Reader System. ASPE  is a low plex genotyping assay based on the use of two 
different  sets  of  oligonucleotides:  PCR-primers  (forward  and  reverse)  for  amplification  of 
genomic DNA region with SNP of interest and, ASPE-probes (a pair for each SNP) composed of 
three parts: 5'- capture sequence (used in subsequent hybridization reactions) - genomic sequence 
(complementary to genomic region preceding the SNP) - wildtype or variant allele SNP -3'. Each 
ASPE probe is associated to a unique VeraCode capture sequence, different between wildtype 
and  variant  allele.  PCR-primers  and  ASPE-probes  were  designed  using  Primer3  software 
(http://frodo.wi.mit.edu/primer3/) taking in consideration the criteria reported in VeraCode Assay 
Guideline:  melting  temperature  of  nearly  60°C  and  100-200  bp  amplicon  length  for  PCR-
primers; melting temperature of nearly 50°C, wildtype and variant allele ASPE-probes design 
from the same strand with a 20-30 bp length (Tables 15-16). For each pairs of primers and probes 
formation of secondary structure, dimers or crosshybridization were rulled out. All five selected 
SNPs were amplified in a multiplex PCR carried out in a 15 μl reaction volume containing, 150 
ng of genomic DNA template, 1X TAQ Buffer, 1.67 mM MgCl, 200 μM dNTPs, 10 pmol each 
PCR-primer, 0.75 units of Platinum TAQ (Invitrogen). PCR amplification was performed by a 
GeneAmp 9700 thermocycler (Applied Biosystems) with the following PCR program: 95°C hot 
start denaturation for 5 min; 30 cycles including a denaturation step at 95°C for 30 sec, annealing 
step at 58°C for 30 sec and extension step at 72°C for 30 sec. After amplification, PCR products 
underwent  a single-step enzymatic  clean-up to eliminate  unincorporated primers and dNTPs. 
ExoSAP-IT® (usb)  was  added  directly  to  the  reaction  products  after  amplification  and  the 
following thermocycler program was run: incubation at 37°C for 45 min and enzyme inactivation 
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at 99°C for 15 min. After this treatment, PCR products were incubated with both wildtype and 
variant ASPE probes and underwent multiple rounds of oligonucleotide extension incorporating 
biotin. ASPE elongation reaction was carried out in a 20 μl reaction volume containing, 1X TAQ 
Buffer, 1.58 mM MgCl, 5 μM dATP, dGTP, dTTP and Biotin 14-dCTP, 5 pmol ASPE-probes 
premix, 1 unit of Platinum TAQ (Invitrogen) and 3 μl of PCR/ExoSAP-IT reaction. The ASPE 
thermocycler  program  was  as  following:  96°C  hot  start  denaturation  for  2  min;  40  cycles 
including a denaturation step at 94°C for 30 sec, annealing step at 54°C for 30 sec and extension 
step at 74°C for 30 sec. During this program, there is the preferentially extension of either probe 
or both, depending on genotype (homozygous for wildtype or variant allele in the first case or 
heterozygous in the second). After probes extension, products were hybridized to the VeraCode 
Beads (that have been previously kitted into a 96-well polypropylene plate) and labeled with a 
streptavidin-fluorophore conjugate according to the manufacture's protocol. After this step, the 
VeraCode  Bead  Plate  was  scanned  by  BeadXpress  Reader  and,  only  streptavidin-labeled 
biotinylated extension products will produce a fluorescent signal. The automatic allele calling 
was performed by the Illumina BeadStudio Data Analysis Software with a GeneCall threshold of 
0.25. The genotype of the SNP was determined by the ratio of the relative fluorescent levels of 
the two bead type. ASPE genotyping accuracy was evaluated and validated comparing the SNP 
genotype obtained using ASPE Assay with available results of direct sequencing and DHPLC 
analysis. 
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6.12.4 Haplotypes reconstruction
In  20  pedigrees  haplotypes  were  reconstructed  using  the  computer  program  Genehunter 
(http://www.broad.mit.edu/ftp/distribution/software/gh2.1/).  For  each  of  the  20  families  the 
haplotype  segregation  proposed  by  the  computer  program was  verified  by a  researcher   to 
evaluate possible alternative segregation patterns involving different haplotype configurations, 
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SNP
Forward Reverse
rs3815188 GGACAGGGTGAGTTTAGGA GTGTCTGCCAGAGTTCAGT
rs10423702 CCATTTGCACCTGTCCT AGCCCATTCACAGACGA
rs10426042 CTGTGCAACCACTGATTTG GGGTGAACCTTGAGAACATA
rs4809030 ACACACACACAGACACAAAGTG CCAGTGTAAGGCTGATTTCC
rs1044009 CTCGTTCCTGCTGCCACT CAGGTAAGGGTGCTCACTG
SNP
Allele 1 Allele 2
rs3815188 CATGAGAATCGGGCA ATGAGAATCGGGCG
rs10423702 CCCATTCACAGACGAC CCCATTCACAGACGAT
rs10426042 CAGACAAAAAAGACCACC CAGACAAAAAAGACCACG
rs4809030 CTCTCTCCCCTTCAC CTCTCTCCCCTTCAT
rs1044009 AGGAGTACCCGGC GAGGAGTACCCGGT
Table 15: oligonucleotide sequences for PCR-amplification of SNPs
PCR-Primer sequence (5' → 3')
Table 16: probe sequences for ASPE-elongation of the SNPs
ASPE-probes sequence (5' → 3')
according to haplotype frequency estimated on the entire family set. Segregation of the mutation 
was linked to a precise haplotype in all the families (Appendix 2. 
In 31 unrelated probands without testable pedigree members haplotypes were reconstructed by a 
maximum-likelihood computation  computation based on a expectation-maximization algorithm 
as implemented in the computer program Gerbil [243].
6.13 Skin biopsy and electron microscopy
Sixteen patients belonging to 13 families harbouring 8 distinct mutations of NOTCH3 underwent 
skin biopsy upon signing an informed consent. Scalpel skin biopsies, carried out at our hospital 
by a singleton operator (S.F.) after patients examination, were taken from the deltoid region and 
included  derma  and  subderma.  Skin  biopsy  specimens  6-8  mm  thick  were  processed  for 
histological and ultrastructural examination according to standard techniques. Skin biopsies from 
CADASIL patients  and  50  unrelated  patients  with  a  leukoencephalopathy  of  undetermined 
etiology, not associated with mutations of NOTCH3 were analysed. In each case, 2 pathologists 
(T.C.  and  N.R.),  blinded  to  clinical  and  genetic  data,  evaluated  the  presence  of  GOM  by 
examining the ultrastructure of at least 10 vessels surrounded by smooth muscle cells. 
6.14 Formalin-fixed Paraffin-embedded immunohistochemistry (IHC)
Brains  of  patients  with  clinical  diagnosis  of  dementia  (Alzheimer's  disease,  Frontotemporal 
Lobar Degeneration) were collected post-mortem in line with Local Ethical Committee approval 
and  after  obtain  informed  consent  from  deceaseds  parents.  After  collection,  they  were 
immediately fixed in 10% buffered formalin for 3-4 weeks. Standard blocks of frontal cortex, 
temporal pole, parietal cortex, occipital cortex, hippocampus and amygdala, caudate nucleus and 
putamen, globus pallidus and thalamus, cerebellum and dentate nucleus, substantia nigra and 
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locus caeruleus, were cut from the fixed brains and processed routinely into paraffin wax. 
In  this  study,  Formalin-Fixed  Paraffin-Embedded  (FFPE)  brain  tissue  blocks  were  cut  in  a 
Autocut  2040  Microtome  (Reichert-Jung)  at  a  thickness  of  approximately  9  microns,  and 
immunostained using a conventional avidin-biotin peroxidase method. 
The  primary  polyclonal  rabbit  anti-ubiquitin  (Dako,  Ely,  UK),  anti-human  PHF-TAU 
monoclonal (Thermo Scientific) and TARDBP monoclonal (ABnova) antibodies were used at a 
dilution of 1:200, 1:1000 and 1:1000 respectively.  
Briefly:
− slides  preparation:  cut  sections  were  affixed  onto  Superfrost  Plus  slides  (Thermo 
Scientific) and dried at 37°C for 24 hours.
− Deparaffinization and hydration of tissue sections: the slides were put into a vertical slide 
rack for IHC and dipped into 2 consecutive staining jars containing xylene (Carlo Erba 
Reagents) for 5 minutes each step. Then, the rack was dipped in 100% and 95% ethanol 
for 5 minutes each step. 
− Quenching the peroxidase: the rack was dipped in 30 volume H2O2 + 8% methanol for 30 
minutes. The slides were then dipped into 4 consecutive staining jars containing 70%, 
50% and 30% ethanol and distillate H2O for 5 minutes every step. 
− Retrieving antigen: an additional step was performed when using primary anti-human 
PHF-TAU and TARDBP antibodies. For the former, an extra treatment in formic acid for 
5 minutes and repeated washing in distillate H2O, for the latter, an autoclaving in 0.1M 
citrate  buffer  (pH  7.6)  at  121°C  for  5  minutes  letting  the  slides  drying  at  room 
temperature. After these treatments, the slides were washed with PBS buffer (pH 7.4). 
The  slides  that  were  going  to  be  treated  with  a  monoclonal  or  a  polyclonal  antibody were 
preincubated  with  2% Normal  Horse  Serum,  NHS (Vector)  or  Normal  Goat  Seruma,  NGS 
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(Dako, Ely, UK) respectively, in PBS for 30 minutes at room temperature and in a wet chamber. 
− Primary antibody incubation: the rack was dipped three times in PBS, 5 minutes each 
ones and the sections were encircled with a PAP pen. Antibody solution (with the proper 
dilution in NHS or NGS) was dropped to cover the section and incubated overnight at 
4°C.
− Secondary antibody incubation: the rack was dipped three times in PBS, 5 minutes each 
ones  and  secondary  antibodies  (diluted  1:200  in  PBS),  anti-mouse  IgG  biotinylated 
(Vector)  for primary monoclonal antibody or anti-rabbit  IgG biotinylated (Vector)  for 
primary polyclonal antibody were dropped to each slides and incubated for 1 hour at 
room temperature in a wet chamber. Three PBS washings were performed, 5 minutes 
long.  ABC elite  standard  (Vector),  prepared  in  PBS as  manufacturer's  data  sheet  45 
minutes  before usage,  was dropped to  each slide and incubated for  45 minutes.  One 
washing in PBS and two in distillate H2O, each 10 minutes long, followed this step.
− Colorimetric detection: this step was carried out using NovaRED Substrate Kit (Vector) 
following manufacturer's protocol. The detection reaction was stopped dipping slides in 
tap water followed by a washing in distillate H2O.
− Counter staining: the slides were quickly dipped into a staining jar  containing Mayer 
hematoxylin and rinsed with distillate H2O. The rack was then dipped 5 times in 70%, 
100% ethanol and xylene consecutively.
− Mounting: Entellan (Merck) was dropped onto the sections and a cover glass was put 
onto the slides.
96
7. Results 
7.1 Alzheimer's Disease and Frontotemporal Lobar Degeneration
During  the  mutational  analysis  of  AD-  and  FTD-associated  genes,  eight  non-synounimous 
nucleotide  variations  were  identified,  those  already  reported  in  literature  and  considered 
pathogenic  mutations  and  others  first  identified  in  this  study  that  represent  putative  novel 
mutations  (See  Table  17).  Clinical  and  genetic  findings  for  each  of  these  substitutions  are 
separately detailed below.  
Table 18 reports many intronic and exonic nucleotide variations identified with high recurrence 
in the series, already reported in literature as single nucleotide polymorphisms (SNPs).
SNPs  frequencies  were  calculated  on  the  entire  series  and,  out  of  this  list  another  PSEN2 
nucleotide variation was identified, p.Arg62His (frequency, 1,4%), for which there is a debate in 
literature about its possible pathogenic role in Alzheimer's Disease due to conflicting findings. 
 
97
Table 17-18.
1 Numbering according to the largest isoforms with GenBank Accession Num ber [NG_007886.1 for PGRN, NG_007398.1 for 
MAPT, NG_007887.1 for VCP, NG_007386.2 for PSEN1 and NG_007381.1 for PSEN2].
2  Numbering according to the largest isoform s with GenBank Accession Number [NM_002087.2 for PGRN and 
NM_001123066.3 for MAPT, NM_007126.3 for VCP, NM_000021.3 for PSEN1 and NM_000447.2 for PSEN2] and starting 
at the translation initiation codon.
3  Num bering according to the largest isoforms with GenPept Accession Number [NP_002078.1 for PGRN and 
NP_001116538.2 for MAPT, NP_009057.1 for VCP, NP_000012.1 for PSEN1 and NP_000438.2 for PSEN2].
Novel probable mutations are reported in bold.
Table 17: DNA nucleotide variations with definite or probable pathogenic nature
Patient id Gene
F1 FTD PGRN 3 g.9420 c.378delC p.Phe86SerfsX170
F2 FTD 8 g.11019_11022 c.813_816delCACT p.Thr272SerfsX10
F3 PNFA 11 g.11910 c.1197delC p.His400ThrfsX12
F4 FTD MAPT IVS10 g.120998 c.2002+16 C>T
A1 AD PSEN1 12 g.87725 c.1310 T>A p.Ile437Asn
A2 AD PSEN2 4 g.16389 c.53 C>T p.Thr18Met
A3 AD 5 g.18203 c.211 C>T p.Arg71Trp
A4 AD 7 g.22541 c.520 A>G p.Met174Val
Clinical 
Diagnosis Exon Genome
1 Predicted RNA2 Predicted Protein3
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Table 18: DNA polymorphisms
Gene SNP frequency
PGRN 3 g.9450 c.264+21 G>A rs9897526 27,7%
5 g.10115 c.359 C>A p.Ser120Tyr rs63750043 0,5%
5 g.10140 c.384 T>C p.Asp128Asp rs25646 3,6%
5 g.10242 c.462+24 G>A rs850713 29,0%
10 g.11464 c.970 G>A p.Ala324Thr rs63750541 0,5%
12 g.12349 c.1533 G>C p.Gly515Ala rs25647 0,5%
MAPT 1 g.72904 c.1-13 A>G rs17650901 30,4%
1 g.73077 c.133+28 C>A 30,4%
9 g.106953 c.1562-26 G>A rs117200923 38,4%
9 g.107022 c.1605 C>T p.Pro200Pro 46,5%
9 g.107103 c.1686 A>G p.Ala227Ala rs1052553 39,7%
9 g.107187 c.1770 T>C p.Asn255Asn rs17652121 40,2%
9 g.107232 c.1815 G>A p.Pro270Pro rs11568305 5,4%
11 g.124781 c.1921-42 T>C 9,8%
11 g.124938 c.2002+34 G>A rs75534191 14,7%
13 g.134785 c.*+26 T>C rs118104841 4,5%
VCP 2 g.9539 c.129+47 G>A rs10972300 38,0%
7 g.14768 c.811+3 G>A rs514492 30,3%
12 g.16785 c.1360-35 A>G  rs2258240 32,2%
12 g.16994 c.1482+52 T>C rs562381 32,2%
13 g.17438 c.1695+8 A>G rs684562 47,8%
PSEN1 4 g.39343 c.104 G>A p.Arg35Gln rs63750592 0,5%
8 g.66540 c.770-21 T>C rs3025786 10,7%
8 g.66675 c.868+16 G>T rs65932 40,6%
9 g.75000 c.953 A>G p.Glu318Gly rs17125721 4,0%
PSEN2 4 g.16405 c.69 T>C p.Ala23Ala rs11405 53,6%
4 g.16465 c.129 C>T p.Asn43Asn rs6759 53,1%
5 g.18092 c.142-42 G>A rs1295643 18,3%
5 g.18105 c.142-29 T>C rs1295644 32,1%
5 g.18253 c.261 C>T p.His87His rs1046240 31,7%
6 g.20138 c.498+30 G>C rs2236910 34,4%
10 g.25683 c.887-24 T>C rs2802267 36,1%
12 g.28578 c.1191+24 G>A rs2855562 13,4%
Exon Genome1 Predicted RNA2 Predicted Protein3
7.1.1 Alzheimer's Disease 
Seventeen out of 50 unrelated index cases with clinical and/or neuropathological diagnosis of 
AD, presented family history for dementia (FAD cases). 
Four  non-synonymous  nucleotide  variations  were  identified  in  four  independent  FAD cases 
including, two novel substitutions one in each Presenilin gene, and two already reported PSEN2 
variations (Table 17).
These variations together account for 23,52% of FAD and for 8% of all analyzed AD patients. 
No APP mutations or gene duplication were detected. 
7.1.1.1 A1 case
7.1.1.1.1 Clinical presentation and neuroradiological features
At the moment in which this study has been draft no detailed clinical and radiological data were 
available about this seventy-three year-old man examined at Bellaria Hospital, with a clinical 
diagnosis of AD. The only known informations included a positive family history and a late 
onset of the disease.
7.1.1.1.2 Molecular genetics
DHPLC analysis disclosed an abnormal chromatographic profile for exon 12 of  PSEN1 which 
was further characterized by direct sequencing leading to the identification of the novel c.1310 
99
1 2
I
II
1
Fig. 15.  A1 pedigree. 
The arrow indicates the proband; circles, females; 
squares, m ale; black symbols, affected family m em bers; 
grey sym bols, affected status not available;  slashed 
sym bols, deceased fam ily members. 
T>A heterozygous transversion (Fig.  16).  This nucleotide variation is  predicted to cause the 
substitution of aminoacid isoleucine with an asparagine at codon 437 (p.Ile437Asn), affecting a 
residue  localized in putative transmembrane domain IX (TM-IX) of the protein. 
This PSEN1 nucleotide variation was excluded in 492 cognitively healthy control subjects.
7.1.1.1.3 Phylogenetic and in silico analysis
Multiple  alignment  of  presenilins  disclosed  high  phylogenetic  conservation  of  the  affected 
residue (Ile 437) among different species, both in PSEN2s and PSEN1s (Fig. 17). The effects of 
this aminoacid substitution on protein function was predicted to be not tolerated and probably 
deleterious.    
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p.Ile437Asn
ex12 WT
A
c.1310 T>A
B
Fig. 16. A1 case: DHPLC and sequencing analysis results.
A: PSEN1 ex12 chromatographic profiles in A1 patient (upper) and wild-type control (lower). B: direct sequence 
of ex12 in A1 patients disclosing the c.1310 T>A heterozygous nucleotide transversion (arrow).
7.1.1.2 A2 case
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Fig. 17. Phylogenetic conservation of PSEN1 Ile437 among different PSEN1s and PSEN2s species.
The Isoleucine residue at codon 437 is highly conserved among PSEN1s and PSEN2s of different species.
Panels A and C differentiate am inoacids according to their physicochem ical properties [pink, aliphatic/hydrophobic residues; 
green, hydrophilic residues; red, negative charged aminoacids; blue, positive charged am inoacids; yellow, cysteines; orange, 
aromatic residues; cyclam en, conform ationally special].
Panels B and D differentiate aminoacids according to their hydrophobicity properties [the m ost hydrophobic residues are reported 
in in red while the more hydrophilic in blue]. 
Fig. 18.  A2 pedigree. 
The arrow indicates the proband; circles, females; squares, m ale; black symbols, 
affected fam ily members; slashed sym bols, deceased fam ily members. I.2: died at the 
age of 80 years with clinical diagnosis of Alzheim er's disease, began when she was 70. 
II.3 and II.4, respectively 68 and 60 years old asym ptom atic proband's sisters. III.1-2-
3-4, respectively 48, 47, 45 and 40 years old asym ptom atic proband's offspring. 
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X. tropicalis
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C D
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7.1.1.2.1 Clinical presentation and neuroradiological features
The  proband,  a  74  years  old  female  (individual  II.2  in  Fig.17)  came  to  the  attention  of 
neurologists at G.B. Rossi  Hospital one year after  onset of symptoms (age 72) consisting of 
social  withdrawal,  mood deflection,  short-term memory deficit  and  anomie.  During  her  first 
neuropsychological examination she scored 21/30 to MMSE, disclosing mild deficit of short-
term memory and word production.  She preserved daily self-care  and instrumental  activities 
[Activities of Daily Living (ADL): 6/6; Instrumental Activities of Daily Living (IADL): 8/8]. At 
age 73 years she underwent a brain CT scan disclosing an accentuation of Cerebral Spinal Fluid 
(CSF)  and  cisternal  spaces.  Eighteen  months  after  symptoms onset  the  patient  underwent  a 
second  neuropsychological  assessment  that  showed  no  significant  changes  except  for  a 
worsening  of  long-term  memory.  Six  months  later  she  was  subjected  to  a  further 
neuropsychological  examination  revealing  a  consistent  worsening  of  cognitive  functions 
(MMSE: 11/30):  severe memory deficits,  impaired word production and a modest decline in 
executive functions affecting her skilfulness of daily life and reducing her autonomy (ADL: 5/6 
and  IADL:  4/8).  Two  years  after  symptoms  onset  a  brain  MRI  disclosed  white  matter 
hyperintensity, enlargement of third and lateral ventricules, CSF and cisternal spaces (Fig. 19). 
At the same time she performed a brain SPECT which revealed slight hypoperfusion of temporal 
cortex, most marked in the left hemisphere. 
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Fig. 19. A2 proband neuroradiological findings.
A: Magnetic Resonance Im aging scan: saggital and coronal sections.
B: 18F-Fluorodeoxyglucose (18FDG) positron emission tom ography (PET). 
7.1.1.2.2 Molecular genetics
DHPLC analysis disclosed an abnormal chromatographic profile for exon 4 of  PSEN2 which 
underwent direct sequencing displaying the novel c.53 C>T heterozygous transition (Fig. 20). 
This nucleotide variation is predicted to cause the substitution of aminoacid threonine with a 
methionine at codon 18 (p.Thr18Met), affecting a residue  localized in the putative N-terminal 
domain of the protein. 
This PSEN2 nucleotide variation was excluded in 492 cognitively healthy control subjects.
7.1.1.2.3 Phylogenetic and in silico analysis
Multiple alignment of presenilins disclosed high phylogenetic conservation of affected residue 
(Thr 18) in PSEN2s of different species not in PSEN1s (Fig. 21). The effects of this aminoacid 
substitution on protein function was predicted as not tolerated and probably damaging by SIFT 
and PolyPhen in silico analyses.    
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ex4 WT
p.Thr18Met
A
c.53  C>T
B
Fig. 20. A2 case: DHPLC and sequencing analysis results.
A: PSEN2 ex4 chrom atographic profiles in A2 proband (upper) and wild-type control (lower). B: direct 
sequence of ex4 in A2 proband disclosing the c.53 C>T heterozygous nucleotide transition (arrow).
7.1.1.3 A3 case
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Fig. 21. Phylogenetic conservation of PSEN2 Thr18 among different PSEN2s and PSEN1s species.
The Threonine residue at codon 18 is highly conserved among PSEN2s of different species, not in PSEN1s. 
Panels A and C differentiate aminoacids according to their physicochemical properties [pink, 
aliphatic/hydrophobic residues; green, hydrophilic residues; red, negative charged aminoacids; blue, positive 
charged am inoacids; yellow, cysteines; orange, aromatic residues; cyclam en, conform ationally special].
Panels B and D differentiate am inoacids according to their hydrophobicity properties [the most hydrophobic 
residues are reported in in red while the more hydrophilic in blue]. 
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Fig. 22.  A3 pedigree. 
The arrow indicates the proband; circles, females; squares, m ale; black 
sym bols, affected fam ily members; slashed sym bols, deceased fam ily members. 
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7.1.1.3.1 Clinical presentation and neuroradiological features
This proband (III.1) is a 63 years old male with a four-year history of behaviour changes and 
multiple  cognitive  decline.  A SPECT scan,  carried  out  at  age  59  years,  demonstrated  mild 
hypoperfusion in both temporal and parietal cerebral cortex, more pronounced on the right side. 
Neuropsychological  evaluation,  two  years  after  his  initial  referral,  revealed  a  prominent 
worsening of cognitive functions with a fair impairment of daily living activities (MMSE: 16/30; 
IADL: 3/5 and ADL:6/6).  Over the following year he developed substantial  behavioural  and 
personality changes characterized by an alternation between a state of apathy and restlessness, 
disinhibition, verbal and physical aggression, foul language. Also his memory (especially long-
term verbal memory) and attentional functions have undergone a further deterioration, associated 
to  impaired  executive  functions,  deficits  of  written  comprehension,  constructive  apraxia, 
agraphia.  He  underwent  a  further  neuropsychological  examination  which  confirmed  a 
progressive global cognitive impairment (he scored 7/30 to MMSE, 1/5 to IALD and 5/6 to 
ADL). 
7.1.1.3.2 Molecular genetics
DHPLC analysis disclosed an abnormal chromatographic profile for exon 5 of  PSEN2 which, 
after direct sequencing revealed the already reported c.211 C>T heterozygous transition (Fig. 
23). This nucleotide variation is predicted to cause the substitution of aminoacid arginine with a 
tryptophan at codon 71 (p.Arg71Trp), affecting a residue localized in the putative N-terminal 
domain of the protein. 
This PSEN2 nucleotide variation was excluded in 492 cognitively healthy control subjects.
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7.1.1.3.3 Phylogenetic and in silico analysis
Multiple alignment of presenilins showed affected residue (Arg 71) to be phylogenetic conserved 
among PSEN2s of many different species not in PSEN1s (Fig. 24). The effects of this aminoacid 
substitution on protein function was predicted as not tolerated and probably damaging by SIFT 
and PolyPhen in silico analyses.    
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Fig. 23. A3 case: DHPLC and sequencing analysis results.
A: PSEN2 ex5 chromatographic profiles in A3 patient (upper) and wild-type control (lower). B: direct sequence of 
ex5 in A3 patient disclosing the c.211 C>T heterozygous nucleotide transition (arrow).
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p.Arg71Trp
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Fig. 24. Phylogenetic conservation of PSEN2 Arg71 among different PSEN2s and PSEN1s species.
The Arginine residue at codon 71 is conserved am ong PSEN2s of m any different species, not in PSEN1s. 
Panels A and C differentiate am inoacids according to their physicochem ical properties [pink, aliphatic/hydrophobic residues; 
green, hydrophilic residues; red, negative charged aminoacids; blue, positive charged aminoacids; yellow, cysteines; orange, 
aromatic residues; cyclam en, conformationally special]. Panels B and D differentiate am inoacids according to their 
hydrophobicity properties [the most hydrophobic residues are reported in in red while the m ore hydrophilic in blue]. 
7.1.1.4 A4 case
7.1.1.4.1 Clinical presentation and neuroradiological features
The proband (III.3) disclosed behavioural impairment by the age of 75. She became increasingly 
apathetic, with personal and daily workhouses neglect. Over the first year after symptoms onset 
she developed mnesic and attentional deficits, temporal disorientation, anomie and ideo-motor 
slowing.  Repeated  neuropsychological  assessments  showed  no  significant  alterations  of 
cognitive  functions.  Three  years  after  her  first  evaluation,  she  underwent  a  further 
neuropsychological  examination  (MMSE:  20/30)  which  revealed  temporal  disorientation 
associated  to  deficits  of  long-  and short-term verbal  memory,  impairment  of  phonemic  and 
semantic verbal fluency, with deficits of attentional and frontal executive functions. Her ideo-
motor slowing worsened in association with a remarkable impairment of quality and autonomy 
of daily living (IADL: 1/8 and ADL: 3/6) accompanied by  depressive symptoms. A brain MRI 
and SPECT, performed at age 78 years, showed respectively a mesial temporal atrophy and, an 
hypoperfusion of both temporal and frontal parieto-occipital cortex, worse in the left hemisphere 
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Fig. 25.  A4 pedigree. 
The arrow indicates the proband; circles, fem ales; squares, m ale; black 
sym bols, affected fam ily members; slashed sym bols, deceased fam ily members. 
with an asymmetric uptake at basal ganglia (Fig. 26). The patient died at age 79 years, four years 
after onset of symptoms. No post-mortem examination was undertaken. 
7.1.1.4.2 Molecular genetics
DHPLC analysis disclosed an abnormal chromatographic profile for exon 7 of  PSEN2 which, 
after direct sequencing revealed the already reported c.520 A>G heterozygous  transition (Fig. 
27). This nucleotide variation is predicted to cause the substitution of aminoacid methionine with 
a valine at codon 174 (p.Met174val), affecting a residue localized in the putative transmembrane 
domain III (TM-III) of the protein.
This PSEN2 nucleotide variation was excluded in 492 cognitively healthy control subjects.
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Fig. 26. A4 proband neuroradiological findings.
Magnetic Resonance Im aging scan: saggital and coronal sections.
p.Met174Val
ex7 WT
A B
c.520 A>G
Fig. 27. A4 case: DHPLC and sequencing analysis results.
A: PSEN2 ex7 chromatographic profiles in A4 proband (upper) and wild-type control (lower). B: direct 
sequence of ex7 in A4 patient disclosing the c.520 A>G heterozygous nucleotide transition (arrow).
7.1.1.4.3 Phylogenetic and in silico analysis
Multiple alignment of presenilins showed that the affected residue (Met 174) was phylogenetic 
conserved among PSEN2s of only few different species but it was not conserved in PSEN1s 
(Fig.  28).  The  effects  of  this  aminoacid  substitution  on  protein  function  was  predicted  as 
tolerated and probably not damaging by SIFT and PolyPhen in silico analyses.    
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Fig. 28. Phylogenetic conservation of PSEN2 Met174 among different PSEN2s and PSEN1s species.
The Methionine residue at codon 174 is conserved in PSEN2s of few different species, not in PSEN1s. 
Panels A and C differentiate aminoacids according to their physicochemical properties [pink, 
aliphatic/hydrophobic residues; green, hydrophilic residues; red, negative charged aminoacids; blue, positive 
charged am inoacids; yellow, cysteines; orange, aromatic residues; cyclam en, conform ationally special].
Panels B and D differentiate am inoacids according to their hydrophobicity properties [the most hydrophobic 
residues are reported in in red while the more hydrophilic in blue]. 
7.1.2 Frontotemporal Lobar Degeneration
Fifteen out of 76 unrelated index cases with clinical and/or neuropathological diagnosis of FTLD 
syndromes, presented family history for dementia. 
Four non-synonymous nucleotide variations  -  two already reported and one novel  frameshift 
PGRN and  one  already  reported  splice-site  MAPT mutations  -  were  identified  in  four 
independent familial FTLD cases (Table 17). 
Together these four variations account for 26,66% of familial FTLD cases and for 5,26% of all 
analyzed FTLD cases. 
No PGRN deletion or VCP, CHMP2B and TARDBP mutations were detected. 
7.1.2.1 F1 case
7.1.2.1.1 Clinical presentation and neuroradiological features
The proband (II.3),  a 70 years old man,  was examined by clinicians at  Girolamo Fracastoro 
Hospital, where he performed neuropsychological and neuroimaging assessments.
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Fig. 29. F1 pedigree. 
The arrow indicates the proband; circles, fem ales; squares, m ale; black symbols, affected family m em bers; slashed 
sym bols, deceased fam ily m em bers. The proband's father (I.2) died of myocardial infarction at age 72 whereas his m other 
(I.3) died of old age. His oldest uncle (I.1) was affected by FTD instead the youngest (I.4) received clinical diagnosis of 
AD. One of the younger brother (II.5) is affected by FTD.
He was first referred at the age of 65 years with a 7-months history of phonetic verbal fluency 
deficits,  verbal  apraxia  with  preserved  ability  in  word  finding,  accompanied  by  mood  and 
behavior  change.  Neuropsychological  examination  revealed  deficits  in  solving  problems and 
abstract reasoning (MMSE: 21/30). A brain MRI carried out a year and a half after the onset of 
the symptoms, revealed a moderate bilaterally symmetrical cerebral atrophy, most pronounced in 
the frontal lobes. The clinical and neuroradiological findings led to a clinical diagnosis of FTD. 
7.1.2.1.2 Molecular genetics
DHPLC analysis  disclosed an abnormal chromatographic profile for exon 3 of  PGRN which 
revealed the presence of a frameshift mutation after direct sequencing. The subcloning of this 
exon allowed to identified the already reported c.378delC single nucleotide deletion, predicted to 
introduce a premature stop codon (p.Phe86SerfsX170) leading to the formation of an unstable 
mRNA, degradated  by a mechanism of Non-sense Mediated Decay (NMD) [170, 171].
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Fig. 30. F1 case: DHPLC and sequencing analysis results.
A: PGRN ex3 chromatographic profiles in a wild-type control (upper) and F1 proband (lower). B: direct 
sequence of wild-type (upper) and m utated (lower) alleles of F1 proband, disclosing the c.378delC 
heterozygous single nucleotide deletion.
7.1.2.2 F2 case
7.1.2.2.1 Clinical presentation and neuroradiological features
The proband (II.3), a 79-year-old male, was hospitalized in Neurology Department of G.B. Rossi 
Hospital  at  the  age  of  74  years  to  carry  out  surveys  on  a  clinical  picture,  reported  slowly 
evolving (first symptoms onset at age 68 years) and characterized by abnormal gait with postural 
instability and slight deficits in working memory and attention. On the basis of these symptoms, 
the patient  was previously subjected to  neurological  examination which revealed ideo-motor 
slowing and bradykinesia, associated with attentional and mnesic decline. He has also undergone 
a brain MRI that showed a triventricular hydrocephalus (Fig. 32A). During this hospitalization 
he performed a cranial CT scan which confirmed the dilatation of lateral and third ventricles. At 
the same time, he underwent a further neuropsychological assessment which showed a normal 
cognitive profile without deficits in attentional or executive functions and the preservation of 
language  functions  with   fluent  speech  devoid  of  anomie  or  paraphasias  and  intact 
comprehension.  One  year  after  the  first  investigation  at  G.B.  Rossi  Hospital,  he  repeated 
neuropsychological evaluation that revealed a slight worsening with the appearance of hint of 
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Fig. 31. F2 pedigree. 
The arrow indicates the proband; circles, fem ales; squares, m ale; black symbols, affected family m em bers; slashed 
sym bols, deceased fam ily members. The proband's father (I.1) died at age 74 after 19-years history of Parkinson disease; 
his affected aunt (I.6)  developed both memory and cognitive deficits. One of his sister (II.7)  has a diagnosis of FTD with 
severe cognitive deficit and, one brother (II.11) with a progressive worsening of Parkinson disease. 
temporal  and  spatial  disorientation  and  perseveration  in  speech.  His  language  skills  were 
preserved as well as comprehension. 
A brain  SPECT  scan,  carried  out  seven  months  later,  demonstrated  a  reduction  in  global 
perfusion of the cerebral cortex,  widespread at mid-inferior frontal and parietal, occipital and 
temporal  cortex  (more  consistent  in  the  left  hemisphere).  Moreover,  tracer  uptake  was 
homogeneously reduced in the cerebellum. The following year the patient performed a brain 
SPECT scan with receptor tracer that showed an initial  damage to presynaptic dopaminergic 
system at the right putamen. He performed a brain PET scan at the age of 77 years that showed 
global and moderate hypometabolism of associative temporal-parietal-occipital cortex, slightly 
more evident on the left, in the superior frontal area and in cerebellum with modest bilaterally 
sparing of primary sensory-motor cortex (Fig. 32B). CINE phase-contrast MRI (CINE-MRI) was 
used  to  measure  cerebrospinal  fluid  (CSF)  flow  through  the  ventricolar  system,  brain 
parenchyman and subarachnoidal spaces in  order to exclude the presence of a normotensive 
hydrocephalus. The study of endo-cranial CSF circulation showed a steady  flow at the aqueduct 
of Sylvius (Fig. 32C). 
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Fig. 32. F2 proband neuroradiological findings.
A: MRI shows a large frontotem poral atrophy and a triventricular hydrocephalus “ex-vacuo” with slight 
asym metry (>left side). B: 18-F FDG cerebral PET displays a global and moderate hypom etabolism of  
associative temporal-parietal-occipital cortex (>left side). C: kinetic MRI for the study of endo-cranial CSF 
circulation shows regular flow at the aqueduct of Sylvius. 
The  patient  underwent  to  a  further  neuropsychological  assessment  that  displayed  a  broad 
worsening of cognitive profile, characterized by intellectual impairment with deficits of long-
term verbal memory, mild attentional deficits and impaired deductive logic. He also exhibited 
deficits of executive functions and his language skills were impaired with problems of phonemic 
verbal fluency.  Test results, assessing life's quality, disclosed the presence of frontal behaviour 
symptoms including  apathy,  carelessness,  logopenia,  disorganization,  loss  of  spontaneity and 
stereotypes behavior. At the present, four years after the first neurological assessment, the patient 
scored 20/30 at MMSE although he did not show spatial or temporal disorientation observed in 
previous evaluations. He has also obtained a pathological score at tests assessing autonomy in 
daily activities (IALD: 1/5 and ADL: 2/6).
7.1.2.2.2 Molecular genetics
DHPLC analysis disclosed an abnormal chromatographic profile for exon 8 of  PGRN which, 
after direct sequencing revealed the presence of a frameshift mutation (Fig. 33). 
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p.Thr272SerfsX10
ex8 WT
A B
c.813-816delCACT
ex8 WT
Fig. 33. F2 case: DHPLC and sequencing analysis results.
A: PGRN ex8 chrom atographic profiles in a wild-type control (upper) and F2 proband (lower). B: direct 
sequence of wild-type (upper) and mutated (lower) alleles of F2 proband, disclosing the c.813-816delCACT 
heterozygous four-nucleotides deletion.
The subcloning of this exon allowed to identified the already reported c.813-816delCACT four-
nucleotides deletion, predicted to introduce a premature stop codon (p.Thr272SerfsX10) leading 
to the formation of an unstable mRNA, degradated  by a mechanism of Non-sense Mediated 
Decay (NMD) [170, 171].
7.1.2.2.3 Biochemical study
For this patient was also available a serum sample that was used in a biochemical ELISA assay 
to  test  whether  this  mutation  (like  already reported  PGRN frameshift  mutations,  which  are 
predicted to introduce a premature stop codon in mRNA with the demonstrated establishment of 
a state of haploinsufficiency [170, 171]) was able to cause a reduction in PGRN protein levels 
[154, 244]. Measured PGRN serum values turned out to be strongly reduced compared to those 
seen in healthy control subjects, indirectly confirming the degradation of mutant allele by NMD 
mechanism (Fig. 34) 
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Fig. 34. F2 proband serum progranulin levels (ng/ml).
FTLD PGRN (-): affected unrelated FTLD patients without PGRN m utation; PGRN (+) Thr272SerfsX10: affected 
F2 proband with Thr272serfsX10 m utation; Controls: healthy control subjects; PGRN c.1-3868 C>G: FTLD-
MND affected patient with PGRN non-coding exon 1 variation.
* Serum  progranulin levels are decreased in affected carrier of PGRN Thr272SerfsX10 m utation with respect to 
PGRN (-) patients with FTLD and Controls [mean values ± SD: PGRN (+) Thr272SerfsX10 carrier 45,42 ng/ml; 
PGRN (-) FTLD affected patients 165,44 ± 30,59; Controls 147,29 ± 37,08].
** Serum  progranulin levels are not decreased in a FTLD patient with a nucleotide variation in PGRN non-
coding exon 1, representing the regulatory region of the gene. 
7.1.2.3 F3 case
7.1.2.3.1 Clinical presentation and neuroradiological features
The proband (IV.2), a clerk woman, began to exhibit language dysfunctions at age 49. During the 
following year there was a progressive language deterioration: her spontaneous speech was non-
fluent, mildly agrammatically, with occasional phonemic and semantic paraphasias. Language 
comprehension and also memory functions were preserved.  She developed an apathetic state 
with reduction of initiative, loss of interests and lack of personal care. Brain MRI, performed one 
year  after  symptoms  onset,  showed  supratentorial  cortical  atrophy  with  light  right  frontal 
predominance (Fig. 36). Brain perfusion SPECT revealed significant hypoperfusion  in the right 
frontal cortex. After neuropsychological assessment (MMSE score of 26.99/30), she received a 
clinical diagnosis of progressive non–fluent aphasia (PNFA). 
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Fig. 35. F3 pedigree. 
The arrow indicates the proband; circles, fem ales; squares, m ale; black symbols, affected family m em bers; slashed 
sym bols, deceased fam ily m em bers. Individuals I.2 and II.2 were affected by late onset dementia, individuals III.5 and 
III.10 were both affected by early onset dem entia with language dysfunctions first  and then memory deficits (III.5 died 
after a disease's duration of 7 years). Individual III.2 started to m anifest language disorders before 50 years, followed by 
dem entia. She died at age 57. 
One year later, at age 51, neuropsychological tests disclosed a progressive decline of language 
functions,  attention  degree  and  memory.  In  particular,  she  developed  both  sequential  and 
phonological errors in repeating words and phrases. Her phonemic fluency performance was 
reduced, while semantic fluency was normal. Objects naming performance was within normal 
limits, while verbs naming was compromised. Comprehension of single words was normal, but 
she had difficulty understanding syntactically complex sentences. The patient scored abnormally 
in  frontal  functions  test  (the  attention  and  the  ability  to  inhibit  irrelevant  information  were 
reduced); she produced more errors in spatial intelligence and her performance on non-verbal 
reasoning  test  was  poor.  The  neuropsychological  evaluation  revealed  prominent  deficits  of 
language and executive functions. No abnormalities were detected in constructive praxis, non-
verbal intelligence ability and visual memory; her verbal memory performance was patchy, being 
poorest for verbal tasks. This profile was consistent with frontal lobe dysfunction , PNFA variant. 
Later  on,  her  spontaneous  language  was  reduced  and  the  comprehension  was  scarce.  Her 
occupational functioning was significant impaired and personal hygiene was poor. Three years 
after  the  onset  of  symptoms  the  patient  developed  behavioural  changes  which  included 
irritability, verbal aggressiveness, apathy and hyperorality. She also began to disclose behaviour 
automatism (such as grinding teeth and blow) and she got uninhibited. She continued to worsen 
until the complete loss of any ability, critical assessment and finally, of autonomy. She died after 
a disease duration of 4 years.
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Fig. 36. F3 proband neuroradiological findings.
Magnetic Resonance Im aging scan: saggital and coronal sections.
7.1.2.3.2 Molecular genetics
DHPLC analysis disclosed an abnormal chromatographic profile for exon 11 of  PGRN which, 
after direct sequencing revealed the presence of a frameshift mutation (Fig. 37). The subcloning 
of this  exon allowed to identified the novel  c.1197C single  nucleotide deletion,  predicted to 
introduce a premature stop codon (p.His400ThrfsX12) leading to the formation of an unstable 
mRNA, possibly degradated  by a mechanism of Non-sense Mediated Decay (NMD).
7.1.2.4 F4 case
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Fig. 37. F3 case: DHPLC and sequencing analysis results.
A: PGRN ex11 chrom atographic profiles in a wild-type control (upper) and F3 proband (lower). B: direct 
sequence of wild-type (upper) and m utated (lower) alleles of F3 proband, disclosing the c.1197delC 
heterozygous single nucleotides deletion.
Fig. 38.  F4 pedigree. 
The arrow indicates the proband; circles, females; 
squares, m ale; black symbols, affected family m em bers; 
grey sym bols, affected status not available;  slashed 
sym bols, deceased fam ily members. 
7.1.2.4.1 Clinical presentation and neuroradiological features
No detailed clinical and radiological data were available about this sixty-four years old man who 
was examined by clinicians in Bellaria Hospital where he performed neuropsychological and 
neuroimaging assessments which led to a clinical diagnosis of FTD syndrome. The only known 
informations included a positive family history and a symptoms onset at age 59 years. 
7.1.2.4.2 Molecular genetics
DHPLC analysis disclosed an abnormal chromatographic profile for exon 10 of  MAPT which 
was further characterized by direct sequencing which led to the identification of the intron 10 
(IVS10) c.2002+16 C>T nucleotide transition.  This substitution has already been reported in 
literature  as a pathological mutation affecting the stoichiometric ratio between four- and three-
repeats  tau  isoforms,  sufficient  to  trigger  off  a  process  of  neurodegeneration  of  FTLD-tau 
subtype [245, 246].
7.1.2.5 FTD-MND pedigree
In the analyzed FTLD series 5 unrelated clinically diagnoses FTD-MND patients were included 
and, among these cases only one belonged to a family characterized by an autosomal dominant 
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Fig. 39. F4 case: DHPLC and sequencing analysis results.
A: MAPT ex10-IVS10 chrom atographic profiles in F4 patient (upper) and wild-type control (lower). B: direct sequence 
of ex10 in F4 patient disclosing the c.2002+16 C>T heterozygous nucleotide transition (arrow) in intron 10 (IVS10).
IVS10 + 16
ex10  WT
A B
c.2002+16 C>T
pattern of inheritance of the disease. 
7.1.2.5.1 Clinical presentation and neuroradiological features
The proband (II.6), an unmarried farmer, deceased at age 58. When he was 48, he started to 
exhibit  a  progressive  psyco-motor  deterioration,  accompanied  by  urinary  incontinence.  He 
underwent  neurological examination that showed a parkinsonian syndrome with rigidity and 
bradykinesia.  Neuropsychological  examination  revealed  no  clear  cognitive  deficits 
(MMSE:30/30).  He was  subjected  to  CT scan  which  pointed  out  a  mild  degree  of  cortical 
atrophy with symmetrical dilatation of ventricular system and third ventricle. Six months later 
the  first  evaluation,  the  patient  performed  two  SPECT  assessments:  the  former  showed  a 
bilaterally hypoperfusion of fronto-temporal  cortex,  basal ganglia and talami while  the latter 
displayed an inhomogeneous uptake for dopamine receptors at basal ganglia (> on right side). 
After  one  year  from  first  symptoms,  his  clinical  conditions  has  worsened:  while  the 
parkinsonian syndrome had a discrete entity, the patient was disoriented in time not in space, 
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Fig. 40. FTD-MND pedigree. 
The arrow indicates the proband; circles, fem ales; squares, male; black symbols, affected family 
members; slashed sym bols, deceased fam ily members. Individual I-2 deceased at age 65 of heart 
disease but she presented a cognitive decline from age 63. The proband oldest sister (II-2) 
deceased at age 54 with a four years history of Alzheimer's disease. Since age 62, individual II-4 
(a 68 years old unm arried accountant) began to manifest progressive cognitive decline with 
temporal disorientation, executive dysfunctions in daily tasks (e.g., cooking) and language 
deterioration. The younger sibling (II-5), a maiden 66 years old, began to display memory 
deficits associated to depression with lack of appetite at age 56. A few months after the onset of 
first symptoms she manifested disequilibrium , progressive purposeless behaviours, pauperization 
of language and echolalia. From the age of 65 years she not longer am bulate and she has 
become m ute.  
with absence of  criticisms and lack of awareness  of the disease.  Sometimes,  behaviour  was 
inadequate at circumstances, associated to a moderate cognitive decline (MMSE:20/30). During 
the following years memory deficit worsened, frequently accompanied by confusional episodes. 
From age 52 the patient was no longer autonomous and two years later he could not longer 
ambulate. At age 54 he was hospitalized for fever-associated confusional state and during clinical 
investigations, he performed a CT scan that revealed a severe triventricular hydrocephalus. He 
was discharged from hospital with the diagnosis of familial FTD-MND, in advanced aphasic-
apraxic state. The patients died at age 58 and, family members gave informed consent to perform 
a brain autopsy. 
7.1.2.5.2 Neuropathological findings
Macroscopical observations revealed a markedly dilated, aligned and symmetrical, ventricular 
system; a prominent bilaterally cerebral atrophy, with thinning of convolutions and deepening of 
frontotemporal grooves and, a symmetric atrophy of central gray nuclei, of both the caudatum 
and putamen-pallido.    
The  substantia  nigra  and  locus  coeruleus  appeared  depigmented  whereas  bulbar  olives  had 
normal conformation. No atrophy of cerebellar folia was evident and dentate nucleus were well 
defined.  Microscopic  examinations  revealed  neuronal  loss,  spongiosis  of  neuropil,  most 
prominent  and sometimes confluent  in  the superficial  layers.  Pathological  process  was  more 
widespread at the level of gray matter of frontotemporal convolutions and it was associated to an 
astrocytic reaction of the white matter. Neuronal loss and reactive astrocytes were also present in 
gray matter of basal ganglia, particularly in the putamen. Free melanin pigment was widespread 
in the substantia nigra and locus ceruleus.    
Immunohistochemical studies excluded the presence of amyloid plaques and tangles deposits; 
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conversely tau-negative,  ubiquitin-positive inclusion bodies were present in the cytoplasm of 
granular cells in dentata fascia of hippocampus and in neurons of cortex superficial layers. In 
affected areas there were also ubiquitin-positive dystrophic neurites. 
Immunostaining  with  TDP-43 antibody also showed a strong presence  of  different  neuronal 
cytoplasmic inclusions in the superficial cortical layers, with a pattern of distribution typical of 
FTLD-TDP neuropathological subtype. 
7.1.2.5.3 Molecular genetics 
DNA sample for mutational  analysis  was available  not  for  the proband but  for  three family 
members of the same generation: two affected (individuals II.4 and II.5) and one asymptomatic 
sisters (II.3).  
The mutational screening failed to find any pathogenetic mutations in FTLD-associated genes, 
including  PGRN copy number variations.  For  this  reason and considering  the occurrence of 
Alzheimer's  Disease  in  the  family,  the  analysis  was  extended  to  autosomal  dominant  AD-
associated  genes  but,  without  positive  results.  This  outcome  was  in  agreement  with  the 
neuropathological  pattern  identified  in  the  proband,  which  had  ruled  out  a  diagnosis  of 
Alzheimer's Disease in favour of a FTLD syndrome. 
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Fig. 41. Brain pathology  in proband II-6 of FTD-MND family
A: Ubiquitinated cytoplasm atic inclusions were observed in cerebral cortex and in 
dentate granular cells of hippocampus. No tau imm unopositive deposits were detected.
B: TDP-43 inclusions colocalized with ubiquitin-im munoreactivity.
CHMP2B
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7.1.2.5.4 Linkage and haplotype analysis
Considering the absence of mutations in FTLD known genes and, the clinical presentations and 
the  neuropathological  features  fulfilling  with  a  diagnosis  of  FTD-MND,  the  other  possible 
molecular base to be evaluated was the association to the 9p21.3-13.3 locus on chromosome 9.   
Twenty-seven  STR markers  were  analyzed  in  an  interval  of  43,36 cM (36,5 Mb),  between 
D9S285  and  D9S1780.  Although  haplotype  reconstruction  was  difficult  due  to  lack  of 
informativity, the two affected sibs (II.4 and II.5) share chromosome 9 haplotypes on both their 
chromosomes, while the asymptomatic sibling most likely inherited the 2 other haplotypes. Thus, 
this family is compatible with linkage to the 9p21.3-13.3 locus on chromosome 9. 
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I-1 I-2
II-2 II-3 II-4II-1 II-5 II-6
Marker
D9S285 (294) (304) (304) (308) (304) (308)
D9S157 (181) (193) (183) (193) (193) (193)
D9S1684 (357) (363) (363) (365) (363) (365)
D9S1846 (228) (238) (228) (228) (228) (238)
D9S1870 (284) (296) (294) (296) (294) (296)
D9S171 (265) (273) (257) (257) (257) (257)
D9S1679 (424) (428) (424) (430) (424) (430)
D9S1833 (448) (448) (448) (456) (448) (456)
D9S1121 (303) (307) (279) (303) (279) (303)
D9S259 (231) (231) (229) (235) (229) (235)
chr9_7 (414) (422) (416) (426) (416) (426)
D9S319 (225) (233) (225) (225) (225) (225)
D9S1853 0 0 (380) (380) 0 (380)
D9S43 (189) (195) (197) (199) (197) (199)
D9S304 0 0 (359) (359) (359) (359)
W1226 (383) (387) (383) (383) (383) (383)
D9S1845 (193) (195) (193) (205) (193) (205)
D9S165 (388) (388) (388) (396) (388) (396)
D9S1804 0 0 (231) (241) (231) (241)
D9S1859 (147) (153) (133) (147) (133) (147)
D9S772 (307) (307) (311) (311) (311) (311)
GATA124G05 (397) (397) (401) (401) (401) (401)
D9S273 (292) (292) (292) (294) (292) (294)
D9S1799 (219) (224) (193) (216) (193) (216)
D9S1837 (327) (327) (310) (329) (310) (329)
D9S175 (375) (377) (361) (363) (361) (363)
D9S1780 (138) (146) (138) (142) (140) (142)
Fig. 42. Segregation of the 9p21.3-13.3 haplotype in the FTD-MND family. 
Haplotypes are based on a selection of 27 inform ative short tandem  repeat m arkers 
at chrom osome 9. The yellow and blue light haplotypes represents the the two 
possible disease haplotype. Haplotypes for other family m em bers were not inferred 
due to the lack of inform ativity within the family.
7.2 CADASIL
7.2.1 NOTCH3 mutational analysis
Twenty-one different  NOTCH3 mutations were identified in the 53 analyzed unrelated index 
cases,  including seven novel variations:  Cys108Ser in exon 3,  Cys366Trp and Ser396Cys in 
exon 7, Arg592Cys and Cys606Arg in exon 11, Cys939Arg in exon 18 and Gly1013Cys in exon 
19 (Table 19).
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Table 19. The spectrum of NOTCH3 mutations. 
Notch3 mutat ions in 53 CADASIL index cases. An asterisk indicates novel 
mutat ions.
EGF domain
3 c.346C>T p.R90C 2 3 4 (7,56%)
c.400T>A p.C108S* 2 1
4 c.475C>T p.R133C 3 2 15 (28,3%) 
c.499C>T p.R141C 3 3
c.514T>C p.C146R 3 4
c.583C>T p.R169C 4 1
c.599G>A p.C174Y 4 1
c.679T>C p.C201R 5 1
c.697C>T p.R207C 5 3
5 c.829T>C p.C251R 6 1 1 (1,9%)
6 c.890G>T p.C271R 6 1 1 (1,9%)
7 c.998T>G p.C366W* 9 1 11 (20,75%)
c.1265C>G p.S396C* 10 10
10 c.1660G>T p.G528C 13 2 2 (3,77%)
11 c.1852C>T p.R592C* 15 1 3 (5,66%)
c.1895T>C p.C606R* 15 1
c.1898C>T p.R607C 15 1
18 c.2893T>C p.C939R* 24 1 1 (1,9%)
19 c.3094C>T p.R1006C 26 12 13 (24,53%)
c.3115G>T p.G1013C* 26 1
22 c.3769C>T p.R1231C 31 2 2 (3,78%)
Exon Nucleotide Change
Aminoacid  
Change
Number of 
index cases
Mutation for Exon 
  No. (%)
All these substitutions, not observed in healthy control subjects, are missense mutations that lead 
to an odd number of cysteine residues, affecting EGF-like repeats by causing the loss or gain of 
one cysteine. Although mutations were distributed unevenly over 10 exons, exons 4, 19 and 7 
represented  the  most  frequently  affected  mutation  sites  accounting  together  for  74% of  the 
affected  individuals  (Table  19).  Several  mutations  seem  to  cluster  in  specific  geographical 
regions of Italy (Fig. 43). In particular, 11 mutations (R90C, C146R, R169C, C174Y, C201R, 
S396C,  R592C, C606R,  R607C, C939R and G1013C) were identified only in  patients  from 
North-East Italy , 4 (C251R, C271F, C366W and R1231C) only in patients from North-West 
Italy  and 2 (C108S and G528C) solely in patients from Central Italy. The novel Ser396Cys 
substitution  was  observed in  10  index  cases  living  in  the  neighboring  provinces  of  Verona, 
Vicenza,  Padua,  Treviso  and Venice (North-East  Italy).  Moreover,  the Arg1006Cys  mutation 
occurred mainly in patients (9 index cases) from Ascoli Piceno and Chieti or nearby villages 
(Central  Italy),  with  the  exception  of 
three individuals living in Northern Italy 
for  whom  no  information  about  the 
origins of grandparents was available.
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Fig. 43. Geographical distribution of 
NOTCH3 mutations in studied series. 
Novel m utations are reported in bold 
character. Underline variations represent 
mutations indentified only in patients 
from  a definite geographical area. 
Num ber of index cases are reported in 
bracket when major than a single case. 
Three m ain clusters are detectable: 
North-East Italy, North-West Italy and 
Central Italy.   
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7.2.2 Tagging-SNP and NOTCH3 Haplotype analysis
Allele and 5 SNP haplotype frequencies, estimated from the probands of the 22 pedigrees, the 31 
unrelated index cases and the 50 controls are reported in Table 20 and Table 21, respectively. All 
the 5 SNPs showed to be in  Hardy-Weinberg equilibrium. Haplotype analysis showed the 10 
haplotypes estimated from the sample set. The 4 most common haplotypes in control population 
(H1, H2, H3, H4) account for nearly 89% of the observed haplotypes (see table 21 for haplotype 
coding).  In  17  pedigrees  the  mutations  were  observed  to  be  linked  to  the  most  common 
haplotype H1. The Arg141Cys mutation was linked to H1 and H5 haplotypes (in 1 index case 
and 2 families respectively) whereas the H4 was associated to the Cys271Phe variation. The 
Ser396Cys mutation was observed in two different haplotypes: H1 (in 3 families and 5 index 
cases) or  H2 (1 family). In one of the Ser396Cys families, where experimental data were not 
completely available, either H1 or H2 were compatible. 
In the 31 unrelated  all the mutations were also compatible with the hypothesis of mapping on 
the most common haplotype H1 with the exception of Arg207Cys. that was observed in two 
index unrelated patients originating in North-Easter Italy, whose haplotypes are likely to be H1 
and H2, and H4 and H9, respectively. 
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Table 20. Genotypes and allele distribution among affected and controls.
p-value: significance of genotype distribution frequencies between affected and controls individuals.
SNP
Affected Controls
p-value
mm MM mm MM
C T 2 19 32 10 18 21 0.022
G C 0 10 40 0 13 37 0.48
A G 1 12 40 0 11 39 1
T C 1 12 40 0 12 38 1
T C 1 16 35 1 15 34 1
Minor allele
 (m)
Major allele
 (M) mM mM
  rs1044009
  rs10426042
  rs10423702
  rs4809030
  rs3815188
7.2.3 Scalpel skin biopsy 
Electron microscopy detected GOM in all  16 patients  examined (Table 22). Ultrastructurally 
typical material accumulated mostly within the basal lamina indenting smooth muscle cells of 
small dermal arteries (Fig. 44). GOM were also detectable in the basal lamina of pericytes and 
endothelial cells of some capillaries.
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A
B
Fig. 44. Electron microscopy of skin biopsy in a 
NOTCH3 mutation carrier.
A: the arteries with several GOM deposits (arrows). 
B: a GOM shown at higher magnification.
Affected Controls p-value
H1 C G C C T 64.17 53.63 2.29 0.1302
H2 C G C C C 4.02 15.88 7.88 0.0049
H3 T G G C C 5.97 9.57 0.90 0.3414
H4 C A C T C 6.04 8.66 0.50 0.4774
H5 T G C C T 7.06 3.16 1.55 0.2121
H6 T G G C T 1.24 2.38 0.36 0.5459
H7 C G C T C 3.77 2.21 0.42 0.5180
H8 T G C C C 0.60 2.10 0.81 0.3681
H9 C A C T T 1.42 1.25 0.01 0.9142
H10 C A C C T 5.71 1.20 3.03 0.0818
Haplotype χ2
rs3
815
188
rs1
043
702
rs1
042
604
2
rs4
809
030
rs1
044
009
Table 21. Haplotypes frequencies (% ) estimated in 50 healthy control individuals and in the 53 affected 
patients (22 pedigree probands and 31 unrelated index cases).
p-value: significance of difference individual haplotype frequencies between affected and controls subjects. 
Table 22. GOM detection in skin biopsy. 
Case Sex Mutation GOM
1 M R141C 48 +
2 F C146R 57 +
3 M C146R 28 +
4 M C146R 37 +
5 F C146R 48 +
6 F R169C 34 +
7 M R207C 49 +
8 M S396C 52 +
9 F S396C 71 +
10 M S396C 58 +
11 M S396C 62 +
12 F G528C 60 +
13 M R1006C 65 +
14 M R1006C 52 +
15 M R1006C 57 +
16 M G1013C 35 +
Age at 
autopsy
7.2.4 A selected case
Among the  575 patients  with  clinical  suspicion  of  CADASIL but  without  typical  NOTCH3 
mutations (characterized by loss or gain of one residue of cysteine), the  NOTCH3 c.3057delG 
frameshift  mutation  (p.Gly994AlafsX277)  was  identified  in  one  index  case  (Fig.  45).  The 
patient, a 38 years old woman, was referred to the attention of G.B. Rossi Hospital neurologists 
because of recurrent headache episodes by the age of 12-18 years, a pattern of MRI characterized 
by white  matter  T2-hyperintensities  and  a  positive  family  history  for  cognitive  decline  and 
psychiatric  disorders  (Fig.  46).  She  also  underwent  a  skin  biopsy  for  electron  microscopy 
analysis which revealed the absence of GOM deposits (Fig. 47).
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Fig. 45. NOTCH3 frameshift mutation: DHPLC and sequencing analysis results.
A: NOTCH3 ex18 chrom atographic profiles in a wild-type control (upper) and  affected patient (lower). B: 
direct sequence of wild-type (upper) and mutated (lower) alleles of affected patient disclosing the c.3057delG 
heterozygous single nucleotides deletion..
p.Gly994AlafsX277
ex18 WT
A B
c.3057delG
ex18 WT
129
Fig. 47. Electron microscopy in skin biopsy of 
NOTCH3 p.Gly994AlafsX277 mutation carrier.
GOM deposits were absent also in subsequent 
investigation of other vessels and in a second 
skin biopsy.
Fig. 46. NOTCH3 ex18 pedigree.
The arrow indicates the proband; circles, females; 
squares, m ale; black symbols, affected family m em bers; 
slashed sym bols, deceased fam ily m em bers. Individuals 
I.2 affected by AD by the age 60 years; II.1 affected by 
memory deficit and depression by the age 62 years; I.3 
and II.2 affected by psychiatric disorder.
I
II
III
2 3 4
1 2
1
2 3 41
Alzheimer's Disease Psychiatric Disorder
8. Discussion
8.1 Alzheimer's Disease and Frontotemporal Lobar Degeneration
Alzheimer's  Disease  and Frontotemporal  Lobar  Degeneration  fall  into  the  same  category of 
primary cortical  dementia,  sharing the general  etiological process represented by progressive 
neurodegeneration.  Despite  these  two  forms  of  dementia  can,  in  principle,  be  distinguished 
according to different onset symptoms and neuroradiological imaging, in clinical practice is not 
always so straightforward and simple because of atypical clinical presentations. For this reason, 
the entire panel of AD and FTLD associated genes was analyzed in all recruited patients, starting 
with the investigation of those genes associated with the clinical subtype of dementia and then 
extended to  the other  genes.  The  mutational  analysis  led to  the identification  of  8  probably 
pathogenetic  mutations  in  8  out  of  210  unrelated  index  cases  with  a  molecular  yield  of 
approximately 4% (Table 17). This low mutational frequency may be attributed to the approach 
used  in  patients  recruitment  and  to  the  limits  of  diagnostic  criteria  nowadays  available  to 
distinguish different forms of dementia. 
Two important informations to be collected during the patient examination, are the presence of 
familiarity for dementia within the family and presumed age of onset of the disease. Actually, the 
genetic  forms  of  Alzheimer's  Disease  and  Frontotemporal  Lobar  Degeneration  are  mainly 
inherited as an autosomal dominant traits,  which means that the disease must occur in many 
individuals over several generations. This is a very important element that might suggest the 
existence of a possible genetic basis for the disease, addressing the clinician to advise a genetic 
analysis to the family. In this study informations about disease familiarity are often missing (not 
available in 144 out of 210 cases), especially those for patients not visited in G.B. Rossi Hospital 
(Table  1-2).  Moreover,  it  is  also  difficult  to  state  how many of  the  referred  familial  cases 
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(50/210) represent Mendelian pathway of inheritance. The absence of these data may explain the 
overall low mutational yield, since many of analyzed cases are probably sporadic form of AD or 
FTLD with no Mendelian inheritance pattern. 
The other important information which may suggest a possible genetic base is the age of onset of 
the disease. Unlike  literature data, where mean ages of onset in autosomal dominant forms of 
AD and FTLD range from 30 to 60 years and 45 to 65 years respectively, in this study the mean 
age at onset tends to be higher (62,5  ±  9,5 years), probably reflecting the inclusion of several 
sporadic cases. Therefore age of onset may be useful to discriminate genetic forms of AD and 
FTLD,  usually  associated  to  an  earlier  onset,  even  though  variability  in  first  symptoms 
manifestation and incomplete penetrance may occur especially in PSEN2  and PGRN mutation 
carriers.    
These considerations highlight the relevance of a thorough clinical assessment as it may allow to 
identify, with more confidence, those patients with a genetic form of AD or FTLD, reducing the 
waste of time and money entailed by the mutational screening adopted in this study. In fact, 
Table 18 shows how analyzed genes are polymorphic: many SNPs have been identified (mostly 
in PGRN, MAPT, VCP, PSEN1 and PSEN2 genes) occurring with an high frequency in the whole 
series,  even  in  more  than 50% of  cases.  The  presence  of  these SNPs makes  the mutational 
screening more laborious, time-consuming and expensive. In fact, although the first mutational 
step  consisting  in  DHPLC analysis  is  rapid,  highly  sensible  and  cheap,  it  only  detects  the 
occurrence of a nucleotide change but it does not characterized its entity. For this reason, direct 
sequencing is necessary to define the occurred nucleotide variation, differentiating SNPs from 
mutations, with an inevitable overload of work and costs. This, in turn, strengthens the necessity 
to  enrol  a  selected  series.  In  this  study,  the  clinical  diagnosis  of  included  patients  is  very 
heterogeneous because of, not only the recurrent atypical presentations of AD and FTLD (as 
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mentioned  upon  and  in  chapters  2  and  3),  but  also  as  a  consequence  of  the  limitation  of 
diagnostic tools available to make a differential diagnosis of dementia. Nowadays, despite of the 
improvements  in  neuropsychological  tests,  neuroimaging  studies  and biologic  fluids  (serum, 
plasma, CSF) biochemical analyses, these diagnostic approaches are not themselves enough to 
write out a clinical diagnosis of a particular subtype of dementia while, the only available tool 
which allows a definite diagnosis of AD or FTLD (or other dementias) is represented mainly by 
neuropathological examination. The need to distinguish different form of dementia ante mortem, 
is emphasised by the possibility to apply ad hoc pharmacological treatments when they would be 
available.  This  justifies  the  spread research  in  the  last  years  of  easy,  quick and inexpensive 
peripheral hallmarks specific of a particular type of dementia in order to make a definite clinical 
diagnosis. This is the case of PGRN serum or plasma levels which have been demonstrated to be 
a useful tool for the identification of  PGRN frameshift mutations carriers, with specificity and 
sensitivity of 100% [154].             
 
8.1.1 Alzheimer's Disease  
In this study 41 patients had a clinical diagnosis of AD while in other 9 cases it was supported by 
neuropathological findings. No mutations in AD-associated genes were identified in the second 
group for which the greater part of clinical informations was unavailable, mostly due to the fact 
that this samples were enrolled in the 1980s when clinicians were not used to collect exhaustive 
informations  but,  brain  autopsy  was  carried  out  only  to  confirmed  or  excluded  a  clinical 
diagnosis of Creutzfeldt-Jacob Disease.
In four unrelated familial cases of clinically diagnosed AD, two already described PSEN2 non-
synonymous changes (p.Arg71Trp and p.Met174Val) and two novel missense variations, one in 
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PSEN1 (p.Ile437Asn) and the other in PSEN2 (p.Thr18Met) were identified (Table 17).  
8.1.1.1 A1 case: PSEN1 p.Ile437Asn
The PSEN1 transition c.1310 T>A is predicted to cause the substitution of an high hydrophobic 
isoleucine with an high hydrophilic asparagine, at codon 437 (Fig. 17B). Considering that this 
residue  is  conserved  between  PSEN1s  and  PSEN2s  and  it  is  located  in  the  putative 
transmenbrane  domain  TM-IX (Fig.  48),  the  introduction  of  an  hydrophilic  aminoacid  in  a 
hydrophobic core could destabilize and alter the physical-chemical interactions between adjacent 
aminoacids, affecting the organization of the transmembrane domain and maybe impairing the 
protein function, as predicted by in silico analysis. 
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I437N
Fig. 48. Schematic representation of putative PSEN1 structure.
Each PSEN1 residue is represented by a circle marked by one-letter am inoacid sym bol. Green outlined circle: not 
pathogenic am inoacid substitution; orange outlined circle: am inoacid substitution with not well-defined pathogenetic 
role; red outlined circle: pathogenetic am inoacid substitution. Blue outlined circle: aminoacid substitution identified in 
Such speculations may be indirectly supported by the identification of few  PSEN1 mutations 
(reported  in  literature)  affecting  other  isoleucine  residues  located  in  putative  transmembrane 
domains of the protein, which are conserved between presenilins and replaced by an asparagine 
or  other  hydrophilic  amino acids  such as  serine  or  threonine (eg.:  p.Ile439Ser  in  TM-IX or 
p.Ile143Thr in TM-II). Furthermore, the p.Ile437Asn does not represent a polymorphism since it 
was excluded in 492 healthy control subjects and in the other 209 analyzed patients. These data 
argue in favour of a probable pathogenetic role for this  PSEN1 variation, even though DNA 
samples of other family members were not available to test its cosegregation with the disease.
Considering the shortage of clinical  informations about the mutation carrier,  it  is  difficult  to 
define possible genotype-phenotype correlations; the only possible consideration regards the first 
manifestation of  symptoms (over  65 years)  that  differ  from most  PSEN1 mutations,  usually 
associated to an earlier onset. 
8.1.1.2 A2 case: PSEN2 p.Thr18Met
The novel PSEN2 c.53 C>T nucleotide transition was identified in a patient with positive family 
history for dementia. Both clinical phenotype and neuroimaging features were compatible with a 
clinical diagnosis of Alzheimer's Disease in the proband. This nucleotide substitution is predicted 
to  cause  the  aminoacidic  replacement  p.Thr18Met.  This  residue,  located  in  the  putative  N-
terminal cytoplasmatic domain of the protein (Fig. 49), is high phylogenetic conserved among 
PSEN2s, but it is not conserved in PSEN1s; by in silico analysis, this substitution is predicted to 
be not tolerated probably because the threonine is replaced by a more hydrophobic aminoacid 
(methionine) (Fig. 21B). In PSEN1s this position is occupied by another hydrophilic residue, a 
phylogenetic conserved asparagine while hydrophobic aminoacids seem to be not tolerated. Even 
this  PSEN2 substitutions does not represent a polymorphism in the studied population since it 
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was excluded in 492 healthy control subjects and in the other 209 analyzed patients. These data 
and the fact that it was identified in a FAD case, devoid of APP or PSEN1 mutations, militate in 
favour of a possible pathogenetic role for this variation.
8.1.1.3 A4 case: PSEN2 p.Arg71Trp
The PSEN2 c.211 C>T nucleotide variation was identified in a patient with early onset FAD (59 
years) with clinical manifestations and disease evolution fulfilling with a clinical diagnosis of 
AD. This change affects an arginine residue at codon 71 which is located in the putative N-
terminal cytoplasmatic domain of the protein (Fig.49) and conserved among not all but many 
PSEN2s of different species, not in PSEN1s (Fig. 24A). The predicted aminoacid substitution 
involves the replacement  of a positive charged hydrophilic residue (arginine)  with an apolar 
hydrophobic  aromatic  aminoacid,  tryptophan (Fig.  24B).  In  a  few PSEN2s and PSEN1s the 
alternative residue at codon 71 is a serine which is probably tolerated within the protein given its 
hydrophilic  polar  nature.  Therefore,  considering  the  difference  in  physical-chemical  and 
hydrophobicity properties of involved aminoacids, the substitution p.Arg71Trp may lead to a 
local conformational change of the protein (predicted not tolerated by in silico analysis) which in 
turn may affect the protein function. Furthermore, the c.211 C>T transition was absent in 801 
unrelated  index  cases  (209  affected  and  492  controls)  excluding  its  possible  role  as  a 
polymorphism. 
8.1.1.4 A4 case: PSEN2 p.Met174Val
The  PSEN2 c.520  A>G  transition  was  identified  in  a  FAD  case  with  late  onset,  a  rapid 
progression of the disease (illness duration: 4 years) with typical memory deficits as first clinical 
presentation.  This nucleotide substitution affects  a  Methionine residue at  codon 174, located 
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within the putative transmembrane domain TM-III of the protein (Fig. 49), which is partially 
conserved only among PSEN2s (Fig. 28A). This aminoacid is predicted to be replaced by a more 
hydrophobic  residue  of  Valine  (Fig.  28B)  with  probably  no  appreciable  variation  in  steric 
hindrance within the protein.  Moreover,  Valine is  present  at  position 174 in  a  few PSEN1s, 
probably indicating that it may be tolerated within the protein, as predicted by in silico analysis, 
even though the p.Met174Val does not represent a polymorphism since it was absent in all other 
analyzed cases. 
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Fig. 49. Schematic representation of putative PSEN2 structure.
Each PSEN2 residue is represented by a circle marked by one-letter am inoacid sym bol. Green outlined circle: not 
pathogenic aminoacid substitution; orange outlined circle: am inoacid substitution with not well-defined 
pathogenetic role; red outlined circle: pathogenetic aminoacid substitution. Blue outlined circle: aminoacid 
substitution identified in this study (Thr18Met; Arg71Trp and Met174Val). 
R71W
M174V
T18M
8.1.1.5 Genotype-phenotype correlations and literature data
The  PSEN2  p.Arg71Trp  and  p.Met174Val  substitutions  have  been  previously  identified  by 
Guerreiro et al in two sporadic index cases of Alzheimer's disease and excluded in 251 healthy 
control subjects [247]. The authors classified these variations as possibly pathogenic on the basis 
of  a  well  defined  pathogenicity  algorithm,  including  criteria  such  as  cosegregation  with  the 
disease,  absence  in  healthy controls,  phylogenetic  conservation  among different  species  and 
alteration of  in vitro Aβ peptides levels (as  PSENs mutations cause an increase in Aβ42/Aβ40 
ratio). In the herein reported series these aminoacid replacements were detected in two unrelated 
index cases of clinically diagnosed Alzheimer's Disease with positive family history for dementia 
and they were excluded in nearly 500 healthy control subjects. These data argue in favour of a 
possible pathogenetic role for the p.Arg71Trp and p.Met174Val variations, which in the first case 
were also supported by  in  silico and phylogenetic  analyses while  in the second they do not 
correlate. These results stress the necessity to perform biochemical studies in order to assess 
possible  functional  changes  in  the  proteins  and  in  particular,  variations  in  Aβ42/Aβ40 ratio 
production. 
Noteworthy,  only 23  PSEN2 non-synonymous nucleotide variations were already reported in 
literature and among this group, only 7 were considered definite pathogenetic mutations (Table 
22),  suggesting  a  low mutational  frequency for  PSEN2 gene,  considered  the rarest  cause of 
EOFAD [248]. 
In the present study 2 already reported and one novel  PSEN2 variations have been identified, 
with  a  possible  pathogenic  role.  If  further  analyses  will  confirm these  data,  the  mutational 
frequency of  PSEN2 in this series will  account for 17,65% of all  analyzed FAD cases.  This 
prevalence would be greater than that of  PSEN1 (5,88%), in contrast with literature data. This 
result may be partially ascribed to the late mean age of onset in the considered series (64,89 ± 
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9,64)  which  fulfils  with  the  range  associated  to  PSEN2 mutations  (while  PSEN1 mutations 
usually correlate with an earlier  manifestation of first symptoms).  An alternative explanation 
may be an underestimation of PSEN2 mutational frequency in literature even if the findings in 
this study might be related to the small size of AD clinical series. Another possibility to consider 
could be that these variations, despite molecular and in silico results, are not mutations but rare 
polymorphisms, an hypothesis which may be rule out only by a cosegregation analysis in the 
families and by testing their ability in vitro to increase the secreted Aβ42/Aβ40 peptide ratio. 
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Literature data
familiarity absence in control population
Polymorphisms
Arg29His N-Term healthy +/-
Leu143His TM-II healthy +++/-
Arg163His HL-II PD F no segregate +++/+
Ala252Thr TM-VI healthy +++/+
Pro334Arg AD F no segregate +/-
Ala85Val N-Term  AD/PK F segregate +++/+
Thr122Pro HL-I AD F segregate +++/+
Thr122Arg HL-I AD/FTD F segregate +++/+
Asn141Ile TM-II AD F segregate +++/+
Met239Val TM-V F segregate +++/+
Met239Ile TM-V AD F segregate +++/+
Thr430Met TM-IX AD F segregate +++/+
Arg62His N-Term AD S +/-
Arg71Trp N-Term AD S ++/-
Ser130Leu HL-I AD F segregate +++/-
Val139Met HL-I AD F +++/-
Val148Ile TM-II AD +++/+
Met174Val TM-III AD S +/-
Ser175Cys TM-III AD F +++/+
Gln228Leu TM-V AD F +++/+
Tyr231Cys TM-V FTD S +++/+
Val393Met TM-VIII AD F +++/+
Asp439Ala C-Term AD F segregate +++/+
This study
familiarity absence in control population
Thr18Met N-Term AD F +++/-
Arg71Trp N-Term AD F ++/-
Met174Val TM-III AD F +/-
Aminoacid 
Variation
protein 
domain
clinical 
diagnosis Cosegregation
phylogenetic 
conservation
In vitro Aβ42/Aβ40 
assay
observed in 1 chr of CEPH-HGDP
observed in 1 chr of CEPH-HGDP
observed in 1 affected and 1 healthy chr
observed in 2 unrelated chrs  of CEPH-HGDP
HL-VIb observed in 67 AD chrs  and in 100 healthy chrs
Pathogenetic mutations
absent in 424 healthy chrs
absent in 100 healthy chrs ↑ Aβ42/Aβ40
↑ Aβ42/Aβ40
AD/bd ↑ Aβ42/Aβ40
absent in 100 healthy chrs ↑ Aβ42/Aβ40
absent in 260 healthy chrs
Pathogenetic nature debated
observed in 20 unrelated chrs  of CEPH-HGDP ↔ Aβ42/Aβ40
absent in 502 healthy chrs
absent in 220 healthy chrs  and in 200 AD chrs ↔ Aβ42/Aβ40
absent in 200 healthy chrs  and in 200 AD chrs
absent in 190 healthy chrs  and in 256 AD chrs ↔ Aβ42/Aβ40
absent in 502 healthy chrs
absent in 200 healthy chrs  and in 200 AD chrs
absent in 200 healthy chrs  and in 200 AD chrs
absent in 768 healthy chrs ↔ Aβ42/Aβ40
absent in 100 healthy chrs  and in 160 AD chrs ↔ Aβ42/Aβ40
Aminoacid 
variation
protein 
domain
clinical 
diagnosis cosegregation
phylogenetic 
conservation
In vitro Aβ42/Aβ40 
assay
absent in 984 healthy chrs
absent in 984 healthy chrs
absent in 984 healthy chrs
Table 22. PSEN2  non-synonymous nucleotide variations reported in literature and identified in this study. 
+++/+ high phylogenetic conserved in PSEN2s and in human PSEN1; +++/-  high phylogenetic conserved in 
PSEN2s not in hum an PSEN1; ++/-  phylogenetic conserved in PSEN2s of m any different species not in PSEN1; +/- 
phylogenetic conserved in PSEN2s of a few different species not in PSEN1; ↑ Aβ42/Aβ40 increased Aβ42/Aβ40 ratio; 
↔ Aβ42/Aβ40 no significant alteration of Aβ42/Aβ40 ratio; CEPH-HGDP Centre d'Etude du Polymorphisme 
As  regards  the  clinical  phenotypes,  there  is  not  an  evident  univocal  correlation  with  the 
associated mutation; despite of the differences in first clinical symptoms (memory and language 
impairment in A2 patient, multiple cognitive domains deficits in A3 and behavioural changes in 
A4),  there  was  a  common disease  evolution  characterized  by severe  deficit  in  memory and 
executive functions coupled to language impairment and loss of autonomy in daily life activities. 
Moreover,  the  age  of  onset  and  illness  duration  fall  within  the  range  reported  for  PSEN2 
mutation carriers (with the exception of A3 case who disclosed the first symptoms by the age 
59). 
8.1.2 Frontotemporal Lobar Degeneration  
In this study 71 patients had a clinical syndrome of FTLD while in other 5 cases it was supported 
by neuropathological findings. No mutations in FTLD-associated genes were identified in the 
second group for which the greater part of clinical informations was unavailable (for the same 
reasons reported for cases with a neuropathological diagnosis of AD) but, it is significant that 
almost all cases were referred as sporadic.
Three already reported (PGRN c.378delC and c.813_816delCACT and, MAPT c.2002+16 C>T) 
and  one  novel  (PGRN c.1197delC)  mutations  were  identified  in  3  FTD  and  in  one  PNFA 
unrelated patients respectively (Table 17). All this cases presented positive family history with a 
Mendelin  pattern  of  inheritance,  even  though  DNA samples  of  family  members  were  not 
available to prove the cosegregation of the disease.   
8.1.2.1 Progranulin Mutations
The three identified PGRN frameshift mutations are predicted to cause the premature termination 
of the coding sequence which leads to degradation of the mutant  PGRN mRNA by Non-sense 
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Mediated  Decay (NMD)  [169,  170].  The  absence  of  mutant  PGRN allele  brings  a  state  of 
haploinsufficiency  that  was  demonstrated  to  be  sufficient  to  give  rise  to  FTLD  [240]. 
Considering  that  the  majority  of  PGRN pathogenic  variations  are  frameshift  null  mutations, 
predicted to act through a mechanism of haploinsufficiency, it would be expected that associated 
clinical  and  pathological  phenotypes  were  common  to  all  these  changes.  Nevertheless,  a 
variability in clinical manifestations (clinical phenotype, age of onset, illness duration, etc.) and 
neuropathological findings is reported in literature, even within the same family. 
Despite the presence of the three mutations in probands relatives have not been molecularly 
confirmed but only presumed, the clinical phenotype disclosed by the affected individuals was 
very variable. 
Both a wide range in age of onset (48-71) and illness duration (3-20) were observed (Table 23), 
probably because of incomplete or age-related penetrance of  PGRN mutations, with a 95% of 
mutation carriers affected at the age 75 years [171]. 
The clinical presentations associated to these mutations is highly heterogeneous, even within the 
same  family,  including  Frontotemporal  Dementia,  Progressive  Non-Fluent  Aphasia,  but  also 
Alzheimer's Disease and Parkinson Disease. Language dysfunctions, encompassing impairment 
in  phonetic  verbal  fluency,  agrammatisms  and  reduction  in  spontaneous  speech,  represent  a 
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Family Mutation Clinical phenotype
F1 p.Phe86SerfsX170 FTD/AD 64 * 6 *
F2 p.Thr272SerfsX10 61 (52-71) 15 (10-20)
F3 p.His400ThrfsX12 49 (48-50) 5 (3-7)
Mean age at onset 
years (range)
Mean Disease duration 
years (range)
FTD/PD/md
PNFA/md/ld
Table 23. Genetic and clinical characteristics of PGRN FTLD families. 
FTD, Frontotem poral Dem entia; AD Alzheimer's Disease; PNFA Progressive Non-Fluent Aphasia; 
prominent finding whether as onset symptoms (in F1 and F3 probands) or in later stages of the 
disorder (F2 proband) (Table 24). In the p.His400ThrfsX12 mutation carrier language deficits 
constitute the main symptom which undergoes a progressive deterioration during illness course, 
corresponding to clinical diagnostic criteria for PNFA syndrome. Behavioural changes are also 
common in the clinical presentations, especially in the form of apathetic state, carelessness and 
loss of interests, becoming relevant in the p.Phe86SerfsX170 and p.Thr272SerfsX10 mutation 
carriers to the point of fulfilling with clinical manifestations of FTD. The F3 proband manifested 
apathy from the first stages according to literature data where it represents the most prevalent 
behavioural  change  in  PNFA-PGRN mutations  carriers  [249].  Another  clinical  feature  in 
common to all three analyzed individuals is the loss of autonomy in daily life activities as has 
been above reported for AD-affected patients.  
Noteworthy are the first disease manifestations in p.Thr272SerfsX10 carrier, characterized by 
memory impairment and attentional deficits which have been lasted unchanged for some years 
falling within a clinical state of Mild Cognitive Impairment. That is, for a long time the patient 
was  thought  to  be  in  the  prodromal  phase  of  Alzheimer's  disease,  indeed  only  after  the 
appearance  of  frontal  type  symptoms  and  implementation  of  clinical  informations  with 
neuroimaging and genetic analyses, clinicians made a clinical diagnosis of FTD. This was further 
supported by detection of low PGRN protein levels in serum (45,42 ng/ml), which differed in a 
statistically significant manner from control values, well below the cutoff previously proposed 
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Mutation Clinical presentation Disease Evolution Last Evaluation
F1 p.Phe86SerfsX170 FTD 64
F2 p.Thr272SerfsX10 FTD 68
F3 p.His400ThrfsX12 PNFA 49
Table 24. Clinical presentation and illness evolution in PGRN mutation carriers probands. 
Proband Clinical diagnosis
Age of 
onset
apathy, language 
impairment
cognitive decline, executive 
deficits , impairment of 
phonemic
behavioural changes, loss of 
autonomy
mild deficit in working 
memory and attention
cognitive decline, episodic 
temporal and spatial 
disorientation
apathy, impairment of phonemic, 
deficit in executive functions, loss  of 
autonomy
language dysfunction, 
apathetic s tate
decline of language function, 
memory and attention
deficit in comprehension, behavioural 
changes, inhibition, loss  of autonomy, 
death 
by Ghidoni et al. (a cutoff of 74.4 ng/ml separates  PGRN mutation carriers from non carriers 
with a specificity and sensitivity of 100%) (Fig. 34) [154]. Find a MCI clinical phenotype in this 
patient did not surprise because, the p.Thr272SerfsX10 mutation has already been reported in 
more than 36 families associated with different syndromes, such as FTD, PNFA, CBD, FTD-
MND, LBD and not least MCI and then AD. Other  PGRN mutations have been described in 
patients with MCI, such as the variation c.388_391delCAGT (Gln130Serfsx125) identified in a 
case who then converted to Alzheimer's Disease and only subsequently disclosed behavioural 
changes and parkinsonian features characteristically observed in PGRN mutation carriers [250]. 
Therefore, these literature data and the results of this study further stress the importance and 
usefulness to have rapid, inexpensive and sensitive non-invasive tests able to identify biomarker 
of a specific type of dementia (as is the case of PGRN serum or plasma levels), to perform also 
in patient with an early atypical clinical presentation.  
8.1.2.2 Microtubule associated protein tau mutation
The  MAPT IVS10+16  C>T  have  been  detected  in  more  than  26  families,  disclosing 
heterogeneous clinical  presentations,  including FTD, FTD combined with Parkinson Disease, 
FTD with AD and PSP. Considerable variations in age of onset (range 37-66 years) and illness 
duration (2-22 years) were described, also within the same family. This nucleotide variation, like 
other MAPT 5'-splice site exon 10 mutations, are predicted to disrupt a stem-loop that regulates 
alternative splicing of exon 10 causing a two- to six-fold increase in the ratio of 4R/3R tau 
isoforms  (increased  levels  of  exon  10+  RNA)  which  in  turn  result  in  a  process  of 
neurodegeneration, by a pathogenic mechanism not fully known [254, 246].
With  regard  to  the  F4  patient,  in  which  this  mutation  was  identified,  the  only  possible 
consideration pertain to the age of onset (59 years) and duration of the disease (5 years) which 
142
fall within the reported range of value. The clinical presentation is also typical of this MAPT 
mutation carriers, mainly characterized by behaviour disorders.
8.1.2.3 Chromosome 9p-linked FTD-MND family
A linkage to 9p21.3-13.3 locus on chromosome 9 was detected in a FTD-MND Italian kindred 
with five affected individuals over two generations (Fig. 40). A few clinical informations about 
deceased family members were collected from the only healthy individuals (II.3) whereas the 
proband and his two affected siblings were visited by clinicians at G.B. Rossi Hospital. 
The clinical phenotypes within this family was very variable including not only FTD with MND 
(in  the  proband)  but  also  atypical  presentations  characterized  by  AD-like  syndrome,  where 
memory deficit represents the recurrent manifestation also in disease evolution (individuals II.2 
and II.5) (Table 25).  This is  in contrast  to clinical  findings described in 27 already reported 
chromosome 9p-linked families, where the main presenting features encompass MND with or 
without FTD and executive dysfunctions [278, 251-257]. Despite not all clinical manifestations 
fit with diagnostic criteria for FTD or MND, the mean age of onset (55.8 years) and disease 
duration (6,4 years) observed in affected individuals were within the range reported in literature 
(onset:  42.2-60.3;  duration:  3-8,6).  Furthermore,  post-mortem examination  of  proband  brain 
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Table 25. Clinical features in affected individuals
Individuals Age of onset Clinical presentation
I.2 63 2 cognitive decline
II.2 50 4 Alzheimer's Disease
II.4 62 6 cognitive decline, executive dysfunctions, language impairment
II.5 56 10
II.6 48 10
Disease 
duration
memory deficit, depression, mutism, loss of autonomy
parkinsonian syndrome, cognitive decline, memory deficit, absence of criticism, loss of autonomy
disclosed   neuropathological  characteristics  of  FTLD-TDP  subtype  which  is  the  only 
pathological pattern nowadays reported in FTD-MND chromosome 9p-linked patients. Besides 
this finding, also microsatellite and haplotype analyses performed in DNA samples of the two 
affected and the one unaffected alive siblings are compatible with linkage of this family to the 
9p21.3-13.3  locus  on  chromosome  9.  Unfortunately,  given  the  data  limitations,  it  was  not 
possible to reduce the linked region in order to identify the candidate disease gene. The only 
certain thing is that haplotypes shared by the two affected siblings differ from that identified in 
the Belgian FTD-MND chromosome 9-linked families  that  have been analyzed by the same 
research group in Antwerp [253].  This means that the disease in Italian and Belgian families is 
most likely caused by different mutations of the same not yet identified gene. In none of the 10 
already reported papers about this topic the candidate disease gene was identified in spite of the 
entire coding region mapping in this locus has been almost completely sequenced. These results 
may  suggest  that  the  pathogenic  mechanism  may  relay  on  variations  in  gene  or  protein 
expression due to genetic defects localized in non-coding regulatory genome regions as guessed 
by Pearson et al [257].   
8.2 CADASIL
8.2.1 NOTCH3 Mutational analysis
Twenty-one different  NOTCH3 mutations  were identified in 22 pedigrees  with an autosomal 
dominant  inheritance  and 31 unrelated  index  cases.  Seven  mutations  were  not  previously 
reported (Table 19). Fifteen patients had a mutation in exon 4 which accounted for 28,3% in this 
series confirming its role as a mutational hot spot although its frequency was lower than those 
reported by Oberstein et al (50%), Joutel et al (55%), Peters et al (58%) and Markus et al (73%). 
The second most frequent mutation site in this study was exon 19 (24,53%) followed by exon 7 
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(20,75%). These data confirm the wide variability in the mutational map of NOTCH3 indeed, the 
second mutational hot spot was represented by exon 3 in French, German and British series and 
exon 11 in Dutch series [258-261]. These differences  point out the heterogeneity in mutations 
distribution along the gene, that may reflect a different history of the populations and might be 
related to the different geographical areas (founder effect) where the mutations appeared for the 
first  time.  In  fact  differences  in  the  geographical  distribution  of  the  mutations  can  also  be 
observed  within  the  same  country  as  the  case  of  Italian  sample  here  reported. Mutational 
frequencies markedly diverge depending on the living Region of mutation carriers. In the study 
of Ungaro et al,  NOTCH3 screening was performed on patients from South-Italy where exon 3 
represented the mutational hot spot (8 families out of 30 analyzed) followed by exon 8 (4/30) 
and exon 4 and 22 (4/30) [262]. 
In Dotti et al series, including patients from Central- and South-Italy, the most mutated exons 
were exon 11 (21,4%) followed by exons 3 and 4 (17,8%) and exon 8 (14,3%) [263]. CADASIL 
subjects from more or less the same geographical areas were analyzed by Cappelli et al but, 
obtained  results  were  different  indeed,  exon  19  was  the  most  affected  exon  with  a  unique 
mutation,  R1006C,  recurring  in  ten  out  of  fifteen  analyzed  families  [264].  This  result  was 
explained by the finding that all those families originated in a restricted geographical area near 
Ascoli Piceno (Region Marche, Central-Italy). In the series reported by Bianchi et al, exon 10 
showed an high mutational frequency (11%), representing the second hot spot site in Central-
Italy [265]. The results of Cappelli and Bianchi are confirmed by the study herein reported where 
nine out of twelve R1006C carriers and the two exon10 G528C affected unrelated individuals 
come from Central-Italy (4 from Chieti and 7 from Ascoli Piceno). In this series a differential 
distribution of mutation between North-East and North-West Italy was also observed: while in 
North-East two clusters, exon 4 (in 11 out of 29 index cases from thus area) and exon 7 (10 out 
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of 29) have been , in North-West mutation were widespread across several exons (exon 4, 19, 22, 
5, 6 and 7). Interestingly, the novel S396C mutation was identified in patients originated in a 
restricted geographical area of Region Veneto (5 families and 5 unrelated index cases from the 
neighboring provinces of Verona, Vicenza, Padua, Treviso and Venice in North-East) suggesting 
a  common ancestor  and hence  a  possible  founder  effect  as  previously demonstrated  for  the 
R133C mutation in 18 Finnish families [266] and, as was postulated for the R1006C mutation in 
Central-Italy [264]. 
8.2.2 NOTCH3 haplotypes analysis
Each of the reported mutations was linked to an haplotype by following the segregation of the 
mutation (see Appendix 1-6) and the haplotype in the pedigrees or by probabilistic methods in 
the unrelated affected individuals. Sixteen of the 21 mutations were linked to the most common 
haplotype H1.
Mutation Arg141Cys was found to be linked to haplotype H5 (tgcct) in two pedigrees and might 
be  linked  to  haplotype  H1  (cgcct)  in  one  unrelated  affected  individual  that  however  was 
heterozygote for 3 SNPs and incompatible for carrying H5 haplotype. Since haplotype H1 and 
H5 differ for the allele at marker rs3815188 it is plausible that mutation Arg141Cys arose once 
on  haplotype  H1  or  H5  and  that  the  chromosome  carrying  the  mutation  underwent  to  an 
intragenic  recombination.  Despite  this  speculation,  since  this  NOTCH3 variation  was  also 
observed in Chinese affected individuals [267], it can not be excluded that it is an old mutation 
or more likely that has arisen several times during human history.
Mutation Arg207Cys was linked to haplotype H1 and to other haplotypes since it was found in 
affected individuals homozygote for the allele opposite to the one contained in the haplotype H1 
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at  marker rs10423702. This mutation has also been described in the Chinese population [267] 
suggesting  that  it  might  have  arosen several  times in  several  populations  due to  independet 
mutational events.
The novel mutation Ser396Cys  was found in individuals from North-Eastern Italy and resulted 
to be linked either to haplotype H1(cgcct) or haplotype H2(cgccc). Since haplotype H1 and H2 
differ for the allele at marker rs1044009 we can argue that mutation Ser396Cys arose once on 
haplotype H1 or H2 and that the chromosome carrying the mutation underwent an intragenic 
recombination.  This  would  indicate  that  mutation  Ser396Cys  is  an  old  mutation  typical  of 
individuals from Northen Italy.
Overall while a few variations were observed in minor haplotypes (H2, H4, H5 and H9), many of 
the identified mutations are linked to the most common haplotype H1; for this reason a founder 
effect was not confirmed even though it is compatible. Moreover, 16 mutations were found to be 
linked to haplotype H1 and this is uncertain for other 3 mutations (R141C, R207C e S396C). 
Assuming the less stringent hypothesis that 16 over 21 mutations were linked only to haplotype 
H1, having a frequency equal to 54% (see Table 21) in the general population (estimated from 
the 50 non affected individuals), haplotype H1 presents more mutations than expected by chance 
(p=0.029). However, this intruding hypothesis should be investigated in a larger sample to be 
confirmed. 
8.2.3 Diagnostic yield of skin biopsy
GOM deposits  were  identified  in  all  16 available  skin  biopsies  in  patients  with a  NOTCH3 
mutation  causing  an  odd number  of  cysteine  residues,  with  a  100% of  both  specificity  and 
sensitivity. This last value differs from data reported by Markus et al. and Malandrini et al. who 
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found a lower sensitivity (45% and 57% respectively) [258, 268] whereas it is in agreement with 
other reports [268-271]. The explanations for these divergences are unclear since no relationship 
have been detected between the presence or absence of GOM and age [258]. Furthermore, no 
variations  in  GOM  amount  were  observed  among  different  NOTCH3 mutations  [260],  nor 
correlations  with  disease  progression  [258,  268].  A plausible  explanation  may  relay  on  a 
methodological limit intrinsic to skin biopsy: the deepness of biopsy influences the number of 
useful observable   vessels. Recent published data emphasize the necessity to mainly investigate 
the presence of GOM in arterioles rather than vein or capillaries where they are not always 
detectable  [271].  Moreover,  if  the first  examination is  negative,  it  is  important  to repeat the 
investigation in additional vessels since GOM deposition may be a focal process. Scalpel skin 
biopsy performed in this study is deeper than the punch biopsy reported in other studies [258], 
providing a higher number of analyzable dermal small  arterioles, maybe explaining the high 
observed sensitivity without excluding a possible sample size effect.
8.2.4 NOTCH3 frameshift mutation
The NOTCH3 c.3057delG frameshift mutation (p.Gly994AlafsX277) is predicted to introduce a 
premature stop codon in mRNA which is probably degraded by a mechanism of NMD. This may 
indirectly imply that  the mutant  allele  does  not  exert  a  negative effect  inducing the vessels 
pathological changes usually detected on skin biopsy electron microscopy of NOTCH3 mutation 
carriers.  Actually,  no GOM deposits  were  identified  in  several  examinations  (more  than  ten 
vessels)  and  in  two different  skin  biopsies,  apparently  excluding  a  CADASIL diagnosis.  In 
agreement  with  this  finding,  clinical  presentation  and  neuroimaging  pattern  assessed  in  this 
patient were not fully comparable with CADASIL diagnostic criteria:  recurrent headache not 
migraine and a few small subcortical signal alterations on brain MRI not properly specific of 
148
CADASIL. Even family history had disclosed the occurrence of cognitive decline but not stroke 
or TIA (suggestive of CADASIL). These findings, together seem to exclude a pathogenic role for 
this  variation,  further  supported  by  literature  data  where  the  only  few  reported  NOTCH3 
deletions  are  small  in-frame  deletions,  identified  in  patients  with  typical  clinical  and 
neuroradiological CADASIL presentations, which are predicted to cause the deletion and loss of 
one cysteine residue [272].     
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9. Conclusions
9.1 AD and FTLD
9.1.1 Alzheimer's Disease
PSEN2 mutations are considered the rarest cause of familial Early-Onset AD. Several  PSEN2 
non-synonymous  nucleotide  variations  whose  pathogenetic  role  is  unclear  are  reported  in 
literature. The result described in this study diverge from literature because they show a more 
likely  pathogenic  role  for  some  of  the  already  reported  variations,  giving  PSEN2 a  higher 
mutational frequency. If these data were not reflected in functional analysis (Aβ42/40 ratio) or 
replicated in larger sample, these substitutions might act as risk factors rather then pathogenic 
mutations.  That  is,  these  aminoacid  replacements,  which  do  not  appear  to  be  neutral 
polymorphisms, might be associated with familial Late-Onset AD, promoting its manifestation 
(as in the case of APOE).
9.1.2 Frontotemporal Lobar Degeneration
The mutational screening of FTLD-associated genes confirmed the genetic heterogeneity of this 
disorder.  The  detected  mutational  frequencies  are  consistent  with  literature  data,  confirming 
PGRN and  MAPT gene  as  the  main  causes  of  familial  FTLD (with  PGRN mutations  more 
frequent than in MAPT). This genetic heterogeneity is further emphasized by the failure to find 
pathogenic mutations in familial cases of FTLD and by the identification of a family linkaged to 
chromosome 9; data implying the existence of other FTLD genes not yet identified. In addition 
to genetic heterogeneity, also observed clinical phenotypes were variable (even within the same 
family), overlapping with parkinsonism- and AD-like syndromes. Finally, the availability of a 
serum sample for a patient with a  PGRN frameshift  mutation stressed the utility to assess a 
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peripheral  marker  as  an  indirect  indicator  of  a  degenerative  process  of  the  central  nervous 
system.  Quantification  of  PGRN serum levels  represents  a  fast  and  reliable  tool  to  identify 
PGRN mutation  carriers  and  to  exclude  or  confirm  the  pathogenic  role  of  non-frameshift 
variations  which  therefore,  might  escape  a  mechanism  of  action  based  on  a  state  of 
haploinsufficiency.
On the basis of obtained results and, in particular, considering the low mutational yield of AD- 
and FTLD-associated genes (whose mutations accounted for less than 4% of entire series), two 
diagnostic algorithms (Fig. 50 and 51) are proposed below for the selection of a small group of 
patients highly suggestive of a genetic basis. These algorithms might help to refine the clinical 
diagnosis in early stages of these disorders, which represents the starting point for the application 
of future therapeutic treatments.
The starting point of these algorithms is the clinical diagnosis (as a result of the integration of 
several informations derived from the neurological examination, neuropsychological tests and 
neuroimaging) of AD or FTLD. The crucial factor in choosing whether to refer a patient for 
genetic analysis is the family history for dementia and, in particular, the presence of a pattern of 
autosomal dominant inheritance within the family.
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Clinical diagnosis of Alzheimer's Disease
Neuropsychological tests MRI and SPECTNeurological examination
APOE
Onset age of the disease
40 < age < 75 yrsAge > 75 yrs
40 < age < 60 yrs
Aggressive clinical presentation
Rapid illness evolution  
60 < age < 75 yrs 
Mild clinical presentation
Slow illness evolution
Autosomal Dominant Inheritance?
APOE PSEN2
Family history for dementia?
YESNO
PSEN1
APP
PSEN2
YES
NO
Fig. 50. Alzheimer's Disease diagnostic algorithm for genetic testing.
Abbreviations: MRI, Magnetic Resonance Imaging; SPECT; Single Photon Em ission Computed 
Tom ography; APOE, Apolipoprotein E; PSEN1, Presenilin1; PSEN2, Presenilin2; APP, Am yloid 
Precursor Protein; dashed arrows; genes being analyzed if no m utation is identified in the preceding. 
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Clinical diagnosis of Frontotemporal Lobar 
Degeneration syndrome
Neuropsychological tests MRI and SPECTNeurological examination
PGRN level quantification in 
serum  or plasm a
Autosomal Dominant Inheritance?
PGRN
Family history for dementia?
YES
FTD FTD-MND IBMPFD
MAPT
CHMP2B
TARDBP
Chr9 locus
VCP
LOW HIGH
PGRN level quantification in 
serum  or plasm a
NO
PGRN
LOW HIGH
YESNO
Fig. 51. Frontotemporal Lobar Degeneration diagnostic algorithm for genetic testing.
Abbreviations: MRI, Magnetic Resonance Imaging; SPECT; Single Photon Em ission Computed 
Tom ography; PGRN, Progranulin; MAPT, Microtubule Associated Protein Tau; TARDBP, TAR DNA 
Binding Protein; VCP, Valosin Containing Protein; CHMP2B, Charged Multivesicular Body Protein 
2B; Chr, chrom osome; FTD, Frontotemporal Dementia; MND, Motor Neuron Disease; IBMPFD; 
Inclusion Body Myopathy with Paget's Disease of Bone and Frontotem poral Dementia; dashed 
arrows; genes being analyzed if no mutation is identified in the preceding. 
9.2 CADASIL
The  results  of  NOTCH3 mutational  analysis  showed  a  wide  variation  in  the  distribution  of 
mutations  along  the  gene;  heterogeneity  observed  either  within  the  same  population  or  in 
comparison to others (French, German, British, Dutch, Italian). In Italy, in particular, there is a 
clustering of mutations which affect distinct exons in patients living in different geographical 
areas.  For  this  reason is  difficult  to  define  a  sole  diagnostic  algorithm but,  the  best  genetic 
approach  is  the  one  that  takes  into  account  these  differences  (Fig.  52).  This  reduces  the 
substantial  costs  that  would  incur  if  all  NOTCH3 exons  were  analyzed.  In  patients  with  a 
negative result at first genetic screening, the analysis extension to other exons may be taken into 
account  in  pedigree  with  a  clear  pattern  of  Mendelian  inheritance  of  the  disease,  after  the 
identification  of  GOM  deposits  in  skin  biopsy  that  closely  correlate  with  the  presence  of 
NOTCH3 mutations. 
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Clinical diagnosis of CADASIL
MRI Neurological examination
Italy geographical area?
ex4
NORTH CENTRAL SOUTH
ex7
ex3
ex11
ex19
ex10
ex4
ex11
ex3
ex8
ex6,11,19,22
ex4,10
Mendelian Inheritance
Skin biopsy GOM+
remaining 
exons
Fig. 52. CADASIL diagnostic algorithm for genetic testing.
Abbreviations: MRI, Magnetic Resonance Im aging; ex, exon; GOM, Granular 
osmiophilic Material; dashed arrows; genes being analyzed if no mutation is 
identified in the preceding. 
Appendix 1: cerebral lobes
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Appendix 2: haplotype reconstruction for CADASIL families
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